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0.0 INTRODUCTION
Since the discovery of radioactivity, mankind has been confronted
with the challenge of understanding biological effects of radiation.
The domestication of nuclear power has heightened the need to fully
comprehend the relation between radiation and human health for the
safety of occupational workers and the public in general. During
recent decades, the field of radiation protection has made tremendous
strides from its infancy. The rapid growth of knowledge has made it
possible to revise the mathematical models for accurate estimation of
internal doses from radionuclides, and update the regulatory guidelines
for control and management of radioactive materials. In view of this,
the International Commission on Radiological Protection approved a new
set of basic recommendations dealing with protection from ionizing
radiation. These are detailed in the ICRP Publication 26 [IC77].
Further, the methods used to evaluate internal dose to comply with the
limits in ICRP-26 along with the tables of specific committed dose
equivalents, limits on annual intake, and air concentrations from
specific radionuclides are shown in ICRP Publication 30 [IC79].
This report describes a computer program "DOSE" in FORTRAN-77 that
generates internal dose factors of the type called for in ICRP-30. The
constraints imposed by the ICRP on exposure of different organs and
tissues of the body singly or together with other organs, in the case
of intake of a radionuclide, are discussed in Chapter 1.0. The general
principles, mathematical models, definitions, and calculational
procedures adopted by the ICRP-30 for calculation of specific committed
dose equivalent are used in this program. Also, the models presented
in Chapter 2.0 for the routes of entry of radionuclides into the body,
namely, the respiratory system and the gastrointestinal tract, are the
ones recommended by the ICRP-30. The metabolic data for the
radioisotopes of different elements are also obtained from ICRP-30. In
the case of iodine, the program follows the alternate model discussed
in the ICRP-30. The specific committed dose equivalents are assumed to
be received by a "reference man" of anatomical and physiological
characteristics described in ICRP Publication [IC75]. The decay
schemes of radionuclides are obtained from Kocher [K081]. The ICRP
uses the decay schemes from its publication 38 [IC83]. This difference
may reflect on the results for some of the radionuclides.
An important feature of this program is its flexibility. The data
files on radiological and biological decay are written in such a manner
that addition of new data on a radionuclide or amendment of the present
data is easy. Also, as is explained in Chapter 3.0, most of the
calculations for important quantities are done by separate, independent
subroutines. This design makes future modifications in the program
convenient and simple.
1.0 FUNDAMENTALS OF RADIATION PROTECTION
The concept of radiation protection centers around two
possible effects in individuals. They are defined as "somatic"
and "heredi tary"
.
"Somatic" effects of radiation are limited to the exposed
individual while "hereditary" effects are manifested in the
individual's progeny. The quality of effect can be described as
"stochastic" or "non-stochastic".
"Stochastic" effects involve probability of occurrence as opposed
to severity, and are therefore considered a function of dose, without
threshold. In contrast, "non-stochastic" effects vary in severity with
dose, and hence may involve a threshold. Hereditary effects are
considered stochastic at the dose range involved in radiation
protection, while somatic effects may be stochastic or non-stochastic.
An example of stochastic effects is carcinogenesis at low doses.
Non-stochastic somatic effects may range from cataract of the lens to
damage of the hematopoietic system.
To quantify health damage, the International Commission on
Radiological Protection (ICRP) has proposed the concept of "detriment".
"Detriment" in a population is described as the mathematical
"expectation" of the deleterious effect from a radiation exposure,
taking into account not only the probability of each type of damaging
effect but also the severity of the effect. In other words.
"detriment" to health G In a group of persons P is given as the
summation over all effects i of the product of probability p. of
suffering the effect and the severity of effect expressed by a
weighting factor g., i.e..
=
P 2 p i g i • d.l)
1.1 DOSE EQUIVALENT. H
This quantity characterizes the severity and probability of the
deleterious health effects of radiation. The dose equivalent H at a
point in tissue is given by
H = D Q N , (1.2)
where D is the absorbed dose,
Q is the effective quality factor, and
N is the product of all modifying factors such as absorbed dose
rate and fractionation specified by ICRP. At present, it is
assigned a value of 1
.
The SI unit of dose equivalent is the sievert (Sv) . 1 Sv 100 rem.
1.2 ABSORBED DOSE. D
This refers to the energy locally deposited (and ultimately
dissipated as heat) per unit mass of the medium. It applies to both
types of radiation, ionizing and non-ionizing. The SI unit of absorbed
dose is the gray (Gy)
. 1 Gy = 1 J kg"
1 (=100 rad)
.
1.3 EFFECTIVE QUALITY FACTOR. Q
Quality factor is introduced to allow for the effect on the
detriment of the microscopic distribution of absorbed energy. It is a
function of the collisional stopping power in water. For a spectrum of
radiation, the ICRP [IC77] recommends an effective value Q to be used
for both external and internal radiation:
X rays, i rays, and electrons 1
Neutrons, protons and singly-
charged particles of rest mass
greater than one atomic mass
unit of unknown energy 10
a particles and multiply-
charged particles (and particles
of unknown charge) of unknown
energy 20
A graphic review of the relationship between these quantities is shown
in Fig. 1.1.
1.4 COLLECTIVE DOSE EQUIVALENT, S
This concept approximates the relationship between detriment and
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where
i
organ or tissue of an individual who is a member of the
subgroup i in the exposed population, and
Source Q
Activity measured
in Curies or Bq
Flux (*)











-. f damage to man
rem = rad x QF
Sv = Gy x QF
Absorbed Dose rad
expresses energy absorbed
in one gram of any medium
1 rad = 0.01 J/kg
1 Gy = 1 J/kg
FIG. 1.1. Relationship of units.
P. represents the number of members in this subgroup i.





where P(H)dH is the number of individuals receiving a dose equivalent
in the whole body or a specific organ or tissue in the range H to
H + dH.
1.4.1 Radiobiological Assumption:
A simple summation over all subgroups of the population of doses
to specific organs or tissues of a typical individual in a subgroup is
used as a measure of detriment to estimate the collective dose
equivalent in a population [IC77]. This process is based on an
assumption regarding stochastic effects; namely, that within the usual
range of radiation exposure a linear relationship without threshold
exists between dose and the probability of an effect.
1.5 COMMITTED DOSE EQUIVALENT. IL^
This is defined as the total dose equivalent averaged throughout a
tissue in the 50 years after intake of a radionuclide into the body.







where H(t) Is the relevant dose-equivalent rate, and
t Is the time of intake,
o
In view of the radiobiological assumption above, it is considered
practical to conceptualize the term "dose equivalent" as a mean dose
equivalent over all cells of uniform sensitivity in a particular tissue
or organ for stochastic effects.
1.5.1 Non-homogeneous radiation:
If the doses to individual cells vary due to non-uniform
irradiation then the relevance of the mean dose equivalent may be
questioned. However, according to the Commission, based on theoretical
concepts and epidemiological evidence, a series of "hot spots" in an
organ or tissue is less likely to be damaging than a uniform
distribution. High doses cause loss of reproductive capacity or death
of cells, neither of which may contribute significantly to stochastic
effects. Thus, for non-homogeneous irradiation, assessment of dose
with the assumption of homogeneous distribution would probably be an
overestimation. So far as non-stochastic effects are concerned, the
limited amount of cell killing at moderate dose levels is thought not
to be a major factor in perturbing the balance of organ function.
1.5.2 Unequal sensitivity of cells:
The problem of dose variance due to differing cell sensitivities
of different organs is handled by the Commission by prescribing risk
factors according to relative radiosensitivities of the irradiated
tissues. A detailed explanation of these risk factors will follow
later.
1.5.3 Rate of dose accumulation:
Based on assumptions and explanations summarized above, the
Commission has found it unnecessary to recommend a maximum rate of dose
accumulation as long as the annual dose equivalent limit is met. The
only exception is the case of occupational exposure of women of
reproductive potential and pregnant women.
1.5.4 Age , sex , and dose-dependency
:
Risk factors for occurrence of malignant cancers are thought to be
lessened in older persons due to long periods of latency needed for
progression and expression of these effects. Also, development of
breast cancer is much more common in females than in males. Such facts
emphasize the importance of age, sex, and dose dependency. The
Commission however, describes average risk levels based on anatomical
and physiological characteristics of "reference man" because, for
protection purposes, it is considered sufficiently prudent to use a
single dose-equivalent limit for each organ or tissue for all workers
regardless of age or sex.
1.6 DOSE EQUIVALENT LIMITS FOR OCCUPATIONAL EXPOSURE
The primary considerations of the Commission in establishing dose
equivalent limits were:
i) For stochastic effects, a single value should not only limit
uniform irradiation of the whole body but also ensure that
the total risk from irradiation to parts of the body does not
exceed the value,
ii) To preclude non-stochastic effects, a value should be
proposed such that no single tissue receives more
dose-equivalent than the value.
1.6.1 Recommended limit for non-stochastic effects:
To prevent non-stochastic effects in all tissues except the lens,
the Commission has proposed a limit of 0.5 Sv (50 rem) in a year. The
dose equivalent to the lens is limited to 0.15 Sv (15 rem) in a year.
1.6.2 Recommended limit for stochastic effects:
For whole-body uniform irradiation, the limit is
H
wb = 5 cSv (5 rem ) in any year. (1.6)
Non-uniform irradiation must adhere to the following condition:
T
where Hj, is the dose equivalent received by tissue T, and
10
w_ is a weighting factor involving relative radiosensitivity
of the tissue T.
The values of these weighting factors are given in Table 1.1.
TABLE 1.1. Weighting factors as










The "remainder" refers to five remaining organs or tissues
receiving the highest dose equivalents, with w„ = 0.06 applied to each.
All other tissues are neglected. Of course, lens and skin are not
members of "remainder" because they are subject to non-stochastic
effects. The gastrointestinal tract is treated as four separate
organs: stomach, small intestine, upper large intestine, and lower
large intestine.
1.6.3 External exposures to penetrating radiation:
In the absence of information on actual distribution of dose
equivalent within the body, the maximum value of dose equivalent in a
30-cm spherical phantom when limited to the 0.5 Sv annual limit will
permit a comparable level of protection.
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1.6.4 Planned special exposures:
The limit under such situations should not exceed twice the
relevant annual limit in any single event, and, in a lifetime, five
times this annual limit. The exposures however, must be justified and
permitted only when alternative techniques are impractical or
unavailable.
1.6.5 Women of reproductive capacity:
Occupational exposure of such women should be restricted to insure
that the embryo receives no more than 0.005 Sv during the first two
months of pregnancy.
1.6.6 Occupational exposure of pregnant women:
Exposure should be minimized and not exceed 30% of the normal
annual limits.
1.7 CONTROL OF INTERNAL DOSE
For control of internal dose for workers, the standards are
derived from the general limits described in the previous section and
are based on the parameters of the "reference man".
1.7.1 Annual limit on intake (ALI) [IC79]:
For a given radionuclide, if I is the annual intake (Bq) either by
ingestion or inhalation, and H^
T
(Sv/Bq) is the specific (per unit
intake) committed dose equivalent in tissue T from the intake by the
12
specified mode, weighted for its sensitivity by weighting factor w
described in Table 1.1, then the annual limit on intake is defined as







50.T * 005 Sv Cl-8)
T
for stochastic effects, and
I H^j < 0.5 Sv (1.9)
for non-stochastic effects.
The summation in the first inequality is over all tissues in Table
1.1, including of course the five "remaining tissues" in "remainder"
which receive the greatest specific committed dose equivalents. A
tissue is considered to be "significantly irradiated" only when it
satisfies the following inequality
W.J1 > 0.1 (w_ IL.
_) (1.10)
I fc>0,I T SO.T'maximum > '
1.7.2 Derived air concentration (DAC) [IC79]:
The DAC for any radionuclide is defined as that concentration in
air (Bq/m ) which, if received by "reference man" for a working year of




DAC = ALI/(2000 x 60 x 0.02).
DAC = ALI/2.4 x 103 Bq/m3
, (111)
where 0.02 m Is the volume of air breathed at work by "reference
man" per minute under conditions of "light activity" as
described by ICRP Publication 23.
For radioactive noble gases other than radon and thoron, DAC's are
the concentrations which would lead to a cumulative weighted average
dose of not more than 0.05 Sv. a dose to the lens of 0.15 Sv, or a dose
to the skin of 0.5 Sv in a working year (2000 h)
.
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2.0 EVALUATION OF SPECIFIC COMMITTED DOSE FOIITVAT.FWT
Specific committed dose equivalent from a radionuclide to a target
organ or tissue is defined as the committed dose equivalent to the
organ or tissue as a result of ingestion or inhalation of unit activity
of the nuclide.
Activity or decay rate A is mathematically expressed as
A -
lim M ,„ t ,_
At-*) At ' C
9
*J
where AN is the number of spontaneous nuclear transformations in a
quantity of radionuclide, and
At is the time interval.




Committed dose equivalent, as explained in the previous chapter,
is the total dose equivalent averaged throughout any tissue in the 50






where i is an index for the type of radiation (a,/3,i, etc.)
released by the radionuclide,
^50 i ls "** tota l absorbed dose in the element of mass dm of
the specific organ or tissue during a 50 year period
following intake of the radionuclide into the body,
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Qj is the effective quality factor for the radiation type i,
Nj is the product of all modifying factors such as dose
rate, fractionation, etc., and
M is the mass of the organ or tissue under consideration.
A value of 1 is recommended for N by the ICRP (Publication 26) and
the value of Q is constant for each type of radiation i; therefore, the
above relation can be simplified to
Hs
° =1 ^iVi • (2-3)
where D
50,i ls the total absorbed dose during the 50 years after
intake of the radionuclide into the body, averaged
throughout the specified organ or tissue for each
radiation type i.
When a radionuclide enters the body, it is distributed in various
source organs or tissues where it may decay or be eliminated by normal
metabolic processes. The committed dose equivalent in a target organ
or tissue T due to the disintegration of a radionuclide j, releasing
radiation of type i in source organ S, denoted by, H^„(T*- S) is50 v i.j'
defined as a product of two factors:
i) the total number of transformations (decays) of radionuclide
j in source organ S during the 50 year period following its
entry into the body, and
ii) the energy absorbed per unit mass in the target organ T,
modified for effective quality factor, from radiation of type
i per transformation of radionuclide j in source organ S.
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Mathematically, for each radiation type i from radionuclide j,
HB0 (T«- SJjj = 07D^(T«- s)
.
or




is the number of transformations (decays) of
radionuclide j in organ S over 50 years following
intake of the radionuclide,
1.6 x 10"' is the number of joules in 1 MeV,
SEE(T«- S)
4
is the specific effective energy, modified by
quality factor, for radiation type i absorbed in
T from each transformation in S. The unit is
MeV/g per transformation, and
10 is the conversion factor from g" 1 to kg"'.
Thus, for all types of radiation emitted by radionuclide j.
HB0 (T<- S). = 1.6 x 10" 10 [u
s j Y
SEE(T<- SjJ . (2.5)
i
If the radionuclide decays into a radioactive daughter j', then
HBO (T<- S) j+j , = 1.6 x
10" 10
• K, I SEE(T<- S) 1 J J
[U
s _., 2SEE(T.S).].,J (2.6)
For a number of radioactive daughters, the committed dose equivalent in
17
target T from decays in source S can be generalized as
I HBO (T<- S) i
= 1.6 x 10"'°
I
[u
sJ I SEE(TV S).^ . (2.7)
J J i
Since the target organ T may receive dose from more than one source
organ, the total value of Hso in target T is given by
H50T = 1.6 x 10-" H [u^.^SEECT^S).]. . (2.8)
s j i
Since our interest is the specific committed dose equivalent, we
express it per unit activity as
«50,T= 1 -6xl0




is the number of transformations of radionuclide j in S
over 50 years after intake of unit activity of the
radionuclide.
2.1 SPECIFIC EFFECTIVE ENERGY
Let us denote the specific effective energy absorbed in target T
per transformation of radionuclide j emitting all types of radiation i
in source S as
SEE(T<- S). = Y SEE(T<- S) . (2.10)
18
As previously stated, each radionuclide may emit a range of
different types and energies of radiation indicated by index i. But it
is not necessary that every transformation (decay) of radionuclide j
should result in emission of all the varied radiations. Hence the
concept of yield. Associated with average or unique (as appropriate)
energy Ej (in MeV) of every radiation type i is a yield Y.. The yield
provides the fraction of transformations that result in the release of
radiation type i. Also, the amount of the energy absorbed in target T
will vary significantly with the energy, kind of radiation, and
location (source organ S) of release. This variance is accounted by
introducing a quantity AF(T«- S) which is defined as the fraction of
energy absorbed in target organ T per emission of radiation i in source
organ S. Of course, in accordance with the definition in the previous
section, the product of all these quantities must be weighted for
effective quality factors Q for each radiation type i, and, since we
are interested in specific effective energy, the whole product must be
taken per unit mass Hj, (in g) of the target organ T. We can thus
write, for each radionuclide j,
_ Y.E. AF(T«- S). Q.
SEEO* 8}^ - I
-U-jjl L_±. (2 . n)
a) Decay Schemes [K081]: The decay schemes of radionuclides used in
this report were obtained from "Radioactive Decay Data Tables," by
D. C. Kocher, DOE/TIC - 11026(1981). In case of positron
emission, a photon of energy 0.511 MeV and yield twice that of the
19
positron is added to the decay scheme to account for the
annihilation photons. The decay scheme used in the ICRP-30
results were from Publication 38 [IC83].
b) Absorbed fraction of energy in target organ: For most target
organs, it is assumed that the energies from non-penetrating
radiations such as alpha particles, beta particles, positrons,
etc. are completely absorbed within the source organ. Hence, if
target organ and source organ are the same, then the absorbed
fraction is equal to 1, else it is equal to zero for
non-penetrating radiation, except in the following cases [SN75]:
i) If the source organ is total body then, regardless of the
target organ, the specific absorbed fraction AF (absorbed
fraction per g of target) is given by
AF(T«- Total body) = 1/69900,
where the denominator represents mass in grams of the total
body of Reference Man.
ii) When the target organ is total body and the source organ is
either bladder content, stomach content, SI content, ULI
content, or IXI content, then
AFfTotal body*- GI tract/Bladder content) = M /(2xM x69900),
where M
w
is the mass of the wall of the source organs.
and
"c
iS t*le mass °f *he contents of the source
organs
.
If the source is any other organ excluding the above and the
target organ is total body then
20
AF(Total body*- S) = 1/69900.
With the specific absorbed fraction, the value of specific effective
energy is given by
SEE(T<- S). =
I Y. E. AF(T - 8), Q. . (2.12)
i
In case of penetrating radiations such as X-rays and ? rays, the
absorbed fraction of energy from photons is estimated by the data in
ICRP Publication 23 [IC75]. The tables in Publication 23 provide
values for discrete energies from 0.01 HeV to 4.0 HeV. If the photon
energy is within this range, then the value of absorbed fraction can be
interpolated from the tables. However, if the energy of the photon is
less than 0.01 MeV, specific absorbed fractions used in calculations
are assumed to be the same as defined for non-penetrating radiations
[SN78], i.e.,
i) AF = 1/ttj. if the source and the target are the same, or
ii) AF = in general if the source and the target are different,
except for the following conditions:
iii) AF = 1/69900 if the source organ is total body,




x69900) if the target organ is total body and
the source is either bladder content, stomach content, SI
content, ULI content, or LLI content,
v) AF = 1/69900 if the target organ is total body and the source
is any organ other than the ones described in (iv).
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This treatment in calculation of absorbed fractions or specific
absorbed fractions is recommended for the majority of target organs.
However, there are exceptions, notably the mineral bone, organs of the
GI tract, and the bladder wall, which are explained below:
2.1.1 Target Organs of the GI Tract and Bladder Wall:
For non-penetrating radiations, if the source organ is different
from a target organ of the GI tract or bladder wall, the specific
absorbed fraction is zero except when the source is total body. In that
case, AF = 1/69900. However, if the source is the content of the target
organ in the GI tract or the bladder content, the only dose received is
that by the mucosal layer ML of the wall of the organ. The specific
absorbed fraction for the mucosal layer of the wall of the target organ
is taken to be equal to 0.5xu/m£. where M^ (in g) is the mass of the
contents of that target organ, and u is a factor between zero and unity
representing the degree to which the radiation penetrates the mucus.
The factor 0.5 is introduced because the absorbed dose rate at the
interface between the contents and the mucus and mucosal layers is
approximately half that deep within the contents. For /3 particles, v is
taken to be unity, and for a particles only 0.01 owing to attenuation in
the mucus layer.
As far as photons are concerned, the fraction of their energy
emitted in source S that is absorbed in the walls of the target T is
obtained from the tables in ICRP Publication 23 by interpolating within
the 0.01 to 4.0 MeV range. However, if the energy of the photon is less
than 0.01 MeV, the specific absorbed fraction is extrapolated as:
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i) AF = l/(2xM
c
) if the source and the target are the same,
where M is the mass of contents of the organ, or
ii) AF = in general if the source and the target are different.
except in the following case:
iii) if the source organ is total body, then AF = 1/69900.
2.1.2 Targe t Organ in Bone
:
In the case of mineral bone, the two target tissues are the cells
near bone surfaces (BS) and the active red bone marrow (RM). The ICRP
model describes source tissues as cortical and trabecular bone for all
non-penetrating radiation. For photon emitters, S is any organ of the
body containing the radionuclide and T is either the BS cells or RM.
Cortical bone (CB) is the compact or dense material of the outside of
the bone. Trabecular bone (TB) is the cancellous or spongy inner
portion of the bone containing the marrow.
Absorbed fractions for non-penetrating radiation are governed by
two major criteria:
i) Radionuclides with half lives of less than 15 days are
considered to be distributed on bone surfaces, since they are
unlikely to move far into the volume of bone before they
decay
,
ii) Isotopes of alkaline earth elements with half lives greater

























' W are assumed to be uniformly distributed
throughout the volume of bone.
If the source organ is any other organ except total body,
trabecular bone, or cortical bone, the specific absorbed fraction is
taken to be zero. If the source is total body, AF = 1/69900.
Recommended values of absorbed fractions for a and ji particles in the
cases of source tissues as TB and CB are given in Table 2.1. Masses of
target organs BS and RM are taken to be 120 and 1500 g respectively.
TABLE 2.1 Absorbed fractions for dosimetry of radionuclides





















E < 0.2 MeV
TB BS 0.025 0.25 0.025 0.025 0.25
CB BS 0.01 0.25 0.015 0.015 0.25
TB RM 0.05 0.5 0.35 0.5 0.5
CB RM 0.0 0.0 0.0 0.0 0.0
For photon emitters, if the energy is within 0.01 to 4.0 MeV,
values of absorbed fraction can be interpolated from the tables in ICRP
Publication 23 for any source organ. Values of absorbed fraction
reported for skeleton in Publication 23 are taken as appropriate for BS
cells. If the photon energy is less than 0.01 MeV and the source is TB
or CB, absorbed fraction is taken to be 1/Jtj., where M_ is 1500 g for
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target organ RM and 10500 g for BS cells. If however, the source is
any other organ except total body. AF = 0. In the case of total body,
specific absorbed fraction AF = 1/69900.
2.1.3 A note on daughters:
The metabolic behavior of daughters is assumed to be the same as
that of the parent radionuclide which enters the body (see Section
2.2.1).
2.2 NUMBER OF TRANSFORMATIONS IN A SOURCE ORGAN OVER 50 YEARS
The number of transformations of a radionuclide in any source
organ during a period of time is defined as the time integral of the
activity of the radionuclide over that period of time.
After ingestion or inhalation of a radionuclide, its translocation
to the body fluids is dependent upon the rate constants of the
different compartments of the gastrointestinal and respiratory systems.
and the decay constant of the radionuclide. A detailed account of the
passage of radionuclides through the GI and respiratory system follows
later. For now. let us examine the kinetics of a radionuclide after it
reaches the body fluid compartment, and how it is deposited in, or
passed for excretion from the different compartments of a tissue or
organ. The mathematical model recommended by the ICRP is illustrated
in Fig. 2.1. Transformations in the body fluid or transfer compartment
are assumed to be uniformly distributed throughout the whole body of
mass 70000 g. Each source organ or tissue may have one or more
compartments where the radionuclide may be retained or translocated at
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different rates. A maximum of three compartments per tissue is
assumed. From each of these compartments, the radionuclide migrates at
an appropriate rate to excretion pathways. In the interest of
simplicity, no feedback to the transfer compartment either from the
tissue compartments or from routes of excretion is assumed, although in
reality the case is otherwise.
2.2.1 A note on daughters:
The immediate daughters and all subsequent progeny produced within
the body are assumed to be associated with, and behave metabolically as
the inhaled or ingested parent radionuclide. In general, there is
little evidence to show whether the daughters behave metabolically like
the parent or if, upon production, they exhibit their own metabolic
behavior. When experimental evidence contrary to the assumption is
available, separate models as shown later are used.
2.2.2 Transfer compartment, T:
Let us represent the radionuclides with an index j. If we suppose
that an initial activity f^, per unit intake, reaches the body fluid or
transfer compartment from the GI tract and lungs, then for the parent
(j = 1) a differential equation expressing the time-dependent behavior




"~dt = " ^r 1T l (t) " X l qTl (t) • ( 2 - 13 )
where qT1 is the activity of the parent in the transfer
compartment.
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FIG 2.1 Mathematical model used by the ICRP-30 to describe
the kinetics of radionuclides in the body.
Xj^ is the radiological decay constant for species 1,
and
\j. is the rate of loss of the stable element from the
transfer compartment.
For most elements, X_ is taken to be equal to ln2/0.25 days, i.e.,
the biological half life for translocation to the organs and tissues of
deposition from the transfer compartment is taken to be 0.25 days.
Following are the exceptions:
i) If the element is fluorine, potassium, gold, or thallium, the
translocation is assumed to be instantaneous and the
biological half life is zero.
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ii) If the element is thorium, cobalt, chromium, or phosphorus,
the biological half life is 0.5 days,
iii) If the element is technetium or rhenium, the biological half
life is 0.02 days,
iv) If the element is ruthenium or rhodium, the biological half
life is 0.3 days,
v) If the element is tellurium, the biological half life is O.S
days,
vi) If the element is bismuth, the biological half life is 0.01
days.
Taking the Laplace transform of Eq. (2.13), we have
» i£["{») - <jt1 (°) - - Xj 5J^(«) - \ i^(s) .
This can be written as
qT1 (0)
QT1 (S) = [s + (^ + Xl} ] • (2- 14)
Now for the daughters, a similar differential equation (see Fig. 2.1)
can be written as
dq
Tj (t)
j = 2 N (2.15)
where j is the index for the daughters,
2S
qT .
is the activity of the species j in the transfer
compartment,
qT,j-l iS the activlty ° l the parent of species j in the
transfer compartment, and
X is the radiological decay constant for species j.






" VT2(t) " X2 qT2 (t) (2.16)
The Laplace transform of Eq. (2.16) is
qT2(s)
- qT2(0) = X2qT1 (s)
-
^ q^s) - A,, q^s),
qT2 (0) * A2 qT1 (s)
qT2lS; " Ls + (^ + X2 )] (2.17)
Substituting for qT1 (s) from Eq. (2.14) in Eq. (2.17), we obtain
qT9 (s) =
X




















II [a + (^ + X )] T J T 2
k=i
In partial fractions, this can be written as
, A A A
i i . 2 m
s + (X-+X ) s + (X_+X„)
' '
' s + (X_+ X )
+
B [s + (V\)] T 2 Y m
k=i ' K
Multiplying throughout by [s + (X-.+X )], we have
s +
<w Am ^ s + tyy] I ^
j = [s + lOrj] + LS + (VAm» 2 [s + (X.A)]
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a if n > m
, and
n
IT a. = 1 if m > n
.
i=m x
Now by definition, the number of transformations in the transfer
compartment U_ for species j is given by
"t^vJoV^ (2.21)
where T = 365.25 x 50 days, and
8.
J
B_ is the branching ratio of radionuclide j. For the
parent, B. = 1.
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The result of the integral is
uT . = b. x yTj J L
1=1 ill "J *
(0)
v ri -e T m 1
m=i (X_+X ) IT (X, -X )v T m', . " k m' Jk=i
k*m
(2.22)
where IT a. = a
m m+1 . . a if n > mn
IT a. = 1 if n ) n, and
i=m
q-pjf ) ls the initial activity of species i in the transfer
compartment which is assumed to be equal to fi..
Calculation of this quantity is shown later.
If X values have units d" 1
,
then this formula for U_. must be
multiplied by 86400 s/d to yield units Bq" 1 for U_ .
.
2.2.3 Tissue compartment, p:
As mentioned earlier, each source organ or tissue can have a
maximum of three compartments, i.e., p = 1, 2, 3. From the transfer
compartment, a fraction f£ may reach each tissue compartment of a
source organ. This fraction is biologically eliminated from the
compartment with a half life of A Since the daughters are assumed to
possess the same metabolic behavior as the parent, the same retention
fractions f£ and biological half-lives X are used for them These
P
retention fractions and biological half lives are obtained from the
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metabolic data in ICRP Publication 30 for each nuclide taken in the
body.
With the knowledge of fS, the total activity of species J
translocated from the transfer to the tissue compartment during the 50
year time period can be given by
%i ' fI *r L «rjCt> ^ . (2.23)
But as shown before,
% " BJ X f qTj (t) dt
Hence
,
%)= Jt- UTj- C2.24)
If we assume that this total activity is transferred
instantaneously as a single intake to the tissue compartment at time
t = 0, then the initial activity deposited in the tissue compartment





v (0) b! • (225 )
For the time dependent behavior of species j in the tissue
compartment, differential equations similar to the ones described in
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the transfer compartment can be written. By a similar treatment of
solution, the number of transformations in a tissue compartment for
species j can be written as
PJ v I IT X.k=i+l K v (0) I s1
-(A +X )T
- e P ° 1




where <L.(0) is given by Eq. (2.25).
Thus, for a source which may have a maximum of 3 compartments, the






where M is mass of the source organ, and
70000 is mass of the total body in grams.
2.2.4 Respiratory system:
When a radionuclide is inhaled, parts of the respiratory system
are irradiated. As a consequence, other organs and tissues of the body
may be irradiated either by translocation of the inhaled material from
the respiratory system to the body tissues or by radiations originating
from the lungs.
Analyses of the dynamics of radionuclide transport within the lung




The model representing the respiratory system is proposed by the
ICRP Task Group on Lung Dynamics (1966) [1066]. It is shown in Fig.
2.2. This model partitions the respiratory system into three regions
— the nasal passage (N-P), the trachea and bronchial tree (T-B), and
the pulmonary parenchyma (P). Each region is further subdivided into
two or four compartments. All three regions have pathways directly to
the body fluid compartment. Only the P region translocates material to
the lymphatic system (L). This pulmonary lymphatic system also serves
to remove the dust from the lungs. A subcompartment of the lymphatic
system releases material to the body fluids while the other
subcompartment is assumed to retain the material indefinitely. The
latter subcompartment is deemed appropriate only for a particular class
Y of aerosols. Both T-B and N-P regions are involved with mucociliary
transport which translocates material to the gastrointestinal tract.
Connection between the P region and the GI tract is only through
feedback via the T-B region.
a) Deposition and Retention of Inhaled Material: Deposition of
inhaled material in the respiratory system is dependent upon the
aerodynamic properties of the aerosol distribution. Three terms D
N-p'
nj._
B . and Dp
represent the fractions of inhaled material initially
deposited in the N-P. T-B. and P regions respectively, the balance
being the fraction exhaled. The pattern of aerosol distribution is
characterized by the activity median aerodynamic diameter (AMAD) . This







































































FIG. 2.2. Mathematical model used to describe clearance
from respiratory system.
Source: ICRP Publication 30, Part I.
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diameter, the aerodynamic diameter of a particle being the diameter of
a spherical particle with the same settling velocity. The pattern of
deposition is related to the AMAD of the aerosol according to Fig. 2.3.
To analyze the clearance of inhaled radioactive materials from the
lung, the radionuclides are categorized as D, W, or Y. These
categories refer to the retention in the pulmonary region. Class D
reflects minimal retention, i.e., a rapid clearance within days while,
class W material takes weeks for clearance, and class Y is cleared
slowly in years. For elements and their compounds, retention
classification is given in Fig. 2.4.
For each chemical classification, the sub-compartments have a half
time of clearance T (days), and a fraction F that refers to the amount
of material leaving each sub-compartment. These values are shown in
Table 2.2. Note that the half lives are given in units of days. When
converting these decay constants in units of s" 1
, one must use the
factor 86400 s/d.
b) Clearance Calculations: To calculate the source-organ trans-
formations of a nuclide, we need to evaluate its time dependent
activity in each subcompartment. Suppose we represent the subcom-
partments with an index « such that i = a, b, c, d, e, f, g. h, i, and
j as shown in Fig. 2.2. Now. if a unit activity of nuclide is inhaled
at time t = 0, then the initial activities in each of the subcompart-
ments a - h of Fig. 2.2 can be given as the product of percent
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Percent deposition
FIG. 2.3. Model of deposition of dust in the respiratory
system as proposed by the ICRP-30. The model
is intended for use with aerosols with AMAD
between 0.2 and 10 um and with geometric standard
deviations of less than 4.5. Provisional estimates
of deposition further extending the size range and
given by dashed lines.
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FIG. 2.4. Pulmonary clearance classification of Inorganic
compounds as proposed by the ICRP.
Source: Report of ICRP Task Group on Lung
Dynamics: Health Physics . 12, 173-207 (1966).
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TABLE 2.2. The values of removal half times and compartmental


























































































n.a. = not applicable.
subcompartment. For example, the initial activity in subcompartment d
1S qd(°) = DT-B Fd - The clearance of the material from each of the
subcompartments is assumed to be governed by first order kinetics, so
that each subcompartment is associated with a biological decay
constant, e.g., X^s" 1 ) = 1n2/(86400 T,) . Activities in each








AT = " (XR + V q« • (2 - 28)
dq
d
dY" = Xf q f + Xg % ~ (XR + \j) qd • (2.29)
dq
l
ST" " ~ <*R
+ \) «4 + Ft Vh • (230 )
dt = " Vj + FjVh • (2-31)
Since daughters are assumed to behave metabolically like the inhaled
parent, similar systems of equations may be written for them using the
partition fractions F and biological half lives as those of the parent.
The approximate expressions for the total number of
transformations of the parent and the daughters in each subcompartment
of the lung is given in Tables 2.3 and 2.4 respectively. These results
are obtained by integrating the activities found from the solution of
the above equations, in a pattern similar to that of the transfer
compartment. All entries, except that for subcompartment j, are based
on the approximation that the clearance times are much less than the
50-year dose evaluation period. In the entry for compartment j, the
symbol n represents 50 years in units compatible with those of \
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TABLE 2.3. Approximate expressions for the number of transformations in
the subcompartments of lung following inhalation of unit Bq
of activity (a)
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(a)
Source: ICRP Publication 30 [IC79].
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TABLE 2.4. Approximate expressions for the number of transformations of
a radioactive daughter in the subcompartments of the lung.
A to Aj refers to the number of transformations of the
immediate parent in subcompartments a to j of the lung.
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Source: ICRP Publication 30 [IC79].
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With the source organ transformations known in each
subcompartment, we can sum them all to determine a total value for the
respiratory system. However, the ICRP model neglects the values for
transformations in the nasopharyngeal region, since for most particle
sizes, the dose received by this region is very small compared to the
other regions. Hence, defining the lung as a single source organ, the







+ £] * \ (2-32)





+ u* + u
k
+ vtP e f g h'
uf = irV + U
k
, and
Bj^ is the branching ratio of nuclide k (B
1
= 1).
The lung is also treated as a single target organ of mass 1000 g.
c) Transfer of a Radionuclide from the Lungs Directly to Body Fluids
or to the GI Tract: From Fig. 2.2 we can see that the rate of transfer














whether the radionuclide is inhaled or produced in lungs. Similarly,
the rate of transfer to the GI tract is given by
c
k
(t) = x^ft) x
d <£( t ) . (2.34)
Thus, the total activity fj^ of an inhaled radionuclide k
transferred directly to the body fluids can be determined as
f
BFDIR = \ * J Q BFk«) dt (2.35)
f









Similarly, the total activity translocated to the gastrointestinal
tract is
f
GI = \ * [\ < * \ Dg] (2.38)
d) Particle Size Correction: If the AMAD is unknown, then a value of
1 urn is used for inhaled materials. Values of specific committed dose
are reported for 1 urn in ICRP Publication 30. Correction for other
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values of AMAD is made as follows:
H
50,T (AMAD) Vp (AMAD) DT-B (AMAD) DP (AMAD )
H50 T (lpm)
= fN-p Vp~7W + fT-B DT_B (mm) + fP Dp (lum)
The fractions fpj_p. fj_g. and fp are respectively the proportions of
H50 T ( 1,In, 5 resulting from deposition in the N-P, T-B, and P regions.
If the AMAD is not 1 jim, then the values of 11. (AMAD), D_N r T—B
(AMAD), and D
p
(AMAD) are determined from a logarithm fit of Fig. 2.3 as
described below:
If the AMAD is between 0.1 and 0.2 pm, then
Qj,_B =
-0.163 - 0.151 (In AMAD). (2.39)
D^p = - 0.059 - 0.068 (In AMAD), and (2.40)
D
p
= 0.289 - 0.126 (In AMAD)
. (2.41)





Dj^p = 0.351 + 0.219 (In AMAD), and (2.43)
Dp = 0.289 - 0.126 (In AMAD) . (2.44)
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If the AMAD is between 10 and 20 um, then
Qj,_B
= 0.229 - 0.065 (In AMAD)
, (2.45)
Dj^p = 0.621 + 0.110 (In AMAD), and (2.46)
D
p =
0.141 - 0.040 (In AMAD) . (2.47)
2.2.5 Gastrointentlnal Tract:
Knowledge of transformations of a nuclide In the various organs of
the GI tract is very crucial to the calculation of other source-organ
transformations, because translocation of the material to the body
fluid compartment and then eventually to the source organ is directly
dependent, in case of ingestion, and partially dependent, in case of
inhalation, upon absorption of the material in the bloodstream through
the small intestine.
The model proposed by the ICRP is illustrated in Fig. 2.5. It
consists of 4 organs. Table 2.5 provides values of wall mass, contents
mass, and mean residence times for the contents of each organ. The
rate constant X for transfer of contents from organ to organ is the
reciprocal of the mean residence time.
In general, the only site of absorption from the GI tract to the
body fluids is assumed to be the small intestine. The rate constant
Xg
F
for transfer from the small intestine to the body fluids after










Upper Large Intestine (ULI)
\lLI
Lower Large Intestine (LLI)
LLI
Excretion
FIG. 2.5. Model of gastrointestinal tract
as proposed by the ICRP-30.
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Values of fj for a number of classes of compounds of each element
are given in the metabolic data. Radioactive progeny are assumed to
have the same fj as the ingested ancestral nuclide.
When a value of fj = 1 is given, it implies that the radionuclide
passes directly from the stomach to body fluids and does not pass
through other sections of the GI tract.
TABLE 2.5. Mathematical model used to describe the kinetics
of radionuclides in the gastrointestinal tract as
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a) Radionuclide Transport in the GI Tract: Consider the ingestion of
unit activity of a radionuclide at time t = 0. For this parent
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radionuclide, the time dependent activity in different sections of the








dT~ _ (XR + XSI + N^W* + AST "ST^ • (251 )
dquLiCt)
~
"dl " <\jLI + V qULI (t > + XSI %I^ < 2 - 52 )
dq
LLlit )







ls the rate of transfer of activity to the body
fluids from the small intestine.
A similar set of equations may be written for the radioactive
progeny. Solution of these equations can then be used in calculating
the number of transformations in each section of the GI tract.
Approximate expressions for numbers of transformations of the parent
and daughters in the various sections of the tract, following ingestion
of unit activity, is given in Tables 2.6 and 2.7 respectively. The
approximation is that the residence times are short in comparison to
the 50 year dose-evaluation time. These values should, of course, be
multiplied by the corresponding branching ratio of the radionuclide.
c
,0
TABLE 2.6. Approximate expressions for the number of transformations
of the parent in the various regions of the gastro-
intestinal tract following ingestion of 1 Bq of activity























TABLE 2.7. Approximate expressions for the number of transformations of
a radioactive daughter in the various sections of the GI
tract. A^, Agj, A^, A^ are the number of
transformations of the parent in the various regions of the
tract. X^ is the radiological decay constant of the
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b) Inhaled Radionuclides: In case of inhaled radionuclides, the
radioactive material is translocated from the various subcompartments
of the lung to the GI tract. The total activity transferred is
different for different nuclides and is given by fjL for species k. In
case of the parent, the number of transformations in the various
sections of the GI tract can simply be found by multiplying the
expressions in Table 2.6 by f^ (k = 1 for parent). However, in case
of the radioactive daughters, the expressions in Table 2.7 cannot be
used, since each daughter may be deposited initially in the GI tract in
different amounts, i.e.. f^ is different, and the immediate parent may
decay into the daughter in the sections of the tract.
For this different set of differential equations for activity in
the GI tract, compared to the ones in the case of ingestion, the number
of transformations, derived in the pattern described in the transfer
compartment, results in








where G is the index for the different sections of the tract
i.e., ST, SI, ULI. and LLI.
T is, of course, the 50 year period.
A
G is the clearance constant corresponding to the section
of the GI tract. For example, in case of the stomach,
*G
=






j is In the index of the radioactive progeny of the
parent, and
qG1 (0) is the total activity deposited instantaneously at time
t = 0.
The last term is given by the following expression
(60y
"Gi {())
= Vl.l J Vl,i (t) dt " (255 )
where G-l represents the compartment immediately preceding the one





IV qG-l.I (tH * B i ' (256 )
Therefore,
"Gi' ' =XG-l,i Vl.i^i • (2-57)
U
G-l,i is the number °f transformations of species i in the preceding
compartment. For example, in the case of calculation of the number of





2.2.6 Activity translocated to the transfer compartment f 1 :
This quantity was assumed to be known in the calculation of number
of transformations in the transfer compartment. After the discussion
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of the respiratory and the gastrointestinal system, we are now in a
position to calculate this quantity.
a) Ingestion: In the case of ingestion of radionuclides, the total
activity of species i translocated to the transfer compartment from the
small intestine, per unit activity ingested, i is given by,
f
T " J ^F qSI^) dt ' (2-58)
f
T = ^F USI • (2-59)
where U
gI
is given in Tables 2.6 and 2.7 for the parent and the
daughters respectively.
If the fraction of the stable element reaching the body fluids f
is 1, then the translocation is considered to be directly from the
stomach. In this case,
fT
= X
ST UST ' (2-60)
b) Inhalation: In case of inhalation, there are two pathways to the
body fluid compartment. One is directly from the different
compartments of the respiratory system and the other is indirectly
through the material deposited in the GI tract from the respiratory
system. Hence, the total initial activity f* of species i deposited in
the transfer compartment is given by
55
4 = f + 1BFDIR *GI *bf U!SI (2.61)
where Bj is the branching ratio of species i
,
f
BFDIR is the total activity of inhaled radionuclide i
transferred directly to the body fluid compartment, which
is given by equation (2.37), and
f
GI
is the total activity translocated
gastrointestinal tract, given by equation (2.38).








2.2.7 Source organ as bone:
According to the ICRP model, the transformations in the cortical
and trabecular bone are taken as a fraction of the transformations in
the mineral bone calculated by the methods described earlier for any
general source organ.
i) For the parent radionuclide assumed to be on bone surface,
trabecular = "cortical = 05 "mineral bone for any sPecies i
including the radioactive progeny.
ii) For the parent radionuclide assumed to be uniformly
distributed throughout the volume of mineral bone,
"trabecular = °' 2 "mineral bone' and "cortical = ' S
il bone for ^y sPecles i-
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2.2.8 Three compartment model for Iodine:
Iodine and all its radioactive isotopes require an exception to
the treatment described for all other radionuclides. The metabolic
model proposed for iodine by the ICRP is shown in Fig. 2.6. The model
consists of three compartments. Since the value of f = 1 for isotopes
of iodine, the material is translocated from the stomach to the body
fluids.
Of iodine entering the body fluid compartment, a fraction 0.3 is
assumed to be translocated to the thyroid while the remainder is
assumed to go directly to excretion. Iodine in the thyroid is assumed














FIG. 2.6. Mathematical model proposed by the
ICRP-30 for radioactive iodine.
57
from the gland in the form of organic iodine. Organic iodine is
assumed to be uniformly distributed among all organs and tissues of the
body other than the thyroid and to be retained there with a biological
half-life of 12 days. One-tenth of this organic iodine is assumed to
go directly to faecal excretion and the rest is assumed to be returned
to the transfer compartment as inorganic iodine.
The time-dependent activity of the nuclide in the three
compartments in accordance with Fig. 2.6 is given by the following
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Indices SO, T, and TH represent tissue sources, body fluid, and thyroid
respectively. Taking the Laplace transform of the above equations, we
obtain
qT.i (s) = [s + (^ + X.)] • (2-66)








Since we are interested in the number of transformations in each of the
compartments, which is the 50 year integral of the activities, we can
use the final value theorem as follows:
Let F(t) =
J
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where H_, is the mass of thyroid.
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3.0 DOCUMENTATION FOR "DOSE FORTRAN"
3.1 OBJECTIVE
"DOSE FORTRAN" is a software package, written in FORTRAN-77, that
implements the methods expounded in Part 1 of Publication 30 of the
International Commission on Radiological Protection (ICRP) to calculate
committed dose equivalents from an internal radionuclide to organs and
tissues of an adult "reference man" (as described in ICRP Publication
23). The program can consider any of the three major modes of intake
of a radionuclide, namely, ingestion, inhalation, or submersion in a
cloud of inert radioactive gas or elemental tritium. Specifically, the
program can calculate the following:
i) Specific committed dose equivalent HFIFTY (Sv/Bq) in 19
target organs,
ii) Weighted committed dose equivalent WDOSE (Sv/Bq) in selected
target organs,
ill) Annual limit of intake ALI (Bq) of the radionuclide,
iv) Derived air concentration DAC (Bq/m3 ) of the radionuclide in
case of inhalation or submersion, and
v) Specific effective energies in a table for 17 source and 19
target organs.
A list of the source and target organs along with the masses in
reference man is given in Table 3.1.
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TABLE 3.1 Masses of organs and tissues of "Reference Man" in this
program.
No. Source Organs Mass (g) No. Target Organs Mass (g)
1. Bladder content 200.00 1. Lungs 999.00
2. Stomach content 250.00 2. Thyroid 19.60
3. SI content 400.00 3. Testes 37.10
4. ULI content 220.00 4. Ovaries 8.27
b. LLI content 135.00 5. Red marrow 1500.00
b. Kidneys 310.00 6. Stomach wall 150.00
7. Liver 1800.00 7. SI + contents 1040.00
8. Lungs 1000.00 8. ULI wall 209.00
9. Muscle 48200.00 9. LLI wall 160.00
lu. Ovaries 11.00 10. Liver 1810.00
11. Pancreas 100.00 11. Kidneys 284
. 00
12. Trabecular Bone 1000.00 12. Bladder wall 45.10U. Skin 2600.00 13. Muscle 48200.00
14. Spleen 180.00 14. Bone surface cells 10500.00
15. Testes 35.00 15. Skin 2830.00
lb. Thyroid 20.00 16. Spleen 174.00
1/. Total body 70000.00 17. Uterus 65 40
is. Cortical Bone 4000.00 18. Pancreas 60.30
19. Total body 69900.00
3.2 REQUIREMENTS FOR EXECUTION
Some text files of auxiliary subroutines need to be linked to the
central program "DOSE FORTRAN" for its execution. The subroutines
(explained later) are as follows:
i) DECAY1 FORTRAN,
ii) AT0MN0 FORTRAN,





vii) INGEST, INHALE, OR SUBMER FORTRAN,
viii) PCLASS FORTRAN in case of inhalation,














xxiii) RESULT FORTRAN, and
xxiv) FLOW FORTRAN
The directly accessed data files for decay schemes of
radionuclides, number of transformations for radioactive alkaline
earths, dose equivalent rates in body tissues from; submersion, absorbed
fractions of photon energies in organs, retention fractions of nuclides
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in source organs, and the fractional transfer of the nuclides to the
body fluid compartment are:













xiv) LIST FILE, and
xv) NOBLE FILE
3.3 EXECUTION OF THE PROGRAM
This program was written on the IBM Mainframe computer at Kansas
State University. Conversational Monitor System (CMS) is the operating
system used there to run under global control program (CP) which
handles the resources of the mainframe computer. A feature of the CMS
is the EXEC processor. A CMS EXEC processor is a CMS file that
6-4
contains executable statements. Hence, In this case, the "DOSE EXEC"
file contains statements to retrieve, expand, and load the compiled
text files of all supporting subroutines and the main program, thus
functioning as a catalogued procedure for execution of the program.
With the file on "A" (temporary) disk, one can invoke its execution by
entering the word "DOSE".
The main program in this package is "DOSE FORTRAN" which calls
other subroutines to perform certain calculations. What follows are
descriptions of the function and role of each subroutine as it is
addressed by the calling program in execution. All three modes of
exposure are considered. A summary of the program flow is illustrated
in Fig. 3.1. We begin with the central code.
3.4 DOSE FORTRAN
This is an interactive, user-friendly code which prompts the user
to enter some basic information for its execution. To avoid confusion,
an explanation of the screen-by-screen sequence in actual execution of
the program is given below:
i) First and Second Screen: The first screen orients the user
with the name of the program as well as the author, with the time and
place of documentation of the code. The second screen explains the
scope of the program.
ii) Third Screen: There are three ways to provide the
preliminary data required for a calculation. They are: 1) data input
from the keyboard, 2) data input from a file, or 3) preparation of a
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DOSE (Central Code).
DECAY1 (finds half-lives and names of the given isotope and
its daughters by reading data files: ISOTIPS, ISOTOPE, and DAUTER
* ATOMNO (provides atomic number of the prescribed radionuclide).
ICLASS
( in case of
inhalation)
PCLASS (describes pulmonary clearance
classification of inorganic compounds).
* F1VALUE FRAC (retrieves fractional transfer of the stable
element to the body fluids from data file: BFFRAC)
.
FACTOR
(generates matrix of specific
effective energy for the nuclide)
SPEFF (see *)
ICRP (calls appropriate subroutines for dose committment
n ±\
INGEST (calculates specific committed dose equivalent
in target organs from the ingested radionuclide).
* DECAY1
THALF (provides half-life of clearance from body
fluid compartment).
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REFMAN (furnishes mass of the target organ in
"reference man").
If the nuclide is an alkaline earth or one of the
exceptions, number of transformations in a source
organ is read from data files: INDEXO, EXCEPT.
TFRAC (retrieves retention fractions and biological
half-lives of the nuclide in source organs from data
file: RETENT).
» II (converts source organ name into an integer).
SOURCE (provides mass of the source organ)
.
TRNSFM (calculates source-organ transformations).
UXP (checks argument of an exponential function
for under flow error).
* FLOW (checks overflow and underflow error).
* SPEFF (calculates specific effective energy
deposited in a target organ due to a source organ).
DECAY (provides the decay scheme of the nuclide
by reading data files: ISOTOPE, ISOTIPS ALPHA
BETA, POSITRN, ELECTRN, and PHOTON)
T
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YERROR (error handling subroutine for
DECAY FORTRAN).
INTRPT (retrieves values of absorbed fraction
of energy by reading data file: ABSFRAC)
.
ENERGY (interpolates values of absorbed
fraction for a given energy)
.
INHALE (generates a specific committed dose equivalent
vector in target organs due to inhaled radionuclides).
* DECAY 1
RESPIR (gives fraction and clearance rates for




If the nuclide is an alkaline earth or one of the
exceptions, number of transformations in a source











SUBMER (retrieves dose equivalent rates in body tissues
and derived air concentration for submersion, from data
files: LIST and NOBLE)
RESULT (evaluates weighted committed dose equivalent using
the 10% exclusion principle, the DAC, and the ALI if the
mode of intake is inhalation or ingestion)
FIG. 3.1. Points of call of subroutines in
execution of the program.
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data input file. The user is queried in this screen to opt for one of
three choices. The choice is stored as an integer variable, NDATA
which may have a value of 0, 1, or 2. Under choices 1 or 2, an error
in program execution results in program termination.
If the user selects the option of data input from an already
prepared file (NDATA = 1) residing on the temporary disk (A disk), the
fourth screen inquires the name of the input file. The name is saved
as a character variable FFILE(3). Since the CMS environment allows
only 7 characters for the name of a file, a longer name is therefore
truncated to 7 characters. The file is then opened and, according to
the data read, the appropriate course of action is taken.
Also, if the user wishes to prepare a data input file, (NDATA=2)
the fourth screen asks for a name that can be associated to such a file
[FFILE(3)] and subsequent screens, then prompt the user for data from
the keyboard which is then entered in the file. These screens for
input data collection are also displayed in the event the user chooses
the first option (NDATA=0) to enter data directly from the keyboard.
These screens are explained below.
iii) Fourth screen: The user is prompted to enter a radionuclide
identification according to displayed example of cesium-137 as CS-137.
This is stored as the character variable WORD. If there is a mistake
in the format of entry, the screen is displayed again until the entry
is corrected. The screen also informs the user, that to begin
termination of the program at this point, the return key may be
pressed. When the return key is pressed, the user is questioned again
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to confirm if termination is really what is desired. Of course, an
assent results in the termination and a dissent shows the fourth screen
again.
At this point, with the nuclide identified, a subroutine DECAY1 is




The objective of this subroutine is to access the half-lives and
names of the daughters of the radionuclide under consideration. The
data files used for this purpose are "ISOTIPS", "ISOTOPE", and DAUTER".
The arguments of the subroutine are:
WORD
- Identification of the entered nuclide.
This is a vector of maximum length 50. It stores half
lives of the given radioisotope and its daughters in
sequential order of decay.
This is a character vector of length 50. It saves units
of half-lives of nuclides in RHALF as a character, e.g.,
S, M, H, D, or Y for seconds, minutes, hours, days, and
years respectively.
This is a vector of branching ratios of the given
isotope (BRA(1)=1). and its daughters. Its maximum
length is 50.
This is a vector of length 50. Its elements are
characters, each of length 8. It stores identities
(i.e., symbol-atomic weight, e.g., CS-137) of given




NO - This is an integer which stands for the number of
daughters plus one (for the given isotope).
The given identification WORD of the nuclide is used to find a match in
the sequentially accessed data file "ISOTIPS". Once a match occurs, a
pointer or record number is read, which is then used to directly access
the decay scheme from data file "ISOTOPE". The variables read are:
ERT - Name of the isotope.
JO - Atomic weight of the isotope.
J - Atomic number of the isotope.
B - Half life of the isotope.
- Half life units (S, M. H. D, or Y).
K - Number of radioactive daughters.
L - Pointer or record no. for first daughter.
M - Number of alpha particles.
N - Pointer or record no. of first alpha particle.
11 - Number of beta particles.
12 - Pointer to first beta-particle record.
13 - Number of positrons.
14 - Pointer to first positron record.
15 - Number of electrons.
16 - Pointer to first electron record.
17 - Number of photons.
18 - Pointer to first photon record.
The pointer to the first daughter is used to directly access the
branching ratio of the daughter from the data file "DAUTER". The
variables read are:
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19 - Pointer to daughter isotope. This record number could
now be used to access the decay scheme of the daughter
from "ISOTOPE", and so on.
YIELD - Branching ratio of the daughter.
The decay mode considered in this program is
A -* B -> C -» ...
Hence, if a nuclide decays into more than one daughter, that is, if
A -» Bl, A -» B2, A -» B3 etc.
then the pointer and yield of only the daughter with the highest
branching ratio is saved.
An inability to read any of the data files results in display of
an appropriate error message and return to the fourth screen of the
main program.
The half lives of the parent and the radioactive progeny are first
converted into days if they are in any other units. If a daughter is a
radioactive noble gas, then the daughter and its subsequent progeny are
neglected and assumed to escape from the body. If the ancestral
nuclide entered in the fourth screen is a noble gas. then an integer
variable OPT is assigned a value of 3. and the following queries are
skipped to the output screen, which asks for the output file name.
iv) Fifth Screen: The user is prompted to enter the sex of the
exposed subject as either M or F. Character variable SEX stores the
entry. An incorrect entry will again lead to same screen display until
it is corrected.
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v) Sixth Screen: The user is questioned whether or not, a full
table of specific effective energies (S-matrix) of the nuclide for 17
source and 19 target organs is desired. To answer yes or no, the user
is asked to enter the integer 1 or 2 respectively. Of course, an error
is again handled with repeated displays of the same screen until proper
entry is made.
If the user opts to see the table, the following screens are
shown:
vi) Seventh Screen: It asks for the file name to which the
matrix can be written. This name is stored as a character variable
FFILE(l).
vii) Eight Screen: There are three units, i.e.. MeV/g, rad/micro
Ci.h. and mSv/GBq.h in which the S-matrix can be seen. The user is
asked to choose one of them as an integer variable NU with a value of
1. 2, or 3.
If from the earlier call of subroutine "DECAY1" it is found that
the radionuclide has daughters, then the ninth screen is as follows:
vii) Ninth Screen: The daughters of the nuclide are shown, and
the user is prompted to enter integer 1 or 2 expressing yes or no to
whether the S-tables of the daughters are desired. This expression is
saved as an integer variable MON.
ix) Tenth Screen: At this point, the user is asked to choose one
of the following options:
1) Continue data entry for calculation of dose committments.
2) Conclude data entry and STOP, or
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3) Proceed with calculations of S-matrix only.
Another choice is added if the user chooses the third option of
preparation of a data input file in the third screen. It is:
4) Continue data entry for calculation of S-matrix only.
The choice is saved as an integer variable INRE with a value of 1, 2,
3, or 4 respectively. Of course, selection of option (1) here, would
result in end of the program. If the user chooses to enter data from
the keyboard in the third screen, and option number (3) here, then the
query screens end, and the program proceeds with calculation of the
S-matrix. However, if the choice was preparation of data input file in
the third screen, then a selection of option (3) or (4) here, would
first lead to writing of the data obtained from screen queries onto the
file named by the user. After that, option (4) would display the
fourth screen again, continuing the data entry process, while option
(3) would read the written data and advance with calculation of the
S-matrix, informing the user with a display of which calculation is
being performed.
Now. regardless of the choice of either data entry from keyboard
or preparation of an input file in the third screen, if option (1) is
selected here, then the screen query continues as follows:
x) Eleventh Screen: The user is prompted to choose a mode of
intake of the radionuclide by entering either 1 or 2 for ingestion or
inhalation respectively. Integer variable OPT stores the selection.
xi) Twelfth Screen: The user is inquired if the transformations
of the nuclide in source organs are fancied. The response can be
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expressed as 1 or 2 for yes or no which is stored as integer variable
MAIS. If the answer is yes, then the following two screens would ask
for the name of a file, saved as character variable FFILE(4). to which
the transformations can be written, and whether the transformations of
the daughters (if any) are also desired. This response is stored as an
integer variable ISAY which has a value of 1 or 2 for yes or no
respectively.
3.4.2 ATOHNO FORTRAN:
At this point, this subroutine is called to assign an atomic
number to the given radionuclide by comparing its symbol to the 103 in
the program. A match results in an assignment of atomic number, or
else, the user is asked through an error message to check the symbol
and try again. The arguments of this subroutine are:
SYM
- First two characters of the variable WORD entered by the
user which describes the symbol of the radionuclide.
If. for instance in the case of phosphorus, the symbol
is represented by only one character "P", then the
second character is "-".
This is the assigned atomic number by the subroutine and
is naturally, an integer variable.
If the mode of intake was chosen to be inhalation in the eleventh
screen, then the following subroutine is called.
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3.4.3 ICLASS FORTRAN:
This subroutine provides the inhalation class of the given
radionuclide. It first displays a laconic definition of the three
classes, D, W, and Y, and then, questions the user if a detailed
explanation aiding in selection of the pulmonary clearance
classification is wished. If the user acquiesces, then another
subroutine "PCLASS FORTRAN" is called, and after that the user is
prompted to enter the inhalation class of the given radionuclide, which
is the argument CLASS of the subroutine.
3.4.4 PCLASS FORTRAN:
This is an information file. It displays pulmonary clearance
categories of different inorganic compounds which may aid the user in
determining the inhalation class of the radionuclide. Its argument
IWISH is merely the selection integer 1 indicating acceptance to view
the file.
The next step is the determination of fractional transfer of the
element from the GI system to the body fluids. For this purpose,
subroutine F1VALU is called.
3.4.5 F1VALU FORTRAN:
An auxiliary function subprogram FRAC FORTRAN is required. The
arguments of this subroutine are:
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KZ - Integer variable describing the atomic number of the
given radionuclide, and
Fl - The fractional transfer of the stable element from the
GI system to the body fluids.
3.4.6. FRAC FORTRAN:
This function subprogram retrieves the fractional transfer Fl of
the stable element to the body fluid compartment from data file
"BFFRAC". Since the fraction may differ according to the inhalation
class of the nuclide, the user is asked to enter the appropriate value
from choices displayed on screen. Of course, a mistake in reading of
data file is handled through an error message, suggested corrective
action, and return to the fourth screen. The arguments of this
subroutine are the atomic number of the nuclide KZ and the integer
ITRACK, which is given a positive value in case of an error.
Again, if the mode of intake was chosen to be inhalation, the
following screen is flashed.
xii) AMAD Screen: The user is inquired if the aerodynamic
diameter (AMAD) for inhalation, is 1 micrometer. An affirmation or
negation assigns a value of 1 or 2 respectively to integer variable
LOT. In the event of a negative response, the user is prompted to
enter the value of AMAD in micrometers between 0.1 and 20. which is
stored as variable AMAD.
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With these basic input values, the execution of "DOSE FORTRAN" can
be initiated with call to appropriate subroutines. But before that,
the name for output table for dose committment results is needed.
xiii) Output Screen: A filename for output table is requested
and a character variable FFILE(2) is assigned the name.
If the parent nuclide is a radioactive noble gas then at this
point, the subroutine "ICRP" is called, and the following steps are
ignored.
If the user is preparing a data input file, then at this stage a
selection must be made from the following three choices:
1) Conclude data entry and STOP,
2) Continue data entry, or
3) Proceed with calculations.
Integer variable MORE is assigned a value of 0, 1, or 2 respectively
according to choices described above. Except for option (1), choice of
any other option would lead to writing of the data onto the named file.
After that, option (2) would return to the fourth screen while option
(3) would read the written data and progress with execution of "DOSE
FORTRAN". To facilitate comprehension of the central code's working,
most of the subroutines are explained in sequence of calling.
The step premiere in execution is S-matrix generation and printing
of its results if, a positive response was given in sixth screen to
view the S-table. A loop is initiated to do the same for the daughters
if there are any, and if the user wishes to see their S-tables too.
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m3.4.7. FACTOR FORTRAN:
As mentioned earlier, this subroutine is called if a full specific
effective energy (SEE) table (S-matrix) is requested in the sixth
screen prompt of the main program. While this subroutine is generating
the matrix, the main program flashes the message that it is calculating
the S-matrix of the radionuclide transferred as an argument, and that
the results are stored in the file named by the user. The arguments of
this subroutine are:
WORD
- This is a character variable of length 8 which describes
the parent radionuclide or its daughters found by the
call of DECAY1 in the main program.
This is also a character variable. It has a length of 16
bytes, and it particularizes the choice of the user to
see the SEE table in any of three sets of units, namely
MeV/g, rad/micro Ci.h, or mSv/GBq.h.
This is the matrix of SEE values. Its size is 19 target
organs in one dimension and 18 source organs in the
other.
This is an integer variable which represents the option
chosen in the main program of entering the data directly
from keyboard or preparing a data input file.
This character variable of length 8 identifies the
parent radionuclide as entered by the user in the main
program.
This variable represents the half-life of the parent






The SFACT matrix is generated with uses of subroutines such as
"DECAY FORTRAN" for the decay scheme of the radionuclide, and the
subroutine "SPEFF FORTRAN", which in turn, calls other subroutines for
effective energy absorbed in a tissue or organ. A detailed account of
these subroutines follows later. The variable NDATA aids in properly
redirecting the subroutine to the fourth screen in the main program if
it has a value equal to zero or stopping the program if it has a value
equal to one, in case of an error.
After generation of SEE values, stored in matrix SFACT, the main
program writes these values as a table in the file FFILE(l) named by
the user. If the mode of entry of data was keyboard, then these
results are also written on screen for user's convenience.
At this juncture, if the user has prepared a data input file or
had one on the A disk before the commencement of the program, i.e.. if
NDATA has a value of either 1 or 2 and. if a selection was made to
proceed with calculations (only the S-matrix, INRE=3) in the screen
prompt number 10, then the program will end here. However, if variable
INRE has a value of 4 representing the wish to generate S-matrices of
other nuclides as well, then the program would return to reading the
data in the input file and will proceed according to the input. On the
other hand, if the user were using the keyboard as mode of data entry,
i.e., NDATA = 0. and if INRE = 3, the program would not end but could
revert to the fourth screen allowing the user to end it personally or
continue for any other nuclide.
S2
Excluding the redirections in the above cases, the program will





This subroutine calls other appropriate subroutines for dose
committments according to the mode of intake. The arguments of this
subroutine are:
INTAKE
- Integer variable with a value of either 1. 2. or 3
representing the mode of intake as ingestion.
inhalation, or submersion respectively.
Name of the given isotope, e.g., IN-113M a character
variable.
Sex of the subject as either M or F, a character
variable.
Fractional transfer of stable element from the GI system
to the body fluids, a real variable.
In case of inhalation, pulmonary uptake classification
of the nuclide, a character variable.
This is a real variable describing the activity median
aerodynamic diameter of the nuclide in case of
inhalation.
Mass of whole body (70000 g) minus the masses of those
organs and tissues mentioned in the metabolic model of
ICRP-30 for a particular radionuclide.










HFIFTY - Specific committed dose equivalent to target organ or
tissue. This is a vector of length 24.
US(I.J) - Matrix of transformations of nuclide I in source organ
J.
An integer variable describing the options chosen in the
main program of mode of data entry.
In case of submersion, this real variable represents
derived air concentration for an inert radioactive gas.
This real variable describes derived air concentration
for an inert radioactive gas if it is determined by
consideration of non-stochastic effects in case of
submersion.
This integer variable gives the organ or tissue number
when the derived air concentration is determined by
non-stochastic effects in case of submersion.
This subroutine merely calls subroutines "INGEST", "INHALE", or
"SUBMER" according to the mode of intake transferred in the argument
INTAKE as 1. 2, or 3 respectively. However, in case of inhalation, if
the AMAD is not equal to 1 micrometer, then it also calculates the
specific committed dose corresponding to the given AMAD from the 1
micrometer specific committed dose by law of proportions. The variable
NDATA helps in properly re-routing the subroutine in case of an error.
The three important subroutines mentioned above are described below.
ORGAN
3.4.9 INHALE FORTRAN:
This subroutine is called if the user chooses inhalation as the
mode of intake. Its purpose is to generate a vector of specific
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committed dose equivalents (Sv/Bq) in target organs or tissues due to
inhaled radionuclides. The arguments of this subroutine are:
WORD - This is a character variable of length 8 which identifies
the given radionuclide.
KZ - The atomic number of the nuclide.
SEX - This is a character variable of length 1. and is either M
or F for male or female respectively.
HFIFTY(24) - This is a vector of length 24. The 19 elements of this
vector represent the specific committed dose equivalents
in 19 target organs or tissues.
FNP(20)
- This is a vector of length 20. The 19 elements represent
the fractions of the committed dose equivalent in the
reference target tissue resulting from deposition in the
naso-pharyngeal (N-P) compartment of the lung model.
FTB(20) - The 19 elements of this 20 element vector represent the
fractions of committed dose equivalent in the target
tissue resulting from deposition in the tracheo-bronchial
compartment (T-B) of the model.
FP(20) - The fractions of committed dose equivalent in the target
tissue resulting from deposition in the pulmonary (P)
region of the lung model are the first 19 elements of this
20 element vector.
ROB - This is a variable which represents the mass of whole body
(70000 g) minus the masses of those organs and tissues
mentioned in the metabolic model of ICRP-30 for a
particular radionuclide. These organs are named in the
data file "RETENT".
CLASS - This is a character variable of length 1 representing the
pulmonary uptake classification of the radionuclide.
Fl - Fractional transfer of the stable element from the GI
system to the body fluids.
US(I,J) - Matrix of transformations of nuclide I in source organ J.
A flowchart of this subroutine is shown in Fig. 3.2. This
subroutine is initiated by calling the subroutine "DECAY1" to find the
daughters of the radionuclide. Details of this subroutine were given
earlier. After accession of the decay scheme from the above
subroutine, half lives of parent and daughters, if not in units of
days, are converted into days and then radiological constants are
calculated. If the daughter is a radioactive inert gas, then that
nuclide and its subsequent progeny are neglected and are assumed to
escape out of the body.
With the use of the fraction of stable element Fl the fraction of
the radioactive parent and its daughters to the body fluid compartment
via the GI tract is calculated. This is saved in a vector of maximum
length 50, named FBF.
The lung model of ICRP-30. described in a previous chapter,
considers fractions of inhaled material to be deposited in three
respiratory regions, the naso-pharyngeal passage (N-P) , the trachea and
bronchial tree (T-B). and the pulmonary region (P), the balance being
the fraction exhaled. Initially, it is assumed that the activity
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SUBROUTINE INHALE (WORK, KZ, SEX, CLASS,
Fl, HFIFTY, FNP, FTB. FP, ROB, US, *)
CALL DECAY1 (WORD, RHALF, ULIFE, BRA, RADIO, NO, *12)
Purpose: Finds half-lives and names of the given
isotope and its daughters.
Convert half-lives into days and calculate radiological
constants of parent and its daughters.
Evaluate fraction of inhaled radionuclide transferred
to the body fluid compartment via the GI tract, FBF.
Assuming the AMAD = lum, assign values to fractions
of inhaled material deposited in three respiratory
regions, the balance being the fraction exhaled.
CALL RESPIR (CLASS. FA. FB. FC. FD. ...)
Purpose: Retrieve fraction and clearance rates for
transfer between compartments of the lung.
Calculate transformations in each sub-compartment of
the lung. Use these results to find fraction of
parent and its daughters going directly to body fluids
FBFDIR, fraction going directly to GI tract FGI, and
total initial activity in the body fluid compartment
FT.
S7
Is the parent nuclide an alkaline earth (Ba, Ca, Ra,
Sr) or any of the exceptions, i.e., Tc, Re Te-131
Te-132. Te-131m, Te-133, Te-133m, Te-134, or C?
No 1
Yes
TSAVE = THALF (KZ)
Purpose: Determine rate of loss of stable element
from the body fluid compartment
Target Organ Loop
Do 50 KTARG = 1, 19
SEX is female
and KTARG = 3
SEX is male
and KTARG = 4
TMASS = REFMAN (KTARG)
Purpose: Retreive mass of
the target organ
Source Organ Loop
Do 55 JSORCE = 17,1,-1
SEX is female
and JSORCE = 15
SEX is male
and JSORCE =10
Is the parent radionuclide an alkaline
earth or one of exceptions?
No
Is the source organ lung,
or a section of the GI
tract, i.e., is JSORCE =










CALL TFRAC (KZ. F2, BHALF, JSORCE. SMASS, *12)
Purpose: Find retention fractions and biolog-
ical half-lives in source organs
No unique retention
fraction
Is KTARG > 1?
No
Yes
Is JSORCE = 8?
Yes
r
















Loop to calculate (SEE * US) from contribution of
parents and daughters























organ, KTARG due to
source JSORCE
Calculate (SEE * US), and the
contribution to committed dose
equivalent in target tissue
from each source and each
nuclide as a result of deposi-
tion in the three regions of
lung, i.e.. TNP(JSORCE, I),




of committed dose equivalent In target
tissue resulting from deposition in
compartments of lung, i.e., FNP (KTARG)
FTB (KTARG), and FP (KTARG).
End of loop
RETURN
FIG. 3.2 Flowchart of "INHAI.E FORTRAN"
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median aerodynamic diameter (AMAD) of the nuclide inhaled is 1
micrometer, and the corresponding deposition fractions in each
compartment of the lung are utilized for calculation of specific
committed dose equivalent. The reason for this assumption is that,
even in alternate cases, when the AMAD is not 1 urn, values of HFIFTY
for 1 urn AMAD are used to estimate HFIFTY in those cases, using the law
of proportions.
The clearance rates and fractions in each sub-compartment of the
three major divisions of the lung is first initialized as zero and
then, a subroutine "RESPIR" is called for their values.
3.4.10 RESPIR FORTRAN:
This subroutine merely provides the fraction and clearance rates
for transfer of nuclide between compartments of the lung according to
the inhalation class of the nuclide. The arguments are:
CLASS
- Character variable of length 1 describing inhalation
class of the nuclide.
FA
- Fraction of material deposited in the body fluid
compartment from the nasal passage region (N-P)
.
FB
- Fraction deposited in the GI tract from the nasal
passage.
FC
- Fraction deposited in the body fluid compartment from
the trachea and bronchial tree region (T-B)
FD
- Fraction deposited in the GI tract from the trachea and













- Fraction deposited in the body fluids from the pulmonary
region (P).
Fraction transferred to the T-B region from the P region
with a half-life.
Fraction transferred to the T-B region from the P region
with a different half life.
Fraction transferred to the lymphatic system (L) from
the P region.
Fraction deposited in the body fluids from the L region
with a half life.
Clearance rate of material from the N-P to the body
fluids which is found from dividing In 2 by the removal
half time (in days) in each compartment.
Clearance rate of material from the N-P to the CI tract.
Clearance rate of material from the T-B to the body
fluids.
Clearance rate of material from the T-B to the GI tract.
Clearance rate of material from the P to the body
fluids.
CLF
- Clearance rate of material from the P to the T-B region.
CLG
- Clearance rate of material from the P to the T-B region.
CLH
- Clearance rate of material from the P to the L region.
CLI
- Clearance rate of material from the L to the body
fluids.
CLJ Clearance rate of material from the L to the body
fluids.
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With the use of these fractions and clearance rates.
transformations in various sub-compartments of the lung for the parent
and its daughters are assessed, and these transformations allow
calculation of the fraction of the inhaled radionuclide and its
daughters transferred directly to the body fluid compartment, and the
fraction transferred to the GI tract. The former is saved as a vector
FBFDIR, and the latter as a vector FGI. Both vectors are of maximum
length 50. These results aid in determining the total initial
activities of the given radionuclide and its daughters in the body
fluid or transfer compartment. The activities are saved as a vector FT
( length = 50).
Since different elements have different clearance times from the
body fluid compartment, function subprogram "THALF" is called to
determine the suitable half-life of clearance. However, if the parent
nuclide is an alkaline earth (Ba. Ca, Ra, Sr) or one of the exception
nuclides, i.e.. Tc, Re, Te-131. Te-132, Te-131m. Te-133. Te-133m,
Te-134, or C, this step is skipped to the target organ loop.
3.4.11 THALF FORTRAN:
This function subprogram uses the argument KZ, the atomic number
of the nuclide, to provide the half-life of clearance from the transfer
compartment. The daughters are assumed to have the same half-life of
clearance as the parent.
9-1
With this half-life of clearance, the rate of loss of the stable
element from the transfer compartment TCONST, is calculated. After
that, the source-organ transformations in each source organ for the
parent and its daughters are initialized to zero, and then, an outer
loop to calculate HFIFTY in each target organ, is commenced. The
target organs ovaries and testes are skipped if the sex of the subject
is male or female respectively. To determine the mass of each target
organ, a function subprogram named "REFMAN" is called.
3.4.12 REFMAN FORTRAN:
This function subprogram uses the target number as the argument
and returns the mass as shown in Table 3.1.
Some variables which will be described later as they are used, are
initialized to zero at this point. For each target organ in the outer
loop, a nested loop to add contribution from all source organs is
initiated. As in the target organ loop, if the subject is male,
ovaries are omitted as source organ and similarly testes are ignored if
the subject is female.
At this juncture, if the ancestral nuclide inhaled is an alkaline
earth or one of the exceptions described above, the number of
transformations in each source organ are not calculated but retrieved
from data files. The first letter of the nuclide symbol is used to
search for a match in file "INDEXI". Once a match occurs, the values
of Fl (described above) and the class of the nuclide are compared.
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Beside each value of Fl and class, is a record number, which is read on
proper match. This record number is a pointer for file "EXCEPT".
Using this record number, the numbers of transformations for different
source organs are read from this file.
In the case of nuclides technetium (Tc) and rhenium (Re), an
anomaly exists. The ICRP 30 describes transformations in stomach wall
as well as stomach content as source organs. However, in this report
both are summed and treated as only one source organ, the stomach
content. Similarly, the ICRP-30 also gives specific effective energy
values (described later) for both source organs. Since this program
cannot generate specific affective energy values for stomach wall as
source organ, the summed value of transformations is multiplied by the
SEE values for stomach content as source organ. Although this
treatment does not affect the results of dose committment in other
target organs appreciably, it does lead to underestimation as compared
to ICRP-30 in the case of target organ stomach wall and hence, must be
used with caution.
For all other nuclides, to find the fractions of nuclide retained
in source organs as a result of transfer from the body fluid
compartment, a subroutine "TFRAC" is called. The contribution to
committed dose in organs of the GI tract and lung through this route is
minimal. Since the nuclide enters the body-fluid compartment after
passage through these organs, the major contribution is direct.




The purpose of this subroutine is to retrieve the retention
fractions F2 and the biological half-lives BHALF of the nuclide in the
source organs from data file ••RETENT". The auxiliary subroutines
needed are "II" and "SOURCE". The arguments used are:
KZ - The atomic number of the nuclide.
F2 - This describes the fraction retained in source organ
except organs of the GI tract and lung. It is a vector
of length 3 since source organs are modelled to have 3
compartments.
This vector of length 3 gives the biological half-lives
of the fractions in the source organs.
This is the source organ number as shown in Table 3.1.
This variable invokes the function subprogram "SOURCE"
to obtain the mass of the source organ, except when the
source organ is total body. In that case, if other
organs are linked with retention fractions, then this
variable is assigned a value of 70000 - (1 M ) where M
1
J j
are the masses of organs associated with different
retention fractions.
A flow diagram of this subroutine is illustrated in Fig. 3.3. A
loop is started to access retention fraction and biological half-lives
associated with source organs for a given nuclide. Variable C2
describes the source organ name. Other variables D, E, and F describe
the retention fractions in different compartments of source organ, and





the source organ name associated with retention fractions, and
biological half-lives from the data file, function subprogram "II" is
called with the source organ name C2 in alpha numeric characters as
argument. "II" converts C2 to an integer from the source list
presented in Table 3.1.
The source integer is now compared with JSORCE, the argument. If
they are equal. then the corresponding retention fractions and
biological half-lives associated with C2 are equated with F2 and BHALF
respectively. The function subprogram SOURCE is called with source
organ integer as argument. This function subprogram provides the mass
of the source organ which is equated with variable SHASS. With these
values, the subroutine "TFRAC" is returned.
If, however, the source integer linked with C2 does not match the
JSORCE, then there are two possiblities. The obvious one is that the
loop is continued until a match is found, and then the values returned,
or no match found, and values = are returned. The other route is
that if JSORCE is 17, i.e., the source organ is total body and if the
source integer corresponding to C2 is not 18, linked with "all other"
then the masses of source organs are summed, and the loop continued,
until the integer is 18, and at that time, retention fractions and
biological half-lives related to it are taken to be the ones sought.
The SMASS variable is, however, assigned a value of 70000 minus the
previous sum of source organs, rather than 70000, the mass of total
body. This mode of accession works because the records in the data
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SUBROUTINE TFRAC (KZ, F2, BHALF. JSORCE, SMASS, *)
T
Loop to access retention fractions and biological
half-lives linked with a given KZ
DO 1 I = 1
, 5
T
Read from data file "RETENT"; C2, D, E, F, G, H, B
T
IOOMP = II (C2)
Purpose: Convert the source organ name in
alphanumeric characteris to an















Is ICOMP = JSORCE?
No
Is JSORCE = 17?





Is ICOMP = 18?
1 Yes










FIG. 3.3. Flowchart of Subroutine "TFRAC FORTRAN".
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file are entered in such a way that for a given KZ, entry of "all
other" is always at the end, after specific organs.
Of course, an error in reading or accessing a data file is
disclosed by a display of appropriate message and suggested corrective
action.
If a source organ does not have a unique retention fraction, that
is, after the subroutine call, the retention fractions and biological
half-lives for that organ are zero, then the source organ is skipped
because often it will be included in the source organ total body.
Since the transformations are evaluated in the source organ, their
values remain the same for different target organs. Thus, if the
target organ number is greater than 1 in the outer loop, repeated
evaluation of source organ transformations is bypassed. Also if the
source organ is lung, the subroutine for transformations is not called.
Instead, the transformations calculated in each subcompartment earlier
are summed, except for the N-P region. This treatment, as explained in
the previous chapter, is based on the assumption that the dose received
by the nasophryngeal region for most particles sizes, is small in
comparison with the doses received by other regions and hence, can be
neglected. For all other sources, though, the subroutine "TRNSFM" is
called.
3.4.H TRNSFM FORTRAN:
This subroutine provides the source-organ transformations of the












A vector of length NO (variable dimensioning) which
describes the total initial activity of the given
radionuclide and its daughters in the transfer
compartment.
A vector of length 3, which describes retention
fractions in three compartments of the source organ.
Also a vector of length 3 which relates to the
biological half-lives of the fraction retained in source
organs
.
This is a vector of length NO which describes the
radiological constants of the parent and the daughters.
Integer variable describing number of daughters plus one
for the parent.
Branching ratio of the parent [BRA(1)=1] and Its
daughter saved as a vector of length NO.
This is a matrix of size 20 x NO. The first dimension
refers to the source integer number, and the second to
the nuclide of interest. This array describes the
transformations in a particular source organ for a
particular nuclide.
Rate of loss of stable element from the transfer
compartment.
Source integer number.







- Integer variable identifying the calling subroutine as
"INHALE" if value = 1. and "INGEST" if value = 0.
A vector of length NO, describing the fraction of the
inhaled radionuclide and its daughter transferred to the
GI tract.
Variable describing mass of the source organ except if
the source organ is total body and other organs of mass
Mi have unique retention fractions. In that event, the
variable equals 70000 - 2 H
. i'
l
A vector of length NO describing the total number of
transformations of each nuclide in rest of the body of
mass, 70000 - 2 M where M is the mass of organ i for
i
each unique retention fraction.
This is a real variable which is assigned the value
equal to 70000 - 2 M. when the source organ is total
i
body.
Atomic number of the given radionuclide.
This subroutine begins with the calculation of biological
constants BOONST from the biological half-lives in different
compartments of the source organ. Depending on the mode of intake,
i.e.. the value of IPROG, the calculations for organs of the GI tract
are directed to appropriate line numbers for the evaluation of
source-organ transformations by alternate methods.
An outer loop is initiated for the calculation of US for each




transfer to the tissue compartment, then calculation of UTJ, the vector
of length NO describing transformations of the nuclide under
consideration in the transfer compartment, is omitted. Otherwise, a
nested loop calculates UTJ for each nuclide. Another nested loop
evaluates the transformations in the three compartments of the source
organ, and adds them. Of course, the initial activity of the nuclide
in the source organ after transfer from the body fluid compartment is
first calculated within the loop. Transformation in each compartment
of the source organ is stored as a variable UJ. Use of UTJ and UJ
allows calculation of US(JSORCE. J) where J is the nuclide under
consideration.
If the source organ is total body, then the source-organ
transformations calculated are equated with UROB(J). This quantity is
associated with transformation in "rest of the body" and the
source-organ transformations used in conjunction with total body as the
source organ is over estimated by multiplying by 70000/SMASS, where
SMASS as expplined previously is 70000 -IK., M. being the mass of the
i
organ with unique retention fraction. This overestimation in case of
total body is compensated for each organ with unique retention fraction
by subtracting the quantity, M. « UR0B(J)/(7O0O0 - 2 M.) for organ i.
The outer loop for each nuclide is closed at this point and the value
of US{JSORCE,J) is returned.
As remarked earlier, for organs of the GI tract, depending on mode
of intake, there are separate blocks for calculation of US(JS0RCE, J)
,
which follows the loop described above. In the case of iodine, a
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separate three compartment model is described in the previous chapter.
Transformations in the source organs are calculated using this model.
A flow chart can be seen in Fig. 3.4.
After the determination of US, another nested loop is initiated to
calculate the product of US and specific effective energy absorbed in
the tissue for each nuclide. For this purpose, use of another function
subprogram called "SPEFF" is required.
3.4.15 SPEFF FORTRAN:
This function subprogram calculates the specific effective energy
deposited in each target organ due to each source organ. The arguments
transferred are:
WORD - Identification of the nuclide.
JSORCE - Source integer number.
KTARG - Target mass in grams.
LOOP - Integer variable which has a value of either 0, 1, or 2.
MOTS - Identification of the parent nuclide.
PLIFE - Half life of the parent in days.
At the outset, the source number is compared with the target
number according to Table 3.1. If the organs are the same, the integer
variable ICOM is assigned a value of 0, otherwise a value of 1. For
the decay scheme, a subroutine "DECAY" is called which will be
explained later. The character variable SAVE stores the identification
of the radionuclide when this function subprogram is first called, and
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SUBROUTINE TRNSFM (FT, F2, BHALF, RCONST, NO, BRA, US TCONST
JSORCE, Fl, IPRQG, FGI, SMASS, UROB, MROB, KZ)
T
Calculate biological constants, BCONST
from biological half-lives BHALF































Outer Loop to calculate US in
nuclide, j
DO 15 J = 1 , NO
Yes




DO 20 I = 1
, J
Calculate SUM for UTJ(J)
Tissue Compartment Loop
DO 65 L = 1 . 3
IS F2(L) = 0?
Yes
No
Loop for each compartment
DO 75 I = 1
, J
Calculate UJ
Calculate US (JSORCE, J), overestimate
when JSORCE = 17, else compensate
End of outer Loop
RETURN
FIG. 3.4. Flowchart of "TRNSFH FORTRAN"
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hence when it is equal to WORD, the function does not have to call
"DECAY" again. At this point, if positrons are found in the decay
scheme, corresponding annihilation photons are added to the list of
decaying photons.
There are alternate methods for calculation of SPEFF for target
organs of the GI tract, bladder, and bone. For all organs, there are
five blocks for treating particles alpha, beta, positron, electron and
photon. For target organs other than the GI tract, bladder, and bone,
in the case of charged particles, the specific absorbed fraction in the
target organ AF is zero if the source and target organs are not equal,
except in the following cases:
i) When the source organ is total body, the specific absorbed
fraction equals 1/69900.
ii) When the target organ is total body and the source organ is
bladder content, the specific absorbed fraction is equal to
45.1/(2 x 200 x 69900).
iii) When the target organ is total body and the source organ is
stomach content. the specific absorbed fraction equals
150/(2 x 250 x 69900).
iv) When the target organ is total body and the source is SI
content, AF = 640/(2 x 400 x 69900).
v) When the target organ is total body, and the source organ is
ULI content, AF = 210/(2 x 220 x 69900).
vi) When the target organ is total body, and the source organ is
LLI content, AF = 160/(2 x 135 x 69900).
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vii) When the target organ is total body, and the source organ is
any organ except ones described above, AF = 1/69900.
In the case of photons, the same cases hold true if the energy is less
than 0.01 MeV. For higher energies a function subprogram "INTRPT" is
called which will be explained later.
For target organs of the GI tract, bone and bladder, in the case
of charged particles, the specific absorbed fraction is zero, if the
sources and targets are not the same except when the source is total
body. In that case, AF = 1/69900. For photons, the same conditions
hold true if the energy is less than 0.01 MeV, or else "INTRPT" is
called. A flow diagram is sketched in Fig. 3.5.
3.4.16 DECAY FORTRAN:
This subroutine provides the decay scheme of the radionuclide.
The data files are based on the radioactive decay data tables by D. C.
Kocher, DOE/TIC-11026 (1981). It uses character variable WORD and
integer variable ICOUNT as arguments. ICOUNT is normally 0. until an
error occurs, in that case, its value is 1. Similar to "DECAY1", the
symbol in WORD is used to find a match in the sequentially accessed
data file "ISOTIPS". Once a match is found, a record number ITR is
read which is then used to access directly the decay scheme from data
file "ISOTOPE". Any error in this subroutine, is recorded as a
particular element of an integer vector, for which subroutine "YERR0R"
is called, which will be explained later. Variables used to access
"ISOTOPE" are:
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SUBROUTINE SPEFF (WORD, JSORCE, KTARG. TMASS. LOOP, MOTS, PLIFE)
I





IS SAVE = WORD?
Yes
I No
CALL DECAY (WORD, ICOUNT)




Any positrons in the decay scheme?
No
Yes
Add annihilation photons to the list
of decaying photons
Target = bone Target = GI tract
or bladder
Target other than








Calculation of SPEFF for a, /5, e*.
e-. For calculation of SPEFF for
i, if
-r > 0.01 MeV
CALL INTRPT (E, ELO, EHI, ILO)









FIG. 3. 5. Flowchart of Function Subprogram "SPEFF FORTRAN"
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ERT - Name of the isotope.
JO - Atomic weight.
J - Atomic number.
B - Half-life.
C - Half-life units (S, M, H, D, Y).
K - Number of daughters.
L - Pointer to first daughter record.
M - Number of alpha particles.
N - Pointer to first alpha particle record.
11 - Number of beta particles.
12 - Pointer to first beta particle record.
13 - Number of positrons.
14 - Pointer to first positron record.
15 - Number of electrons.
16 - Pointer to first electron record.
17 - Number of photons.
18 - Pointer to first photon record.
The pointer to first alpha particle is used to access the data
file "ALPHA". The variables read are:
AL1 - Energy in MeV.
AL2 - Intensity.
The pointer to beta is used to access the data file "BETA" with
the variable being:
BE1 - Endpoint energy in MeV.
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BE2 - Average energy in MeV.
BE3 - Intensity.
The pointer to positron is the key to access the data file
"POSITRN" for reading the following variables:
P0S1 - Endpoint energy in MeV.
PQS2 - Average energy in MeV.
P0S3 - Intensity.
The pointer to electron is the record number to access "ELECTRN".
Variables read are:
ELE1 - Energy in MeV.
ELE2 - Intensity.
Similarly, pointer to photon is used for file "PHOTON" with
variables:
PH01 - Energy in MeV.
PH02 - Intensity.
Each of these variables starting from AL1 are stored as a vector
for the decay of parent and daughters, and all of these vectors are
common to function subprogram "SPEFF". Besides these vectors other
variables that are common are M, II, 13, 15, 17, HLIFE. HLIFE. a
variable, describes the half lives in units of days.
3.4.17 YERROR FORTRAN:
This is the error handling subroutine for the subroutine "DECAY
FORTRAN". It gives error messages when called from "DECAY" in case of
an error in reading data files, discloses the source of error as
"DECAY", and suggests appropriate action. The argument of this
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subroutine is DECERR(7). This is an integer vector of length 7. Each
kind of error relates to a particular element of this vector. The
element is assigned an integer value greater than zero in case of an
error.
3.4.18 INTRPT FORTRAN:
This function subprogram is called by "SPEFF" for calculation of
SPEFF in the case of photon decay for energy greater than 0.01 MeV.
The purpose of this subprogram is to interpolate the values of absorbed
fraction. The data file required is "ABSFRAC" and the subroutine
"ENERGY". The arguments of this subprogram are:
E - Energy of gamma.
JSORCE - Source integer.
KTARG - Target integer.
It utilizes subroutine "ENERGY" to obtain the upper and lower
bounds of energy which aids in interpolation. The data file "ABSFRAC"
is used to read absorbed fraction for the upper and lower bounds of
energy.
After determining the specific effective energy SEE the product of
SEE and US is required for calculation of HFIFTY from contributions of
all radionuclides. If the source organ is mineral bone and the target
is either red marrow or bone surface cells then the contribution from
both trabecular bone and cortical bone as part of mineral bone is
calculated by first calling "SPEFF" with a value of variable LOOP as
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which implies photon decay from radionuclies, then with a value of LOOP
= 1 which takes care of charged particle dose in trabecular bone, and
finally with LOOP = 2 which accounts for charged particle dose in
cortical bone.
For other source organs, value of LOOP = 0. To determine the
contribution to committed dose equivalent in target tissue from each
source and each nuclide as a result of deposition in the N-P, T-B and P
regions of the lung model, three matrices named TNP, TTB, and TP are
evaluated which have a maximum size of 20 x NO where 20 represents each
source integer, and NO. the number of nuclides.
The products (SEE » US) are added from contribution of each source
in variable GRNSUM. The source loop is now closed at this point. FNP.
FTB, FP, and HFIFTY described earlier is calculated at this point for
each target organ and the target loop is then closed. The calculated
values are returned to the subroutine "ICRP".
If the value of AMAD is not equal to 1. the subroutine "ICRP"
calculates the committed dose by law of proportions, and then returns
the calculated value to the control code "DOSE".
As mentioned earlier, the subroutine "ICRP" will call the
subroutine "INGEST" to calculate the specific committed dose equivalent
in target organs from the ingested radionuclide, if the value of
variable, INTAKE is 1. The mode of operation of this subroutine is
very similar to "INHALE" and hence the subroutines called by "INGEST"
which are common to "INHALE" are not described to avoid redundancy.
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3.4.19 INGEST FORTRAN:
The arguments passed by the subroutine "ICRP" for calculation of
the specific committed dose equivalent due to the ingested radionuclide
are:
WORD - The character variable of length 8 which identifies the
radionuclide.
KZ - The atomic number of the nuclide.
SEX - Character variable of length 1 identifying the sex of
the exposed subject.
Fl - Fractional transfer of the stable element from the GI
system to the body fluids.
HFIFTY(24)
- The first 19 elements of this vector represent the
specific committed dose equivalents in 19 target organs
or tissues.
ROB - This variable stands for the mass of whole body minus
the masses of those organs and tissues with unique
retention fractions mentioned in the metabolic model.
US(I,J) - This is a matrix of transformations of nuclide I in
source J.
This subroutine like its counterpart "INHALE" is initiated by
calling "DECAY1" for half-lives and names of the parent isotope and its
daughters. The half-lives are converted into days and radiological
constants calculated. :Again. if the progeny is a radioactive inert
gas, it is assumed to escape out of the body.
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The initial activity FT of the parent and its daughters in the
transfer compartment is evaluated using the fractional transfer of the
stable element from the GI tract to the body fluids.
Except for the alkaline earths and the nuclides Tc, Re, Te-131.
Te-131m, Te-132. Te-133. Te-133m
. Te-134. and C. for which the number
of transformations in source organs are retrieved from a data file
"EXCEPT", the half life of clearance for other nuclides is obtained
from function subprogram "THALF".
A target organ loop to calculate HFIFTY is started at this point.
Mass of each target organ is given by function subprogram "REFMAN".
For each target organ, contribution from all source organs is evaluated
through a nested source loop.
To calculate the number of transformations in source organs, the
retention fractions of the nuclides in these source organs must first
be determined. Subroutine "TFRAC" retrieves these retention fractions
and their biological half lives in the source organs. After this step,
subroutine "TRNSFM" is called for the source organ transformations of
each nuclide, and then subroutine "SPEFF" for specific effective energy
in each target organ due to each source organ. The product of both the
quantities is added from contribution of all sources in each target
organ. The source loop is closed and then the specific committed dose
equivalent in each target organ is calculated. After covering all 19
target organs, the loop is closed and the values returned to "ICRP"
which in turn routes it to "DOSE". A flow diagram for "INGEST" is
shown in Fig. 3.6.
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SUBROUTINE INGEST (WORD. KZ. SEX, Fl , HFIFTY, ROB, US. *)
T
CALL DECAY1 (WORD, RHALF, ULIFE. BRA, RADIO, NO, * 12)
T
Convert half-lives Into days and calculate
radiological constants for parent and daughters
Is the parent nuclide an alkaline
earth or one of the exceptions?
No i
Yes
Calculate total initial activity of each
nuclide in the transfer compartment, FT
T
TSAVE = THALF (KZ)
Target Organ Loop
DO 25 KTARG = 1 , 19
SEX is female
and KTARG = 3
SEX is male
and KTARG = 4
THASS = REFMAN (KTARG)
T
Source Organ Loop
DO 30 JSORCE =17, 1, -1
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SEX is female
and JSORCE = 15
i
SEX Is male
and JSORCE = 10
Is the parent an alkaline earth or
one of the exceptions?
No I
Yes
Is the source organ







CALL TFRAC (KZ. F2, BHALF. JSORCE. SMASS. * 12)
1













Loop to calculate (SEE * US)




1IS JSORCE = 12?
I
Is KTARG 5 or 14?
No No
Yes
Calculate SEE * US
by alternate method
SEE = SPEFF (WORD...)
Calculate SEE * US
Calculate HFIFTY (KTARG) End of loop
RETURN
FIG. 3.6. Flow Diagram for "INGEST FORTRAN"
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After receiving all the values that were originally requested, the
main program now writes these results onto the named files. To begin
with, if the source-organ transformations were asked (i.e., MAIS = 1)
in the twelfth screen prompt, then the values of US are written to the
file FFILE(4). Again, if the mode of data entry was keyboard, then
these values are also written on screen for user's convenience.
Before the results of dose committment can be written onto the
named file, a subroutine "RESULT" is called to evaluate weighted
committed dose and other quantities as explained below.
3.4.20. RESULT FORTRAN:
The purpose of this subroutine is to evaluate the weighted
committed dose equivalent using the 10% exclusion principle. In other
words, weighted dose equivalents that are reported are greater than or
equal to 10% of the maximum weighted dose. The subroutine also
calculates the annual limit on intake. In addition, if the mode of
intake is inhalation, it determines the derived air concentration of
the nuclide. The arguments of this subroutine are:
HFIFTY(24) - This vector of maximum length 24, represents the
specific committed dose equivalent (Sv/Bq) in 19 target
organs or tissues.
WD0SE(24) - Also a vector of length 24, it describes the weighted
committed dose equivalent (Sv/Bq) in 19 target organs or
tissues which are greater than or equal to 10% of the
maximum.
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ALI - This is a real variable which gives the annual limit on
intake (Bq) of the radionuclide. It is equal to
variable POST. However, when the annual limit on intake
is determined by the nonstochastic limit, this variable
stands for the greatest value of the annual intake (Bq)
that satisfies the Commission's recommendation for
limiting non-stochastic effects.
POST - This real variable describes the greatest value of
annual intake (Bq) that proscribes to the criterion for
limiting stochastic effects as recommended by the
ICRP-30.
IRGANT - When the annual limit on intake is determined by the
non-stochastic limit on dose equivalent in a particular
organ or tissue, that organ or tissue number (according
to Table 3.1) is given by this integer variable.
DAC - This variable gives the concentration of the
radionuclide which if inhaled at the (occupational) rate
of 9600 liters per day, 5 days per week. 50 weeks per
year, would lead to the annual limit of intake for
inhalation (Bq/mD ).
KZ - Atomic number of the nuclide.
REMDR - Maximum committed dose equivalent in a target organ or
tissue which is not included in the metabolic model, GI
tract model, and the table of weighting factors shown in
Table 1.1.
WTF - This is a weighting factor determined by the number of
target organs and tissues, up to a maximum of 5. which
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are not eliminated under the 10% rule or included in
metabolic model, GI tract, and Table 1.1, which also
qualify for a weighting factor of 0.06.
WREMDR - Weighted committed dose equivalent that is obtained by
multiplying REMDR and WTF.
SUM - Sum of all the weighted committed dose equivalents
(Sv/Bq)
.
This subroutine first finds a maximum of target organs or tissues
collectively called "remainder" that are not included in organs in
Table 1.1, receiving the highest dose equivalents; the exposure of all
other remaining tissues is neglected. After that, the weighted
committed dose equivalent in each target organ is calculated by
multiplying the specific committed dose equivalent with respective
weights.
The weighted doses are then compared with the maximum, and if any
of the target organ or tissue has a weighted dose less than 10% of the
maximum, it is neglected.
The committed dose equivalent assigned to the "Remainder" as a
variable REMDR is the maximum committed dose equivalent in any target
or tissue which is not included in the GI model. Table 1.1, and the
metabolic model. The metabolic model is checked by using the data file
"RETENT". A weighting factor WTF is determined by the number of
organs, which are not eliminated under the 10% rule or included in the
above categories, which also qualify for a weighting factor of 0.06.
In the event of no such organ or tissues, no committed dose equivalent,
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or weighted committed dose equivalent WREMDR which is merely the
product of REMDR and WTF, is given for remainder tissues.
The annual limit on intake for occupational exposure is calcualted
as the greatest value which satisfies both the stochastic and
non-stochastic limit set forth by the Commission in ICRP-30. If the
non-stochastic limit overrides the stochastic, then the value that
meets both the criteria are reported with the particular organ or
tissue concerned.
With the value of ALI. the derived air concentration is then
calculated in the case of inhalation, and all these values returned to
the main program.
3.4.21 SUBMER FORTRAN:
This is the third possible route from the subroutine "ICRP" when
the value of integer variable INTAKE equals 3. This subroutine opens
data files "LIST" and "NOBLE" for dose equivalent rate in target organs
from submersion in a semi-infinite cloud of radioactive noble gas or
elemental tritium.
The arguments are:
WORD - Identification of the radionuclide.
HRATE(24) - A vector of length 24, it represents the dose equivalent
rate in target organs or tissues from submersion in unit
concentration of the isotope.





- A real variable that describes derived air concentration
when determined by the non-stochastic limit.
ORGAN
- An integer variable which gives the organ number when
DAC is determined by consideration of non-stochastic
effects.
A search Is done In data file "LIST" by comparing the variable
WORD with the nuclides in the file. In the event of a proper match, a
record number beside the identification of nuclide is retrieved. This
record number is the pointer to dose equivalent rates and DAC for that
nuclide in data file "EXCEPT". After retrieval of these quantities,
the values are returned to the subroutine "ICRP" which directs them to
the main program "DOSE".
The results from the above subroutine are then written onto the
file FFILE(2) named by the user. After that according to the data
input in earlier screens, the program is either stopped automatically,
returned to the fourth screen for more data entry or manual stop, or
reads more data from the input file.
3.5 RESULTS AND DISCUSSION
Sample calculations of specific effective energy in a target organ
from each transformation in a source organ is shown in Table 3.2, 3.3,
and 3.4 for radionuclides 131 I, 113mIn, and 121Te respectively. These
radionuclides were chosen due to their different modes of radioactive
131decay. I decays by emission of a beta particle into 131Xe. 121Te
decays by positron emission Into 121Sb, and 113raIn goes through
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isomeric transition from metastable to stable state by emission of
gamma radiation.
Results of calculations of specific committed dose equivalents,
along with the annual limits of intake, are presented in Tables 3.5 -
3.13 for selected radionuclides. Both modes of intake, ingestion and
inhalation are considered in these tables. These results are compared
against the published values of the ICRP-30 in Tables 3.14 - 3.17 for a
few radionuclides. The ICRP-30 selects data for inclusion in the
tables by applying the 10% rule for exclusion of target organs. Only
those values are reported which are greater than or equal to 10% of the
maximum. Hence, comparison is possible only for selected target organs
in tables 3.14 - 3.17.
One can see from the Tables 3.14 - 3.17 that except for three
radionuclides, namely. 89Sr. 99mTc, and 131mTe
, all values of specific
committed dose equivalents are almost identical (differences in decay
schemes used by the two programs account for these minor discrepancies)
to the results of ICRP-30. The differences in the exceptions are
explained below:
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a) Sr: To understand the difference in the specific committed dose
equivalent of the target organ red marrow, first the S-table for 89Sr
was checked against the one in ICRP-30. The results were identical.
After that, the table of number of transformations in source organs was
compared. It seemed that the difference was due to the number of
transformations in the source organ mineral bone. In the case of
ingestion for fl = 0.3, the ICRP-30 reports a value of 1.7E05 for the
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number of transformations per unit intake of activity in cortical bone
and a value of 1.4E05 for trabecular bone as source organ. The half
89life of Sr is 50.5 days. Now, according to the criteria described in
Part I of Publication 30, isotopes of alkaline earth elements with
radioactive half-lives greater than 15 days should be considered to be
uniformly distributed throughout the volume of mineral bone, and for
radionuclides assumed to be uniformly distributed throughout the volume
of mineral bone, U . = 0.2 U and U -ORtrabecular u ^ mineral a cortical U ' 8
U
mineral' We can see that there ls a discrepancy between stated and
applied ICRP criteria since the values that are given for U
cortical
'
the number of transformations per unit intake of activity in the
cortical bone, and u
trabecular are not in the required ratio. The same
is the case with inhalation as the mode of intake.
b) Tc: The difference in the results of specific committed dose
equivalents for stomach wall as the target organ, both in the case of
ingestion and inhalation, is expected. As described earlier, there is
an anomaly in the case of isotopes of elements technetium and rhenium.
The ICRP-30 reports both the stomach content and the stomach wall as
source organs, and describes transformations for each of them. This is
in contrast to all other radionuclides in which only the stomach
content is treated as the source organ. In this program, the
transformations per unit intake of activity given in the ICRP-30 for
both the stomach content and the stomach wall were summed and treated
as only one source organ, the stomach content.
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c) Te: The difference In this cae Is due to the mode of
radioactive decay. This program, as mentioned earlier, considers only
one major branch, i.e.,
A -» B -» C -» . . .
whereas, the ICRP program can consider a decay mode like
A -» Bl. A -» B2, etc.
For the vast majority of nuclides, this lack of feature does not affect
the result appreciably since one major mode of deacy is usually
predominant. But in this special case. 131mTe decays 77.8% of the time
into I and 22.8% of the time into 131Te. But this program can





and thus will underpredict the results.
d) Features: As explained earlier, the whole program is divided into
separate subroutines for calcuation of important quantities. The
central code "DOSE" merely calls the subroutine "ICRP" with the given
input data and prints the output data received from the "ICRP" in a
prescribed format. The "ICRP" subroutine, in turn, calls different
subroutines for calculation of different quantities according to the
given input. This feature of independent subroutines allows more
freedom to manipulate or modify the program, e.g., if the specific
committed dose equivalent is described in any other subject other than
the "reference man", the masses of source and target organs can be
changed in the appropriate subroutines.
12V
This convenience of alteration is also provided in the case of
biological and radiological decay data. In the case of biological
decay, each element is linked with five lines of records in the data
files "BFFRAC" and "RETENT" with the unused ones as blanks, so that new
data can be entered or the present data can be changed easily. Also
with the use of pointers described earlier, an appendage or change in
the data files on radiological decay can be done easily.
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TABLE 3.2. 1-131 S-FACTORS FOR THE ADULT - Hev/g
TARGET
ORGAN Bladder Stomach SI ULI LLI Kidneys Liver Lungs Muscle
Bladder 5.73E-04 4.84E-07 4.02E-O6 2.67E-M 7.97E-06 4.75E-07 3.50E-07 S.66E-08 2.36E-06
Stomach 4.2OE-07 4.4OE-04 4.66E-06 4.85E-06 2.37E-06 4.46E-06 2.54E-06 2.46E-06 1.86E-06
SI 3.61E-06 3.47E-06 2.79E-04 2.19E-05 1.21E-05 3.70E-06 2.15E-06 3.29E-07 2.06E-06
ULI 3.10E-06 4.48E-06 3.07E-05 4.69E-04 5.60E-06 3.82E-06 3.33E-06 4.33E-07 2.16E-06
LLI 9.37E-06 1.70E-06 9.I9E-06 4.00E-O6 7.73E-04 1.15E-06 3.81E-07 1.23E-07 2.25E-06
Kidneys 4.52E-07 4.49E-06 4.13E-06 3.63E-06 1.I8E-06 7.65E-04 5.01E-06 1.30E-06 1.89E-06
Liver 3.40E-07 2.66E-06 2.42E-06 3.35E-06 4.28E-07 5.21E-06 1.39E-04 3.21E-06 1.46E-06
Lungs 5. HE-OS 2.37E-06 4.02E-07 4.20E-07 1.31E-07 1.21E-06 3.22E-06 2.10E-04 1.77E-06Muscle 2.3M-06 1.86E-06 2.06E-06 1.96E-06 2.25E-06 1.89E-06 1.47E-06 1.76E-06 5.92E-06Ovaries 8.94E-06 6.S8E-07 1.27E-05 1.60E-05 2.34E-05 1.60E-06 4.S4E-07 1.88E-07 2.64E-06Pancreas 3.71E-07 2.35E-05 2.73E-06 2.73E-06 9.66E-07 8.63E-06 5.82E-06 3.52E-06 2.38E-06
Bone Supf 8.72E-07 2.24E-06 1.16E-06 1.06E-06 1.52E-06 1.40E-06 1.07E-06 1.42E-06 1.44E-06
Red Marr. 1.91E-M 1.53E-06 3.75E-06 3.23E-06 4.58E-06. 3.59E-06 1.56E-06 1.80E-06 1.95E-06
skin B.21E-07 7.22E-07 6.68E-07 6.86E-07 7.51E-07 8.38E-07 7.64E-07 8.54E-07 1.14E-06Spleen 2.65E-07 1.29E-05 2.07E-06 1.73E-06 1.17E-06 1.13E-05 1.30E-06 2.92E-06 1.95E-06
Testes 6.41E-06 6.36E-08 4.86E-07 5.S3E-07 2.69E-06 1.83E-07 1.44E-07 2.70E-08 1.61E-06Thyroid 9.95E-09 1.87E-07 4.49E-0B 4.85E-08 1.97E-08 1.12E-07 2.68E-07 1.41E-06 1.80E-06
uterus 2.O1E-0S 1.15E-06 1.19E-05 6.07E-06 8.19E-06 1.24E-06 5.5SE-07 1.30E-07 2.80E-06
Tot. Body 2.79E-06 3.17E-06 4.B0E-06 3.84E-06 4.14E-06 4.96E-06 4.98E-06 4.65E-06 4.60E-06
SOURCE ORGAH
Ovaries Pancreas Trab Bone Cort Bone Skin Spleen Testes Thyroid Tot. Body
Bladder 8.96E-06 2.35E-07 7.61E-07 7.61E-07 7.95E-07 2.12E-07 6.60E-06 1.01E-08 5.11E-06
stoawch 1.08E-06 2.34E-0S 7.71E-07 7.71E-07 8.14E-07 1.2SE-0S 1.16E-07 1.24E-07 5.15E-06
si 1.57E-05 2.39E-06 1.05E-O6 1.05E-06 7.00E-07 1.86E-06 6.47E-07 1.64E-08 5.35E-06
ULI 1.48E-05 2.89E-06 9.58E-07 9.5SE-07 7.15E-07 1.77E-06 4.57E-07 1.65E-08 5.23E-06
LLI 1.89E-05 7.32E-07 1.33E-06 1.33E-06 7.50E-07 8.SSE-07 3.71E-06 1.64E-08 5.19E-06Kidney* 1.41E-06 8.31E-06 1.23E-06 1.23E-06 9.43E-07 1.15E-05 1.19E-07 6.43E-08 5.04E-06Liver 8.02E-07 5.58E-06 9.22E-07 9.22E-07 8.43E-07 1.40E-06 6.61E-08 1.92E-07 4.9BE-06Lungs 1.30E-07 3.23E-06 1.31E-06 1.31E-06 8.83E-07 2.93E-06 1.88E-08 1.36E-06 4.71E-06Muscle 2.64E-06 2.39E-06 1.44E-06 1.44E-06 1.KE-06 1.95E-06 1.61E-06 1.80E-06 4.60E-06Ovaries 2.40E-02 5.09E-07 1.23E-06 1.23E-06 5.20E-07 1.12E-06 O.OOE-Ol 1.94E-08 5.03E-06Pancreas 7.28E-07 3.43E-03 1.30E-06 1.30E-06 7.68E-07 2.54E-0S 7.47E-08 1.12E-07 5.24E-06Bone Surf 1.37E-M I.34E-06 3.87E-04 3.86E-04 1.14E-06 1.11E-06 9.35E-07 1.05E-06 4.S0E-06
5.05E-06
Red Marr. 4.65E-06 2.55E-06 6.78E-05 4.29E-06 1.07E-06 1.66E-06 7.53E-07 1.16E-06Skin 6.62E-07 6.38E-07 1.08E-06" 1.08E-06 6.98E-05 7.74E-07 2.04E-06 1.12E-06 3.36E -06Spleen 8.43E-07 2.34E-05 1.D2E-06 I.02E-06 8.40E-07 1.26E-03 1.11E-07 1.71E-07 5.09E-06
4.79E-06
Testes O.OOE-01 9.43E-08 7.95E-07 7.95E-07 1.25E-06 1.13E-07 5.60E-03 3.46E-09
Thyroid 1.94E-08 2.20E-07 1.34E-06 1.34E-06 1.07E-O6 1.80E-07 3.45E-09 1.03E-02 4.S3E-06
5.28E-06
4.62E-06
Uterus 2.55E-05 S.42E-07 8.11E-07 8.11E-07 0.72E-07 5.91E-07 O.OOE-01 1.83E-08
Tot. Body 5.39E-06 5.34E-06 4.63E-06 4.63E-06 3.8BE-06 4.97E-06 4.59E-06 4.44E-06
TABLE 3.3. IN-113H S-FACTORS FOR THE ADULT - MeW/8
TARGET
ORGAN Bladder Stomach SI ULI LLI Kidneys Liver Lungs Muscle
8 1 adder 3.V8E-04 3.30E-07 2.79E-06 1.78E-06 5.40E-O6 3.17E-07 2.48E-07 5.82E-08 1.6IE-06
Stomach 2.72E-07 3.12E-04 3.15E-06 3.32E-06 1.61E-06 3.01E-06 1.71E-06 1.67E-06 1.28E-06
SI 2.42E-06 2.3SE-06 1.94E-04 1.53E-05 8.UE-06 2.49E-06 1.45E-06 2.21E-07 1.40E-06
ULI 2.11E-06 3.05E-06 2.23E-05 3.39E-04 3.92E-06 2.57E-06 2.27E-06 2.93E-07 1.48E-06
LLI 6.39E-06 1.UE-06 S.47E-06 2.74E-06 5.35E-04 7.74E-07 2.60E-07 8.08E-08 1.54E-06
Kidneys 3.08E-07 3.02E-O6 2.79E-06 2.43E-06 7.82E-07 5.33E-04 3.40E-06 8.81E-07 1.30E-06
Liver 2.29E-07 1.80E-06 I.63E-06 2.26E-06 2.B7E-07 3.55E-06 9.70E-05 2.20E-06 1.00E-06
Lungs 3.54E-OS 1.62E-06 2.72E-07 2.81E-07 8.56E-08 8.12E-07 2.18E-06 1.46E-04 1.23E-06
Muscle 1.62E-06 1.27E-06 1.41E-06 1.34E-06 1.53E-06 1.30E-06 1.00E-06 1.23E-06 4.10E-06
Ovaries 6.10E-06 4.19E-07 8.63E-06 1.13E-05 1.63E-05 1.05E-06 2.72E-07 I.26E-07 1.83E-06
Pancreas 2.46E-07 1.62E-05 1.S4E-06 1.80E-06 6.50E-07 5.83E-06 3.99E-06 2.41E-06 I.6SE-06
Bone Surf 5.81E-07 1.44E-06 7.82E-07 7.14E-07 1.05E-O6 9.51E-07 7.2SE-07 9.74E-07 9.78E-07
Red Harr. 1.27E-06 1.03E-06 2.54E-06 2.20E-06 3.20E-O8 2.44E-06 1.05E-06 I.23E-06 1.36E-06
Skin 5.54E-07 4.90E-07 4.49E-07 4.64E-07 5.08E-07 5.72E-07 5.18E-07 5.80E-07 7.97E-07
Spleen 1.75E-07 8.74E-06 1.40E-06 1.15E-06 7.81E-07 7.78E-06 8.68E-07 1.9SE-06 1.34E-06
Testes 4.35E-06 3.52E-08 3.191-07 3.9SE-07 1.84E-06 1.23E-07 9.14E-08 1.79E-08 1.10E-06
Thyroid 6.53E-09 1.25E-07 3.00E-08 3.24E-08 1.31E-08 7.53E-08 1.78E-07 9.49E-07 1.27E-06
Uterus 1.38E-05 7.72E-07 8.12E-06 4.07E-06 5.49E-06 8.27E-07 3.76E-07 8.58E-08 1.91E-06
Tot. Body 1.«E-06 2.20E-06 3.32E-06 2.67E-04 2.87E-06 3.44E-06 3.45E-06 3.23E-06 3.19E-06
SOURCE ORGAN
TARGET
ORGAN Ovaries Pancreas Trab Bone Cort Botm Skin Spleen Testes Thyroid Tot. Body
Bladder 6.03E-06 1.62E-07 5.26E-07 5.26C-07 5.33E-07 1.31E-07 4.46E-06 6.61E-09 3.54E-04
stomach 7.31E-07 1.63E-05 5.22E-07 5.22E-07 5.52E-07 S.78E-06 8.18E-08 8.54E-08 3.57E-06
SI 1.09E-05 1.6OE-06 7.07E-07 7.07E-07 4.71E-07 1.25E-06 4.38E-07 9.34E-09 3.70E-06
ULI 1.05E-05 1.94E-06 6.41E-07 6.41E-07 4.81E-07 1.19E-06 3.01E-07 9.60E-09 3.63E-06
LLI 1.34E-05 4.89E-07 B.92E-07 8.92E-07 5.04E-07 6.01E-07 2.53E-06 1.09E-0S 3.60E-06
Kidneys 9.55E-07 5.63E-06 8.16E-07 8.16E-07 6.43E-07 7.94E-06 7.91E-08 4.03E-08 3.4SE-06
Liver 5.37E-07 3.78E-06 6.22E-07 6.22E-07 3.73E-07 9.38E-07 4.23E-08 1.29E-07 3.45E-06
Lungs 8.66E-0S 2.18E-06 8.83E-07 8.83E-07 5.98E-07 2.00E-06 1.21E-08 9.11E-07 3.28E-06
Muscle 1.S3E-06 1.65E-06 9.76E-07 9.76E-07 7.95E-07 1.34E-06 1.10E-06 1.27E-06 3.19E-06
Ovaries 1.66E-02 3.13E-07 8.4BE-07 8.48E-07 3.30E-07 7.90E-07 0.00E-01 1.2SE-08 3.S0E-06
Pancreas 4.73E-07 2.38E-03 8.70E-07 8.70E-07 S.22E-07 1.78E-0S 4.61E-0S 7.47E-08 3.63E-06
Bone Surf 9.27E-07 B.99E-0? 3.40E-05 2.32E-0S 7.96E-07 7.50E-07 6.24E-07 7.07E-07 3.35E-06
Red Harr. 3.15E-06 1.71E-06 4.69E-05 3.27E-06. 7.45E-07 1.12E-06 5.01E-07 7.77E-07 3.52E-06
Skin 4.45E-07 4.28E-07 7.41E-07 7.41E-07 4.82E-0S 5.25E-07 1.4SE-06 7.71E-07 2.67E-06
Spleen 5.73E-07 1.78E-05 6.94E-07 6.94E-07 5.43E-07 8.81E-04 8.07E-08 1.12E-07 3.52E-06
Testes O.OOE-01 6.O2E-0S 5.29E-07 5.29E-07 8.69E-07 7.59E-08 3.89E-03 2.22E-09 3.33E-06
Thyroid 1.29E-08 1.56E-07 9.38E-07 9.3BE-07 7.42E-07 1.21E-07 2.22E-09 7.17E-03 3.15E-06
Uterus 1.75E-05 5.66E-07 5.29E-07 5.29E-07 4.48E-07 3.91E-07 0.00E-01 1.21E-08 3.6IE-06
Tot. Body 3.73E-06 3.69E-06 3.21E-06 3.21E-06 2.68E-06 3.44E-06 3.18E-06 3.0SE-06 3.21E-06
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TABLE 3.4. TE-121 S-FACTORS FOR THE ADULT • MeV/g
TARGET
ORCAN Bladder Stomach SI Ull LLI Kidneys Liver Lungs Muscle
Bladder 1.83E-04 8.S5E-07 6.30E-06 3.73E-06 1.I0E-05 7.53E-07 6.30E-07 1.46E-07 3.55E-06
Stomach 6.65E-07 1.30E-04 6.70E-06 7.23E-06 3.46E-06 6.51E-06 3.68E-06 3.66E-06 2.81E-06
SI 5.06E-06 5.O9E-06 7.77E-05 3.37E-05 I.84E-05 5.32E-06 3.0&E-06 5.41E-07 3.07E-06
UL I 4.46E-06 6.44E-06 4.96E-05 1.I3E-04 8.56E-06 5.56E-06 4.98E-06 7.40E-07 3.25E-06
LLI 1.39E-05 2.46E-06 1.41E-05 6.10E-06 1.45E-04 1.68E-06 6.07E-07 1.53E-07 3.36E-06
Kidneys 7.30E-07 6.36E-06 6.14E-06 5.28E-06 1.61E-06 1.95E-04 7.35E-06 2.01E-06 2.9OE-06
Liver 5.47E-07 3.92E-06 3.51E-06 4.80E-06 6.68E-07 7.83E-06 6.01E-05 4.76E-06 2.23E-06
Lungs 1.00E-07 3.64E-06 6.48E-07 6.67E-07 2.08E-07 1.85E-06 4.64E-06 4.2DE-05 2.75E-06
Muscle 3.55E-06 2.S1E-06 3.0SE-06 2.94E-06 3.36E-06 2.9OE-06 2.24E-06 2.75E-06 3.32E-06Ovaries 1.19E-05 1.19E-06 1.8IE-05 2.44E-05 3.37E-05 2.31E-06 4.93E-07 2.97E-07 4.03E-06
Pancreas 5.04E-07 3.54E-05 3.98E-06 3.49E-06 1.44E-06 1.291-05 9.28E-06 5.32E-06 3.65E-06
Bone Surf 1.13E-06 1.20E-06 1.57E-06 1.44E-06 2.20E-06 1.99E-06 1.49E-06 2.07E-06 2.17E-06
Red Marr. 2.42E-06 2.04E-06 5.08E-06 4.40E-06 6.76E-06 5.06E-06 2.13E-06 2.59E-06 2.89E-06
skin 1.2SE-06 1.16E-06 1.04E-O6 1.0SE-06 1.15E-06 1.31E-06 1.18E-06 I.33E-06 1.87E-06
Spleen 4.40E-07 1.88E-05 3.02E-06 2.39E-06 1.83E-06 1.69E-05 1.95E-06 4.27E-06 2.98E-06
Testes 9.84E-06 7.87E-08 7.29E-07 I.00E-06 3.88E-06 2.92E-07 2.51E-07 4.95E-08 2.46E-06
Thyroid
. 1.9SE-08 2.96E-07 7.99E-08 8.55E-08 3.70E-O8 1.86E-07 3.55E-07 2.35E-06 2.87E-06
Uterus 3.00E-05 1.72E-06 1.74E-05 S.72E-06 1.09E-05 I.60E-06 8.31E-07 I.88E-07 4.08E-06
Tot. Body 3.S4E-06 3.68E-06 4.1OE-06 3.96E-06 3.96E-06 3.60E-06 3.63E-06 3.14E-06 3.08E-06
SOURCE ORGAK
ORGAR Ovaries Pancreas Trap Bone Cort Bon* Skin Spleen Testes Thyroid Tot. Bod
Bladder 1.31E-05 3.61E-07 1.21E-06 1.21E-06 I.27E-04 3.07E-07 9.V9E-M 2.00E-08 3.89E-06
Stomach 1.59E-06 3.51E-05 1.12E-06 1.12E-06 1.28E-06 1.94E-05 2.17E-07 2.48E-07 3.74E-06
SI 2.40E-05 3.39E-06 1.57E-06 1.57E-M 1.0SE-06 2.66E-06 1.02E-06 2.16E-08 4.15E-06
ULI 2.31E-05 4.15E-06 1.37E-06 1.37E-06 1.15E-06 2.70E-06 6.34E-07 2.81E-0S 4.10E-06
LLI 2.97E-05 I.03E-06 1.89E-06 1.B9E-06 1.18E-06 1.33E-06 5.39E-06 3.10E-08 4.HE-06
Kidneys 2.16E-06 1.21E-05 1.83E-06 1.83E-06 1.49E-06 1.72E-05 2.06E-07 1.11E-07 3.71E-06
Liver 1.18E-06 8.02E-0O 1.38E-06 1.38E-06 1.33E-06 2.05E-06 1.11E-07 3.13E-07 3.70E-06
Lungs 2.26E-07 4.65E-06 1.93E-06 1.93E-06 1.35E-0O 4.37E-06 3.11E-08 2.07E-06 3.31E-06
Muscle 4.03E-O6 3.65E-06 2.17E-06 2.17E-06 1.86E-06 2.97E-06 2.46E-06 2.S6E-06 3.09E-06
Ovaries 2.81E-03 8.67E-07 2.11E-06 2.11E-06 6.54E-07 1.92E-06 0.00E-01 3.69E-08 3.S2E-06
Pancreas 1.15E-06 6.28E-04 1.77E-06 1.77E-06 1.11E-06 4.01E-05 8.74E-08 1.28E-07 3.67E-06
Bone Surf 1.87E-06 1.82E-06 1.99E-05 1.97E-05 1.79E-06 1.56E-06 1.28E-06 1.48E-06 3.36E-06
Red Marr. 6.32E-06 3.42E-06 1.02E-05 7.49E-06 I.66E-06 2.25E-06 1.01E-06 1.63E-06 3.69E-06Skin 1.02E-06 9.87E-07 1.70E-06 1.70E-06 7.44E-06 1.24E-06 3.32E-06 I.76E-06 1.96E-06Spleen 1.31E-06 3.96E-05 1.65E-06 1.65E-06 1.32E-06 3.43E-04 2.36E-07 2.64E-07 3.77E-06
Testes O.OOE-01 1.34E-07 1.13E-06 '.m OS 1.79E-06 1.87E-07 1.05E-03 7.39E-09 3.86E-06
Thyroid 3.69E-08 3.22E-07 2.02E-06 2.02E-06 1.64E-08 2.88E-07 7.38E-09 1.55E-03 3.11E-06
Uterus 3.62E-05 1.20E-06 1.20E-06 1.20E-06 1.14E-06 9.29E-07 0.00E-01 3.50E-08 3.S4E-06
Tot. Body 4.20E-06 4.12E-M 3.12E-06 3.I2E-06 2.01E-06 3.61E-06 3.05E-O6 2.85E-06 3.11E-06
131
TABLE i.5 SB.cificMM do.. •**»>«. „»,„, <or ..loeMd lv« r«n««ll*, M ,,



























































































































































































































































































































































































































































































TABLE 3.6 Specific committed dose equiva lents CSv/Bq) for selected ingested rad i onuc
I
ides and their daughters.
Annual i imi
t
s of intake are the lesser of the va lues for stoehasti c and non
-stochast ic risks.
Nuclide Y-90 Y-91m r-9i r-92 Y-93 Zr-95 2r-97 Mb- 95 Mo- 99 Tc-99m Tc-101
fl 0.0001 0.0001 0.0001 0.0001 0.0001 0.002 0.002 0.01 0.8 0.8 0.8
ALI (Bq) 1 .66*07 4.86*09 1.76*07 9.9€*07 4.1E+07 5.4E*07 2.36*07 8.26*07 6.0E*07 3.5E+09 3.3E+09
Lungi 1.26-14 1.3E-12 1.66-13 1.46-12 8.76-13 2.36-11 1.86-11 2.86-11 2. 06-10 2.96-12 3.3E-13
Thyroid 1.2E-14 1.2E-13 B. 96-14 1.8E-13 1.36-13 8.26-12 2.76-12 1.26-11 1.76-10 8.46-11 2.6E-14
Testes O.OE-01 0.06-01 0.0E-01 O.OE-01 O.OE-01 O.OE-01 O.OE-01 0.06-01 0.06-01 0.06-01 O.OE-01
Ovaries 1.2E-K 6.96-12 3.56-12 2.0E-11 2.2E-11 8.2E-10 6.36-10 8.16-10 2.36-10 9.56-12 5.16-13
Bed Harrow 3.6E-13 2.2E-12 4.46-12 4.9E-12 4.9E-12 2.16-10 1.36-10 2.0E-10 4.8E-10 6.0E-12 3.4E-13
Stomach wall 1.1609 4.96-11 6.96-10 1.4E-09 1.3E-09 3.66-10 1.26-09 2.8E-10 6.7E-10 3.96-11 1.56-10
SI * contents 2.66-09 3.16-11 1.76-09 2.0E-09 2.5E-09 1.16-09 3.46-09 9.2E-10 4.76-10 2.26-11 2.3E-11UU wall 1.46-08 3.1E-11 1.0E-08 3.3E-09 7.96-09 3.1E-09 1.2E-08 1.96-09 1.56-09 3.66-11 1.6E-12
LLI uall 3.1E-08 2.46-11 3.06-08 1.7E-09 8.7E-09 7.8E-09 1.BE-08 4.06-09 3.26-09 2.46-11 5.3613
L iver 3.5E-13 2.SE-12 4.16-12 4.6E-12 3.6E-12 7.96-11 8.1E-11 8.46-11 2.7E-09 5.7E-12 4.46-13
K i dneys 1.2E-H 3.9E-12 5.86-13 6.5E-12 4.6E-12 1.1E-10 1.16-10 1.46-10 2.7E-09 4.9E-12 7.66-13
Bladder wall 1.2E-H 2.3E 12 1.26-12 5.66-12 6.5E-12 2.46-10 1.86-10 2.46-10 1.9E-10 4.36-12 1.96-13
Muse 1
e
1.2E-14 1.86-12 5.26-13 3.5E-12 3.16-12 1.16-10 8.26-11 1.1E-10 1.9E-10 3.36-12 3.2E-13
Bone Surface 3.6E-13 8.76-13 4.06-12 1.8E-12 1.86-12 4.86-10 4.66-11 2.96-10 7.66-10 4.16-12 4.2E-13
Skin 1.2E-14 7.16-13 2.5E-13 1.46-12 1.26-12 4.26-11 3.16-11 4.46-11 1.66-10 1.8E-12 1.2E-13
Spleen 1.2E-14 6.46-12 4.76-13 6.5E-12 3.96-12 8.96-11 8.16-11 1.16-10 2.06-10 6.2E-12 1.8E-12
Uterus 1.2E-14 5.86-12 1.6E-12 1.36-11 1. 16-11 3.36-10 2.9E-10 3.46-10 2.16-10 6.9E-12 5.56-13
Pancreas 1.2E-14 1.1E-11 5.36 13 1.06-11 5.76-12 1.16-10 1.1E-10 1.16-10 2.4E-10 9.3E-12 3.36-12
Total Body 1.46-10 2.5E-12 1.26-10 3.9E-11 7.3E-11 1.5E-10 2.06-10 1.46-10 3.0E-10 4.0E-12 9.1E-13
Remainder 1.1E-11 9.36-12
Nuclide Ru-103 Ru-105 Ru-106 Ag-IIOm Te-125m T«-127 Te-129» Te-129 Te-131m Te-131 Te-132
fl 0.05 0.05 0.05 0.05 0.2 0.2 0.2 0.2 0.2 0.2 0.2
ALI CBq) 6.96+07 1.96*08 7.16+06 1.76*07 3.56*07 2.7E*08 1 .96*07 9.76*08 1 .2E*07 1 .26*08 8.4E*06
Lungs 7.46-11 6.1E-12 1.4E-09 8.3E-10 4. 86-11 2.96-12 1.66-10 4.96-13 4.4E-11 3.36-12 3.16-10
Thyroid 6.26-11 1.7E-12 1.4609 1.8E-10 4.36-11 2. 96-12 1.66-10 3.46-13 4.3E-08 4.36-09 6.0E-Q8
Testes 0.06-01 O.OE-01 0.0E-01 O.OE-01 O.OE-01 0.0E-01 0.06-01 0.0E-01 O.OE-01 0.06-01 0.0E-01
Over 1 es 5.9E-10 9.56-11 1.6E-09 3.0E-09 1.36-10 4.06-12 2.4E-10 1. 66-12 6.76-10 1.56-11 4.56- 10
Red Marrow 1.76-10 2.3E-11 1.5E-09 9.4E-10 1.46-09 6.46-12 3.4E-09 7.5E-13 1.76-10 6.16-12 3.5E-10
Stomach wall 3.16-10 5.0E-10 3.1E-09 1.5E-09 2.16-10 2.46-10 6.3E-10 4.0E-10 1.66-10 6.36-10 3.3E-10
SI * contents B. 66-10 7.9E-10 5.5E-09 3.5E-09 4.26-10 3.96-10 1.5E-09 2.76-10 1.2E-09 5.6E-10 4.16-10
ULI wait 2.56-09 1.66-09 2.5E-08 5.96-09 1.96-09 1.26-09 8.6E-09 1.96-10 2.9E-09 5.4E-10 3.76-10
LLI uatl 6.36-09 1.2E-09 7.1E-08 1.1E-08 5.46-09 1.2E-09 2.5E08 3.66-11 4.8E-09 9.3E-12 3.6E-09
Liver 1.1E-10 1.96-11 1.4E-09 8.5E-09 4.6E-11 3.0E-12 1.66-10 6.76-13 1.0E-10 5.26-12 3. 36-10
K i dneys 1.3E-10 2.7E-11 1.5E-09 1.5E-09 4.66-11 3.1E-12 1.76-10 8.76-13 1.3E-10 7.2E-12 3.3E-10
Bladder wall 2.3E-10 2.7E-11 1.5E-09 1.06-09 5.26-11 3.26-12 1.76-10 6.6E-13 2.26-10 4.86-12 3.96-10
Muscle 1.2E-10 1.6E-11 1.4E-09 7.56-10 5.06-11 3.0E-12 1.76-10 6.06-13 1.16-10 4.8E-12 3.2E-10
Bone Surface 9.BE-11 9.06-12 1.4E-09 4.9E-10 1.4E-08 6.4E-12 7.76-09 5.66-13 7.4E-11 3.56-12 3.1E-10
Skin 6.96-11 6.46-12 1.4E-09 3.76-10 4.26-11 2.96-12 1.66-10 4.1E-13 5.3E-11 2.66-12 2.4E-10
Spleen 1.26-10 2.5E-11 1.5E-09 7.16-10 4.76-11 3.16-12 1.66-10 1.2E-12 9.06-11 9.16-12 3.3E-10
Uterus 2.7E-10 5.56-11 1.5E09 1.46-09 5.76-11 3.46-12 1.8E-10 1.26-12 3.2E-10 1.11-11 4.0E-10
Pancreas 1.3E-10 3.86-11 1.5609 1.66-09 4.86-11 3.2E-12 1.66-10 1.96-12 1.0E-10 1.4E-11 3.2E-10
Total Body 1.56-10 3.2E-11 1.7E-09 1.0E-09 1.96-10 1.4E-11 5.46-10 4.6E-12 1.6E-10 1 .46-11 3.4E-10
Remainder
nMMm 1.66-09
TABLE 3.7 Specific conn it ted dose equivalents (Sv/Bq) for selected ingested radionuclides and their
























TABLE 3.8 Specific committed dose equiva Lents (Sv/Bq) for selected inhaled r adionucl
i
des and their daughters.
Annual limits of intake are the lesser *>f the va lues for stochasti c and non
-stochast ic risks.
Nuclide Mi -24 P-32 P-32 K-40 Cr-51 Cr-51 Cr-51 Mn-54 Hn-54 Mn-56 Mn-56
fl 1.0 0.8 0.8 1.0 0.01 0.01 0.01 0.1 0.1 0.1 0.1
Class y D D u Y D y D V
AL1 (Bq) 1.96+08 1.46+07 3.56+07 1.76+07 1.76+09 8.7E+08 7.0E+08 3.66+07 3.26+07 5 . 7E+08 7.8E+08
DAC (Bq/m-3) 7.96+04 5.9E+03 1 .46+04 7.16+03 7.06+05 3.6E+05 2.9E+05 1.5E+04 1 .3E+04 2.4E+05 3.2E*05
Lungs 1.ZE-09 2.6E-08 2.56-09 4.16-09 3.71-11 3.7E-10 5.2E-10 1.2E-09 6.6E-09 4.46-10 5.4E-10
Thyroid 1.5E-10 3.4E-10 4.8E-10 2.76-09 1.76-11 9.4E-12 9.3E-12 6.5E-10 7.4E-10 1.2E-11 6.2E-12
Testes 0.06-01 0.0E-01 0.0E-01 0.06-01 0.06-01 O.OE-01 O.OE-01 0.0E-01 O.OE-01 0.06-01 0.0E-01
Ovaries 1.86-10 3.4E-10 4.86-10 2.86 09 2.7E-11 2.2E-11 2.DE-11 8.9E-10 7.1E-10 2.26-11 9.4E-12
Red Marrow 2.1E-10 4.0E-09 5.86-09 2.7E-09 3.1E-11 1.86-11 1.76-11 1.8E-09 1.1E-09 2.3E-11 1.01-11
Stomach wall 3.16-10 6.7E-10 6.16-10 2.86-09 2.4E-11 2.26-11 2.4E-11 9.4E-10 1.26-09 1.4E-10 7.6E-11
51 • contents t .71*10 5.0E-10 5.56-10 2.86-09 3.0E-11 2.76-11 2.5E-11 1.1E-09 8.46-10 1.6E-10 8.2E-11
UL1 wall 1.66-10 1.3E-09 8.56-10 2.86-09 4.1E-11 6.16-11 6.3E-11 1.36-09 1.16-09 2.0E-10 1.11-10
lli wall 1.76-10 3.1E-09 1.5E-09 2.86-09 6.86-11 1.46-10 1.5E-10 1.26-09 1.3E-09 8.46-11 4.3E-11
Livtr 1.9E-10 3.4E-10 4.8E-10 2.8E-09 2.16-11 2.1E-11 2.4E-11 4.6E09 2.5E-09 4.0E-11 1.71*11
Kidneys 1.66-10 3.4E-10 4.8E-10 2.7E-09 2.1E-11 1.2E-11 1.11-11 1.4E-09 8.9E-10 1. 76-11 8.0E-12
Bladder wall 1.66-10 3.4E-10 4.86-10 2.8E-09 2.2E-11 9.2E-12 6.4E-12 7.26-10 3.8E-10 1.36-11 4.76-12
Muscle 1.6E-10 3.4E-10 4.8E-10 2.76-09 1.96-11 1.36-11 1.4E-11 9.16-10 8.66-10 1.56-11 7.86-12
Bone Surface 2.6E-10 4.0E09 5. 86-09 2.7E-09 2.66-11 1. 36-11 1.2E-11 2.56-09 1.26-09 2.06-11 8.2E-12
Skin 1 .21-10 3.4E-10 4.8E-10 2.66-09 1.36-11 7.06-12 6.6E-12 6.26-10 4.9E-10 1
.
IE- 11 4.8E-12
Spleen 1.86-10 3.4E-10 4.86-10 2.76-09 2.26-11 1.96-11 2.26-11 9.2E-10 1.2E-09 2.0E-11 I ,88-11
Uterus 1.76-10 3.4E-10 4.86-10 2.86-09 2.4E-11 1.2E-11 8.6E-12 9.2E-10 4.9E-10 1.9E-11 7.6E-12
Pancreas 2.36-10 3.4E-10 4.86-10 2.7609 2.46-11 2.3E-11 2.66-11 1.4E-09 1.4E-09 2.4E-11 1.46-11
Total Body 1.96-10 1.0E-09 9.76-10 2.7609 2.06-11 1.96-11 2.26-11 1.1E-09 9.9E-10 2.4E-11 1.76-11
Remainder 2.86-09 2.46-11 1.4E-09 1.4E-09
Nuclide Ft-55 Fe-55 Fe-59 Fe-50 Co -58 Co- 58 Co-60 Co-60 81 -18 Nf-63 Ni-65
ft 0.1 0.1 0.1 0.1 0.05 0.05 0.05 0.05 0.05 0.05 0.C5
:;ass D u w U T W Y w W
ALI (Bq) 7.56+07 1
-4E+08 1.36*07 1 .96+07 4.1E+07 2.6E+07 6.7E+06 1.2E+06 9.86*07 5.96+07 1.16*09
DAC lBq/m- 3> 3.16*04 6.36+04 5.2E+03 7.9E+03 1.7E+04 1.1E+04 2.8E+03 5.0E+02 4.1E+04 2.5E*04 4.66+05
.unqs 5.1E-10 1.16-09 3.5E-09 1.46-08 7.9E-09 1.66-08 3.6E-08 3.4E-07 3.1E-09 8.8E-10 3.86-10
Thyroid 4.96-10 1. 76-10 3.0E-09 1.2E-09 5.5E-10 8.7E-10 3.7E-09 1.66-08 2.5E-1D 8.2E-10 2.3E-12
Testes O.OE-01 O.OE-01 O.OE-01 0.06-01 O.OE-01 O.OE-01 0.0E-O1 O.OE-01 0.0E-01 O.OE-01 0.06-01
Ovar i es 4.96-10 1.76-10 3.3E-09 1.4E-09 6.5E-10 6.2E-10 4.06-09 4.86-09 2.5E-10 8.2E-10 3.36-12
Red Marrow 4.96-10 1.71-10 3.26*09 1.3E-09 6.3E-10 9.2E-10 4.2E-09 1.76-08 2.56-10 8.2E-10 3.0E-12
Stomach wal
I
4.9E-10 1.71-10 3.4E-09 1.76-09 9.06-10 1.4E-09 5.4E-09 2.7E-08 2.6E-10 8.3E-10 4.8E-11
SI * contents 4.96-10 1.76-10 3.96-09 1.76-09 7.SE-10 7.SE-10 4.7E-09 7.1E-09 2.76-10 8.3E-10 5.56-11
ULI wall 5.06-10 2.1E-10 4.1E-09 2.6E09 1.2E-09 1.2E-09 5.96-09 9.76-09 3.96-10 8.7E-10 7.16-11
LLI wall 5.3E-10 3.0E-10 4.8E-09 4.5E-09 2.0E-09 2.0E-09 S.1E-09 7.96-09 6.76-10 9.5E-10 2.8E-11
Llvw 1.6E09 S.5E-10 7.16-09 2.76-09 1. 16-09 1.66-09 9.2E-09 3.4E-08 2.5E-10 8.2E-10 4.1E-12
Kidneys 4.96-10 1.76-10 3.86-09 1.4E-09 5.7E-10 7. 66-10 4.5E-09 1.6E-08 2.5E-10 B.2E-10 3.1E-12
Bladder wall 4.96-10 1.76-10 3.7E-09 1.2E-09 3.46-10 2.4E-10 3.4E-09 3.0E09 2.56-10 8.2E-10 2.0E-12
Muscle 4.96-10 1.7E-10 3.0E-09 1.36-09 6.16-10 9.4E-10 4.26-09 1.86-08 2.5E-10 8.2E-10 2.9E-12
Bone Surface 4.96-10 1.71-10 2.96-09 1.16-09 4.86-10 6.9E-10 3.56-09 1.46-08 2.5E-10 8.26-10 2.4E-12
Skin 4.96-10 1.7E-10 2.26-09 8.56-10 3.36-10 4.86-10 2.66-09 1.0E-08 2.5E-10 8.26-10 2.0E-12
Sp I een 2.7E-09 9.3E-10 8.56-09 3.0E-09 8.96-10 1.5E-09 5.26-09 2.7E-08 2.56-10 8.2E-10 4.06-12
Uterus 4.96-10 1.7E-10 4.06-09 1.4E-09 4.26-10 3.1E-10 3.96-09 4.66-09 2.56-10 8.2E-10 3.06-12
Pancreas 4.96-10 1.76-10 3.86-09 1.86-09 1.06-09 1.7E-09 6.06-09 3.26-08 2.56-10 8.2E-10 4.96-12
Total Body 5.2E-10 1.96-10 3.16-09 1.5E-09 7.1E-10 1.1E-09 4.6E-09 2.2E-08 2.9E-10 8.3E-10 9.26-12
Remainder S.2E-10 4.06-09
TABLE 3.9 Spctcific comnitted dose equiva lents CSv/Bq) for selected inhaled r;idionuclides and their daughters.
Annual limit: % of intake are th e lesser iIf the vb lues for stochastii : and non stochast ic risks.
Nuclide Ni-65 Clf-tf Cu-64 Cu-64 Zn-65 2n-69 Br-83 Br-83 Br-84 Br-84 Rb-88
f1 0.05 0.5 B.3 0.5 0.5 0.5 1.0 1.0 1.0 1.0 1.0
ClMi D D w Y V T u D u D
ALl <Bq) 8.71*08 1.16+09 8.7E*08 8.01+08 1 .21+07 5.3E+09 2.5E*09 2.3E+09 2.1E+09 2.4E+09 2.3E*09
DAC (Bq/m-3) 3.6E*05 4.4E*05 3.6E+05 3.3E+05 4.91+03 2.2E+06 1.DE+06 9. BE +09 8.8E+05 1.0E+06 9. 71+05
-Lings 3.1E-10 2.0E-10 3.4E-10 3.5E-10 2.1E-08 7.8E-11 1.5E-10 1.8E-10 1.6E-10 1.76-10 1.5E-10
Thyroid 5.5E-I2 1.18*11 6.0E-12 4.9E-12 3.0E-Q9 2.6E-14 3.2E-12 1.1E-12 3.1E-12 1.46-12 1.46-12
Testes o.OE-ai 0.0E-01 0.0E-01 O.0E-01 O.OE-01 O.OE-01 O.OE-01 0.01-01 O.OE-01 0.0E-01 O.OE-01
Ovaries S.5E-12 1.6E-11 1.2E-11 1.2E-11 2.0E-09 2.6E-14 3.2E-12 1.1E-12 2.9E-12 8.6E-13 1.3E-12
Red Marrow 6.71-12 1.3E-11 7.9E-12 7.0E-12 3.9E-09 3.2E-14 3.2E12 1.1E-12 3.3E-12 1.5E-12 1.SE-12
Stomach wall 9.21-11 3.7E-11 4.16-11 4.7E-11 3.8E-09 B.4E-12 4.3E-11 2.1E-11 7.5E-11 1.56-11 6.2E-11
SI * contents 1.1E-10 4.2B-11 4.7E-11 5.4E-11 2.6E-09 4.2E-12 3.2E-12 1.1E-12 3.1E-12 1.0E-12 1.46-12
ULI wall 1.41-10 1.0E-10 1.3E-10 1.6E-I0 2.7E-09 2.3E-12 3. 21-12 1 -IE- 12 3.2E-12 1.1E-12 1.46-12
LL1 wall 5.5E-11 1.2E-10 1.6E-10 1.91-10 2.7E-09 3.8E-13 3.2E-12 1.1E-12 2.9E-12 8.0E-13 1.36-12
Lfvtr 7.7E-12 3.3E-11 1.71-11 1.41-11 4.3E-09 2.6E-14 3.2E-12 1.1E-12 4.2E-12 2.36-12 1.66-12
Kidneys 7.1E-12 1.4E-11 7.71-12 6.81-12 3.1E-09 2.6E-14 3.2E-12 1.1E-12 3.5E-12 1.46-12 1.56-12
Bladder wall 6. 21-12 1.3E-11 6.6E-12 5.71-12 2.3E-09 2.6E-14 3.2E-12 1.1E-12 2.7E-12 7.BE-13 1.36-12
Muscle 6.5E-12 1.2E-11 7.2E-12 6.41-12 3.1E-09 2.6E-14 3.2E-12 1.1E-12 3.3E-12 1.6E-12 1.46-12
Bone Surface 5.8E-12 1.2E-11 6.2E-12 5.2E-12 3.4E-09 3.21-14 3.2E-12 1.1E-12 3.0E-12 1.36-12 1.98*12
Skin 5.3E-12 9.8E-12 5.0E-12 4.1E-12 1.9E-09 2.6E-14 3.2E-12 1.16-12 2.6E-12 1.1E-12 1.3E-12
Spleen 7.9E-12 1.4E-11 9.2E-12 8.4E-12 4.0E-09 2.6E-14 3.2E-12 1.1E-12 4.9E-12 2.3E-12 1.71-12
Uterus 7.81-12 1.46-11 7.9E-12 7.4E-12 2.7E-09 2.6E-14 3.2E-12 1.16-12 3.0E-12 9.0E-13 1.31-12
Pancreas 9.21-12 4.6E-11 2.3E-11 1.9E-11 4.2E-09 2.6E-14 3.2E-12 1.16-12 6.1E-12 2.6E-12 2.0E-12
Total Body 1. 21-11 1.88-11 1.3E-11 1.3E-11 3.3E-09 1.2E-12 5.3E-12 3.71-12 5.7E-12 4.0E-12 3.71-12
Remainder 4.3E-09
Nuclide Rb 69 SP-89 Sr-89 Sr-90 Sr-90 r-90 Y-90 T-91m Y-91-i Y-91 Y-91
fl l.O 0.3 0.01 0.3 0.01 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
:Lass D T D T w Y V Y u Y
ALI (Bq) 4.9E+09 3.71+07 5.21+06 7.31+05 1 .4E+05 2.5E+07 2.3E+07 9.0E+09 6.0E+09 7.06*06 4.2E+06
DAC <Bq/m*3) 2.1E*06 1.51*04 2.21+03 3.0E*02 5.BE+01 1.0E*04 9.SE+03 3.BE+06 2.5E*06 2.96*03 1 .8E*03
Lungs 6.9E-11 2.2E-09 8.1E-08 1.1E-09 3.0E-06 8.9E-09 9.3E-09 4.2E-11 7.0E-11 5.3E08 9.9E-08
Thyroid 1.66-12 3.9E-10 7.5E-12 0.0E-01 O.OE-01 9.4E-12 5.1E-13 6.0E-13 S.0E-13 7.36-11 6.4E-12
Testes 0.0E-01 0.OE-01 0.0E-01 0.0E-01 O.OE-01 O.OE-01 O.OE-01 O.OE-01 0.0E-01 O.OE-01 0.01-01
Ovaries 1.3E-12 3.9E-10 7.51-12 O.OE-01 O.OE-01 9.4E-12 5.1E-13 4.1E-13 3.2E-13 7.3E-11 6.11-12
Red Harrow 2.3E-12 2.8E-09 5.31-11 2.3E-07 2.2E-08 2.71-10 138-11 2.7E-12 7.1E-13 3.5E-09 2.0E-10
Stomach wall 3.0E-11 3.9E-10 7.5E-12 o.OE-ai O.OE-01 3.8E-10 4.3E-10 2.4E-12 2.71-12 3.9E-10 3.4E-10
SI • contents 1.5E-12 3.9E-10 7.5E-12 O.OE-01 O.OE-01 8.9E-10 1.0E-09 1.6E-12 1.76-12 8.71-10 8.4E-10
LLI wait 1.5E-12 1.5E-Q9 5.0E-09 6.6E-10 5.7E-09 4.7E-09 5.4E09 3.8E-12 4.0E-12 4.9E-09 5.0E-09
LLI wall 1.3E-12 3.7E-09 1. 41-08 2.81-09 2.0E-08 1.1E-08 1.3E08 B.5E-12 8.8E-12 1.4E-08 1.5E-08
Liver 2.26-12 3.9E-10 7.SE-T2 0.0E-01 O.OE-01 2.71-10 1.5E-11 3.2E-12 1.2E-12 3.5E-09 2.0E-10
Kidneys 1.7E-12 3.9E-10 7.4E-12 O.OE-01 O.OE-01 9.4E-12 5.1E-13 6.61-13 5.71-13 7.3E-11 6.3E-12
Bladder wall 1.2E-12 3.9E-10 7.4E-12 O.OE-01 O.OE-01 9.4E-12 5.1E-13 2.6E-13 1.21-13 7.2E-11 4.BE-12
Muscle 1.7E-12 3.9E-10 7.5E-12 0.0E-01 O.OE-01 9.4E-12 5.1E-13 6.9E-13 6.11-13 7.31-11 6.8E-12
Bone Surface 2.4E-12 7.6E-09 1.4E-10 6.9E-07 6.6E-08 2.7E-10 1.5E-11 2.6E-12 5.5E-13 3.61-09 2.0E-10
Skin 1.3E-12 3.9E-10 7.4E-12 0.0E-01 O.OE-01 9.4E-12 5.1E-13 3.8E-13 3. 01- 13 7.2E-11 5.5E-12
SpLeen 2.6E-12 3.9E-10 7.5E-12 O.OE-01 O.OE-01 9.4E-12 5.1E-13 1.1E-12 1.1E-12 7.46-11 8.11-12
Uterus 1.3E-12 3.9E-10 7.4E-12 0.0E-01 O.OE-01 9.4E-12 5.1E-13 3.6E-13 2.5E-13 7.26-11 5.21-12
Pancreas 3.2E-12 3.9E-10 7.5E-12 O.OE-01 O.OE-01 9.4E-12 5.1E-13 1 .56-12 1.56-12 7.46-11 8.6E-12
Total Body 2.BE-12 1.2E09 1.2E-09 6.9E-08 4.9E-08 2.1E-10 1.9E-10 1 .56- 12 1.6E-12 1.3E-09 1.5E-09
Remainder 1.2E09 6.9E-08
< noit J- IU A nni tteo a se equiv iients (s ffwm tor selected inhaled -adionucl es a.id heir dau< hters.
Annual limi is of intake are the lesser of the v Lues for stochest c and non-stochastic risks
Nuclide T-92 T-92 r-93 Y-93 Zr-95 2r-95 Zr-95 Zr-97 Zr-97 Zr-97 Nb-95
f1 0.0001 0.0001 0.0001 0.0001 0.002 0.002 0.002 0.002 0.002 0.001 0,01
Class w t y y u y D U y D g
All (S3! 3.2E*08 2.9E*08 1.1E*08 8.9E*07 1.4E*07 1.0E+07 4.9E*06 5.26*07 4.76*07 7.4E*07 4.8E*07
OAC (Bq/nT3) 1 .3E*05 1.2E+05 4.4E*04 3.7E+04 6.0E*03 4.3E+03 2.0E+03 2.2E*04 2.0E+04 3.1E+04 2.06*04
-ungs 1.2E-09 1.2E-09 2.4E-09 2.5E-09 1.8E-08 4.0E-08 2.26-09 3.9E-09 4.0E-09 2.1E-09 5.SE-09
Thyroid 3.7E-12 1.1E-12 5.1E-12 9.2E-13 7.8E-10 1.2E-09 1.4E-09 3.7E-11 2.3E-11 9.6E-11 3.1E-10
Testes 0.06-01 O.OE-01 0.0E-O1 0.0E-O1 O.OE-01 O.OE-01 0.0E-01 O.OE-01 O.OE-01 0.0E-01 0.0E-01
varies 4.9E-12 2.6E-12 8.7E-12 5.3E-12 8.4E-10 5.7E-10 1.9E-09 1.7E-10 1.8E-10 1.8E-10 4.86-10
Red Marrow 1.3E-11 2.1E-12 4.1E-11 4.0E-12 3.2E-09 1.3E-09 1.3E-08 1.4E-10 6.36-11 4.86-10 6.7E-10
Stomach wait 1.4E-10 1.76-10 2.4E-10 2.9E-10 1.1E-09 1.8E-09 1.16-09 4.1E-10 4.7E-10 3.0E-10 5.3E-10
SI 4 contents 1.9E-10 2.4E-10 4.7E-10 5.7E-10 9.8E-10 8.4E-10 1.7E-09 8.8E-10 1.0E-09 6.2E-10 5.6E-10
ULI wall 3.2E-10 4.0E-10 1.56-09 1.8E-09 1.9E-09 1.9E-09 1.8E-09 3.0E-09 3.5E-09 2.0E-09 9.9E-10
LL1 wall 1.7E-10 2.0E-10 1.66-09 2.0E-09 4.1E-09 3.9E-09 3.0E-09 4.2E-09 5.1E-09 2.8E-09 1.9E-09
Liver 1.36-11 2.86-12 4.1E-11 4.3E-12 1.2E-09 2.1E-09 1.3E-09 7.4E-11 6.4E-11 1.2E-10 5.36-10
< i dneys 4.2E-12 1.7E-12 5.9E-12 1.9E-12 6.1E-10 9.6E-10 1.9E-09 6.1E-11 5.1E-11 1.2E-10 5.2E-10
Bladder wait 3.5E-12 B.9E-13 5.7E-12 1.8E-12 3.8E-10 2.1E-10 1.1E-09 6.1E-11 5.3E-11 1.2E-10 2.0E-10
Muscle 4.16-12 1.5E-12 5. 86-12 1.76-12 9.3E-10 1.2E-09 1.9E-09 5.8E-11 4.7E-11 1.1E-10 3.86-10
Bone Surface 1.2E-11 1.SE-12 4.0E-11 3.16-12 2.2E-08 2.3E-09 1.0E-07 1.2E-10 3.5E-11 5.1E-10 2.46-09
Skin 3.46-12 8.16-13 5.0E-12 9.4E-13 5.8E-10 6.3E-10 1.5E-09 3.3E-11 2.1E-11 8.6E-11 2.16-10
Spleen 4.96-12 2.4E-12 6.4E-12 2.4E-12 1.1E09 1.9E-09 1.66-09 7.2E-11 6.1E-11 1.2E-10 6.9E-10
Uterus 4.36-12 1.8E-12 6.7E-12 2.9E-12 S.1E-10 2.8E-10 1.5E-09 8.9E-11 B.6E-11 1.4E-10 2.7E-10
Pancreas 5.4E-12 3.0E-12 6.9E-12 2.9E-12 1.3E-09 2.2E-09 1.7E-09 8.6E-11 7.7E-11 1.3E-10 5.9E-10
Total Body 2.5E-1T 2.3E-11 5.76-11 5.4E-11 1.4E-09 1.8E-09 3.1E-09 1.SE-10 1.4E-10 1.9E-10 4.8E-10
Remainder
Nuclide Mb- 95 Mo-99 Mo-99 Te-99« Te-99* Te-101 Tc-101 Ru-103 Ru-103 Ru-103 Ru-105
fl 0.01 0.05 o.a 0.8 0.8 0.8 0.8 0.05 O.OS 0.05 0.05
Class Y y D w D u U D y M
AL! CBq) 4.1£*07 5.0E+07 9.4E+07 9.66*09 6.4E*09 1.4E*10 1.2E*10 3.8E*07 6.3E+07 2.56*07 5.7E+08
OAC (Bq/m*3) 1.7E*04 2.TE*04 3.9E+04 4.0E*06 2.7E+06 5.8E+06 5.1E+06 1.66*04 2.66*04 1.06*04 2.4E*05
Lur.gs 8.3E-09 4.3E-09 1.2E-09 3.0E-11 2.2E-11 3.0E-11 2.8E-11 9.SE-09 1.0E-09 1.5E-08 S.2E-10
Thyroid 3.6E-10 1.5E-11 1.2E-10 2.1E-11 S.0E-11 7.4E-U 7.1E-14 2.8E-10 6.0E-10 2.66-10 6.2E-12
Testes 0.06-01 0.0E-01 O.OE-01 0.OE-01 O.OE-01 O.OE-01 O.OE-01 O.OE-01 0.0E-O1 0.0E-01 0.0E-01
Ovaries 4.3E-10 9.7E-11 1.3E-10 1.7E-12 2.8E-12 1,41-14 4.66-14 4.0E-10 7.4E-10 3.2E-10 1.5E-11
Red Marrow 4.4E-10 5.1E-11 3.4E-10 2.4E-12 3.4E-12 1.0E-13 1.2E-13 3.5E-10 6.7E-10 3.36-10 9.1E-12
Stomach wall 6.3E-10 2.3E-10 2.2E-10 9.5E-12 1.6E-11 1.7E-I2 1.2E-11 4.9E-10 7.2E-10 5.1E-10 6.8E-11
SI • contents 5.26-10 5.2E-10 1.8E-10 3.5E-12 4.9E-12 2.0E-13 1.6E-12 5.5E-10 8.5E-10 4.7E-10 1.0E-10
ULI wall 9.9E-10 2.4E-09 3.4E-10 S.5E-12 6.9E-12 3.7E-14 1.4E-13 1.3E-09 1.1E-09 1.3E-09 2.2E-10
LLI wall 1.96-09 5.5E-09 S.SE-10 3.7E-12 5.0E-12 1.2E-14 4.6E-14 3.0E-09 1.76-09 3.DE-09 2.1E-10
Liver 6.7E-10 1,11-10 1.9E-09 2.8E-12 4.0E-12 1.8E-13 2.0E-13 4.6E-10 6.8E-10 5.1E-10 1.2E-11
Kidneys 3.5E-10 1.0E-10 1.9E-09 1.66-12 2.6E-12 7.7E-14 1.2E-13 3.1E-10 6.96-10 2.7E-10 8.8E-12
Bladder wall 1.46-10 3.3E-11 1.3E-10 9.0E-13 1.96-12 6.2E-15 1.8E-14 2.4E-10 7.1E-10 1.3E-10 6.4E-12
Muscle 4.U-10 2.8E-11 1.3E-10 1.5E-12 2.2E-12 9.9E-14 1.1E-13 3.2E-10 6.1E-10 3.2E-10 3. IE - 12
Bone Surface 5.1E-10 4.16-11 5.3E-10 1.8E-12 2.8E-12 8.3E-14 1.1E-13 2.8E-10 6.2E-10 2.4E-10 6.5E-12
Skin 2.1E-10 1.41*11 1.1E-10 7.4E-13 1.2E-12 4.7E-14 5.2E-14 2.0E-10 4.6E-10 1.7E-10 4.9E-12
Spleen 6.3E-10 3.6E-11 1.4E-10 2.SE-12 3.8E-12 1.8E-13 2.9E-13 4.3E-10 7.0E-10 4.7E-10 1.26-11
Uterus 1.9E-10 4.56-11 1.3E-10 1.3E-12 2.5E-12 1.2E-14 4.6E-14 2.6E-10 7.0E-10 1.6E-10 9.9E-12
Pancreas 7.1E-10 4.36-11 1.7E-10 3.6E-12 5.1E-12 2.2E13 4.3E-13 5.1E-10 6.9E-10 6.0E-10 1.46-11






TABLE 3.11 Specific committed dose equivalents (Sv/Bq) for selected inhaled radionuclides and their daughters.
Annual limits of intake are the lesser of the values for stochastic and non-stochastic risks.
Nuclide Ru-105 llu-IOS Ru-106 Ru- 106 Ru-106 Ag-llOm *.9-110m Ag-llOm Te-125m Te-125m Te-127m
fl 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.2 0.2 0.2
Class Y D W Y D M Y D U
ALI CSq) 4.86+08 5.66+08 2.0E*06 4.06+05 3.3E*06 7.56+06 3.56+06 5.2E+06 1.4E*07 2.4E+07 9.66+06
DAC (Bq/m-3) 2.0E+05 2.46+05 8.3E+02 1.7E+02 1
-4E+03 3.16+03 1.56*03 2.2E+03 5.76+03 9.9E+03 4.06+03
-urgs 5.56-10 3.6E-10 2.1E-07 1.0E-06 1.8E-08 3.1E-08 1.2E-07 8.06-09 5.2E-10 1.26-08 8.96-10
Thyroid 4.0E-12 1.46-11 4.0E-09 1.7E-09 1.4E-08 2.0E-09 6.3E-09 1.76-09 1.11-10 4.2E-11 2.46-10
Testes 0.OE-01 0.0E-O1 0.OE-01 0.06-01 0.OE-01 0.06-01 0.06-01 0.06-01 0.0E-01 0.OE-01 0.06-01
Ovaries 1.51-11 2.6E-11 4.0E-09 1.3E-09 1.4E-08 2.36-09 2.46-09 3.26-09 1.3E-10 8.2E-11 2.56-10
Red Harrow 7.4E-12 1.86-11 4.1E-09 1.8E-09 1.4E-08 2.96-09 6.76-09 4.06-09 3.4E-09 1.36-09 1.46-08
Stomach wall 8.0E-11 8.8E-11 5.0E-09 2.96-09 1. 46-08 4.56-09 1.0E-08 6.56-09 1.4E-10 1.46-10 2.6E-10
SI * contents 1.2E-10 1.3E-10 6.0E-09 3.4E-09 1.5E-08 3.46-09 3.4E-09 6.0E-09 1. 76-10 2.16-10 2.9E-10
ULI wall 2.6E-10 2.4E-10 1.66-08 1.46-08 1.86-08 5.1E-09 5.2E-09 8.4E-09 4.0E-10 9.1E-10 7.2E-10
ULI wall 2.5E-10 1.9E-10 3.96-08 3.76-08 2.5E-08 5.86-09 5.8E-09 3.96-09 9.4E-10 2.5E-09 1.9E-09
Liver 9. 9E-12 2.0E-11 4.2E-09 2.3E-09 1.4E-08 2.56-08 1.86-08 8.0E-08 1-16-10 8.06-11 2.46-10
Kidneys 7.0E-12 1.8E-11 4.1E-09 1.76-09 1.46-08 4.56-09 6.26-09 1. 16-08 1.1E-10 4.56-11 2.4E-10
Bladder wall 4.4E-12 1.76-11 4.0E-09 1.26-09 1.46-06 1.16-09 1.06-09 2.26-09 1.1E-10 4.4E-11 2.4E-10
Muscle 6.4E-12 1.66-11 4.0E-09 1.86-09 1.4E-08 2.9609 7.1E-09 4.1E-09 1.2E-10 7.4E-11 2.4E-10
Bone Surface 4.46-12 1.5E-11 4.0E-09 1.66-09 1.4E-08 2.1E09 5.2E-09 3.0E-09 3.7E-08 1.3E-08 S.2E-08
Skin 3.06-12 1.2E-11 3.96-09 1.46-09 1.3E-08 1.6E-09 3.7E-09 2.4E-09 1.1E-10 4.4E-11 2.46-10
Spleen 1.06-11 2. 06-11 4.2E-09 2.26-09 1.4E-08 3.8E-09 1.1E-08 4.26-09 1.2E-10 7.66-11 2.4E-10
Uterus 8.66-12 2.1E-11 4.0E-09 1.26-09 1.46-08 1.5E-09 1.5E-09 2.96-09 1.16-10 4.76-11 2.4E-10
Pancreas 1.3E-11 2.3E-11 4.2E-09 2.56-09 1.46-06 6.76-09 1.3E-08 1.3E-08 1.16-10 6.66-11 2.46-10
Total Body 1.7E-11 2.46-11 7.1E-09 1.7E-08 1.4E-08 3.76-09 8.4E-09 5.9E-09 4.3E-10 3.66-10 1.46-09
Remainder 1.4E-08 6.76-09 1.3E-08
Nuclide Te-127m Te-127 Te-127 Te-129m Te-129m Te-129 Te-129 Te-I31m Te-131 Te-132 1-125
fl 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 1.0
ALI CBq) 9.56+06 8.4E+08 6.46+08 2.4E+07 9.16+06 2.4E+09 2.76+09 1.5E+07 1 .86+08 8.4E+06 2.4E+06
DAC (Bq/m'3) 4.06+03 3.5E+05 2.76+05 9.86+03 3.8E+03 9.86+05 1.16+06 6.3E+03 7.76+04 3.5E+03 1.0E+03
Lungs 3.36-08 2.86-10 4.36-10 2.26-09 4.06-06 1.36-10 1.56-10 5.96-10 2.56-10 6.2E-10 1.16-10
Thyroid 9.66-11 6.5E-12 1.86-12 3.96-10 1.56-10 1.66-12 5.16-13 3.3E-06 2.76-09 6.0E-08 2.16-07
Testes 0.06-01 0.0E-01 0.06-01 0.06-01 0.06-01 0.06-01 0.06-01 0.0E-O1 0.06-01 0.OE-01 0.06-01
Ovaries 1 .16-10 6.6E-12 2.06-12 4.16-10 1.86-10 1.86-12 5.06-13 1.66-10 5.76-12 3.46-10 1.36-11
Red Marrow 5.36-09 1.46-11 4.06-12 8.6E-09 3.0E-09 2.06-12 6.1E-13 9.46-11 5.56-12 3.56-10 3. 66-11
Stomach wall 2.26-10 4.26-11 4.56-11 4.76-10 4.56-10 5.26-11 1.66-11 9.96-11 8.76-11 3.4E-10 1.96-11
SI + contents 3.56-10 6.46-11 7.16-11 6.06-10 7.86-10 3.66-11 1.16-11 2.5E-10 7.66-11 3.66-10 1.46-11
ULI wall 1.8E-09 1.SE-10 2.16-10 1.76-09 3.96-09 2.56-11 7.56-12 5.1E-10 7.56-11 3.66-10 1.46-11
LLI wall 5.6E-09 1. 9E-10 2.2E-10 4.2609 1.1608 6.16-12 1.86-12 7.96-10 5.16-12 8.76-10 1.36-11
Lfvtf 1.1E-10 6.5E-12 1.9E-12 3.96-10 1.86-10 1.86-12 6.06-13 9.56-11 5.66-12 3.5E-10 1.56-11
Kidneys 9.76-11 6.56-12 1. 96-12 4.0E-10 1.66-10 1.76-12 5.2E-13 B. 66-11 5.26-12 3.5E-10 1.26-11
Bladder wall 9.36-11 6.5E-12 1.96-12 3.96-10 1.56-10 1.66-12 4.76-13 9.46-11 4.56-12 3.76-10 1.36-11
Muse I
e
1.16-10 6.56-12 1.96-12 4.06-10 1.76-10 1.76-12 5.46-13 8.36-11 5.26-12 3.36-10 8.9E-11
Bone Surface 2.0E08 1.46-11 4.1E-12 1.96-08 6.86-09 2.0E-12 6.26-13 7.46-11 4.96-12 3.36-10 3.6E-11
Skin 9.56-11 6.46-12 1.86-12 3.96-10 1.56-10 1.66-12 4.86-13 5.46-11 4.26-12 2.56-10 4.16-11
Spleen 1.16-10 6.56-12 1.96-12 4.0E-10 1.86-10 1.86-12 6.16-13 9.16-11 6.0E-12 3.5E-10 1.56-11
Uterus 9.56-11 6.56-12 1.96-12 4.06-10 1.5E-10 1.76-12 4.96-13 1.26-10 5.4E-12 3.96-10 1.36- 11
Pancreas 1.16-10 6. 66-12 2.06-12 4.0E-10 1.86-10 1.96-12 6.5E-13 9.56-11 6.96-12 3.56-10 1.56-11
Total Body 1.16-09 1.3E-11 1.0E-11 1.16-09 1.0E-09 4.1E-12 2.96-12 1.06-10 1 .06- 11 3.5E-10 1.36- 10
Remainder
-—
TABLE 3-12 Specific committed dose equivalents (Sv/Bq) for selected inhaled radionuclides and their daughters.
Annual limits of intake are the lesser of the values for stochastic and non-stochastic risks.
Nuclide 1-130 1-131 1-133 1-134 1-135 Cs-134 Cs-136 Cs-137 Cs-138 Ba-139 Ba-140
fl 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.1 0.1
Class D D D a D D D D D D
All (Bq) 2.8E*07 1.66*06 1.16*07 1.7E+09 6.46*07 4.1E+06 2.6E+07 6.1E*06 2.1E+09 1.15*09 5.26*07
DAC (Bq/m*3> 1.2E+04 7.5E+02 4.66*03 7.3E+05 2.7E+04 1.75+03 1.1E*04 2.66*03 8.7E+05 4.6E+05 2.2E*04
Unti 5.96-10 6.56-10 8.2E-10 1.4E-10 4.46-10 1.2E08 2.3E-09 8.5E-09 1.66-10 2.5E-10 1.65-09
Thyroid 1.8E-08 2.36-07 4.5E08 2.6E-10 7.SE-09 1.16-08 1.76-09 7.6E-09 3.6E-12 2.4E-12 2.46-10
Testes 0.OE-01 0.06-01 0.06-01 O.OE-01 O.OE-01 0.06-01 0.06-01 O.OE-01 O.OE-01 0.06-01 0.05-01
Ovaries 2.7E-11 2.2E-11 1.96-11 4.2E-12 1.71*11 1.15-08 1.7E-09 7.85-09 3.3E-12 2.5E-12 4.26-10
Red Marrow 4.56-11 5.7E-11 2.7E-11 6.06-12 2.26-11 1.2E-08 1.9E-09 8.06-09 4.06-12 2.5E-12 1.46-09
Stomach wall 1.26-10 7.1E-11 1.06-10 7.06-11 1.06-10 1.2E-08 2.0E-O9 8.36-09 7.86-11 9.36-11 2.66-10
SI * contents 3.4E-11 2.3E-11 2.26-11 5.56-12 1.96-11 1.4E-08 2.1E-09 6.86-09 3.75-12 7.36-11 5.16-10
UU wall 3.56-11 2.3E-11 2.2E-11 5.76-12 1.96-11 1.3E-08 2.0E-09 8.75-09 3.95-12 5.96-11 1.46-09
LLI wad 3.16-11 2.2E-11 2.16-11 4.86-12 1.86-11 1.4608 2.1E-09 8.8E-09 3.4E-12 1.5E-11 4.3E-09
Liver 5.4E-11 3.5E-11 2.96-11 8.4E-12 2.86-11 1.35-08 2.0E-09 8.3E-09 5.2E-12 2.5E-12 2.76-10
Kidneys 4.06-11 2.66-11 2.4E-11 6.6E-12 2.26-11 1.36-08 2.0E-09 8.35 09 4.36-12 2.46-12 2.85-10
Bladder wall 3. 06-11 2.16-11 2.0E-11 4.5E-12 1.76-11 1.3E-08 2.1E-09 8.65-09 3.16-12 2.45-12 3.06-10
Muscle 4.8E-11 7.26-11 2. 96-11 6.1E-12 2.36-11 1.1E-08 1.7E-09 7.56-09 4.06-12 2.46-12 2.66-10
Bone Surface 4.06-11 5.26-11 2.56-11 5.36-12 2.06-11 1.1E-08 1.7E-09 7.6E-09 3.6E-12 2.4E-12 2.65-09
Skin 3.1E-11 4.86-11 2.26-11 4.16-12 1.76-11 7.86-09 1.2E-09 6.3E-09 3.1E-12 2.4E-12 2.2E-10
Spleen 5.66-11 3.56-11 2.96-11 1.06-11 2.86-11 1.36-08 2.06-09 8.3E-09 6.26-12 2.5E-12 2.6E-10
Uterus 3.1E-11 2.26-11 2.06-11 5.05-12 1.96-11 1.46-08 2.46-09 8.7E09 3.4E-12 2.5E-12 3.OE-10
Pancreas 6.46-11 3.66-11 3.26-11 1.36-11 3.46-11 1.26-08 1.9E-09 8.1609 8.06-12 2.6E-12 3.0E-10
Total Body 5.96-11 1.56-10 5.26-11 8.26-12 3.16-11 1.16-08 1.76-09 7.56-09 6.46-12 7.06-12 4.16-10
Remainder 1.46-06 2.45-09 8.75-09
Nuclide Ba-141 La-140 La-140 La- 142 La- 142 Ce-141 Ce-141 Ce-143 Ce-143 Ce- 144 Ce-144
fl 0.1 0.001 0.001 0.001 0.001 0.0003 0.0003 0.0003 0.0003 0.0003 0.0003
Class D D H D W w Y w Y u Y
ALI <Bq) 2.66*09 5.56+07 4.3E+07 8.06*08 1.26*09 2.66+07 2.26+07 6.66+07 5.96*07 9.5E*05 5.36*05
DAC (Baym'3) 1.16*06 2.36+04 1.8E+04 3.46*05 4.86*05 1.1E-04 9.36+03 2.76+04 2.46*04 4.06*02 2.2E*02
Lungs 1.1E-10 1.7E-09 4.2E-09 3.1E-10 3.6E-10 1.16-06 1.75-08 3.65-09 3.96-09 1.86-07 7.8E-07
Thyroid 1.3E-12 1.26-10 6.96-11 9.0E-12 5.0E-12 4.6E-11 2.66-11 1.26-11 6.0E-12 1.9E-09 2.9E-10
Testes 0.06-01 0.06-01 O.OE-01 0.05-01 O.OE-01 O.OE-01 0.06-01 O.OE-01 O.OE-01 O.OE-01 0.0E-01
Ovaries 1.46-12 3.66-10 4.5E-10 1.7E-11 6.2E-12 8.5E-11 5.66-11 6.96-11 7.4E-11 1.9E-09 2.3E-10
Red Harrow 1.56-12 4.4E-10 2.1E-10 1.4E-11 7.0E-12 4.1E-10 9.0E-11 7.6E-11 2.9E-11 2.5E-08 2.7E-09
Stomach wal
I
3.9E-11 3.9E-10 4.7E-10 1.26-10 5.16-11 1.9E-10 1.6E-10 1.96-10 2.1E-10 2.7609 1.1E-09
SI * contents 2.36-11 6.56-10 9.76-10 1.16-10 4.36-11 3.16-10 2.96-10 4.35-10 4.96-10 3.85-09 2.15-09
UL1 wall 3.16-11 1.66-09 2.96-09 1.1E-10 4. 11-11 1.46-09 1.55-09 1.86-09 2.16-09 1.35-08 1.25-08
LLI wall 1.7E-11 2.8E-09 5.4E-09 3.4E-11 1. 26-11 3.65-09 4.16-09 3.75-09 4.36-09 3.46-08 3.46-08
.',ver 1.7E-12 3.5E-09 7.6E-10 3.9E-11 1.6E-11 3.46-09 2.65-10 5.16-10 4.85-11 2.56-07 2.56-08
K i dneys 1.5E-12 3.4E-10 1.7E-10 1.4E-11 6.3E-12 9.66-11 3.25-11 2.46-11 1.56-11 2.16-09 3.15-10
Bladder wall 1.2E-12 1.96-10 1.7E-10 9.7E-12 3.2E-12 4.76-11 1.85-11 2.3E-11 2.0E-11 1.95-09 2.06-10
Muscle 1.46-12 2.06-10 1.5E-10 1.2E-11 6.4E-12 7.16-11 4.5E-11 2.2E-11 1.6E-11 1.9E-09 3.4E-10
Bone Surface 1.3E-12 4.06-10 1.46-10 1.1E-11 5.5E-12 3.8E-09 2.5E-10 7.8E-11 1.6E-11 4.SE-08 4.7E-09
Skin 1.26-12 1.46-10 7.66-11 7.86-12 3.9E-12 4.4E-11 1.8E-11 1.26-11 6.4E-12 1.95-09 2.5E-10
Spleen 2.06-12 2.16-10 1.76-10 1.76-11 1.06-11 2.9E-09 2.26-10 4.4E-10 4.3E-11 2.2E-07 2.26-08
Uterus 1.36-12 2.36-10 2.3E-10 1.5E-11 5.36-12 5.6E-11 2.66-11 3.2E-11 3.06-11 1.96-09 2.16-10
Pancreas 2.4E-12 3.96-10 2.4E-10 2.3E-11 1.2E-11 1.4E-10 6.2E-11 3.5E-11 2.5E-11 2.2E-09 4.7E-10
Total Body 3.4E-12 3.46-10 2.5E-10 1.8E-11 1.2E-11 3.76-10 3.1E-10 1.1E-10 9.4E-11 1.4E-08 1.3E-08
Remainder
TABLE 3.13 Specific committed dose equivalents (Sv/Bq) for selected inhaled radionuclides and their daughters.





































































































































































































TABLE 3.14 Comparison of specific committed dose equivalents CSv/Bq) to the results in ICRP Publication 30 for
selected ingested radionuclides and their daughters. Values reported are greater than or equal to
nuc I i de | P-32 [ Mn-54 | Co 60 | Ni-63 1 Zn 65
fl
| 0.8 | 0.1 1 o. H | 0.05
1 o.
Program
| ICRP DOSE | 1 CRP DOSE | ICRP DOSE | 1 CRP DOSE | ICRP DOSE
LUflfl
1 I 2.3E-10 2.3E-10 | 8.7E-10 8.8E- 10 | 8.5E-11 B.5E-11 | 3.1E-09 3.1E-09
Thyroid
1






6.5E-10 6.6E-10 | 9.5E-10 9.5E-1Q | 3.2E-09 3.2E-09 | 8.5E-11 8.5E-11 | 3.5E-09 3.5E-09
Red Harrow
I





1 | 1.0E-10 1.0E-10
1
SI + contents
I | 9.8E-10 9.9E-10 | 3.6E-09 3.6E-09
|












! 2.2E-09 2.2E-09 i 1. 1E-0B 1*11-08 i 9.2E-10 9.2E-10 5.0E-09 5.0E-09
Liver







| 6.5E-10 6.6E-10 2.8E-10 2.8E-10 1.1E-09 1.11-09 8.5E-11 8.5E-11 3.3E-09 3.3E-D9













1 5.0E-10 5.0E-10 2.1E-09 2.1E-09 4.8E-09 4.7E-09
Nuclide
| Sr-89 Y-91m Mo- 99 Tc-99m Ru- 05
fl
1 0.3 0.0001 0.8 0.8 0.05
Program
I








1 6.9E-12 6.9E-12 2.2E-10 2.3E-10 9.7E-12 9.5E-12 9.7E-11 9.5E-11
Red Marrow
| 3.2E-09 1.6E-09 5.3E-10 4.8E-10 6.3E-12 6.0E-12
Stomach wall
I 4.9E-11 4.9E-11 6.7E-10 6.7E-10 7.2E-11 3.9E-11 5.0E-10 5.01-10
SI * contents
I 3.1E-11 3.1E-11 2.2E-11 2.2E-11 7.9E-10 7.9E-10
ULI Mall | 7.3E-09 7.2E-09 3.1E-11 3.1E-11 1.4E-09 1.5E-09 3.7E-11 3.6E-11 1.6E-09 1.6E-09
LLI wall












































. iE- n \. n*ii | 1. lt-11 9.3E-12 |
TABLE 3.15 Comparison of specific cammed dole equivalents CSv/Bo.) to the results in ICRP Publication 50 for
selected ingested redionuclides and their daughters. Values reported are greater than or equal to
'e-127





0.2 | 1.0 |






4.3E-08 4.3E-08 | 4.8E-07 4.5E07 | 1.8E-08 1.7E-0S I 1.3E-08 1 2E-1
Testes








stomach wall | 2.4E-10 2.4E-10 | |
•'.content.
| 3.9E-1D 3.9E-10 | |
, ,.„.„ ,
-all
| I.2E09 1.2E-09 | 4.6E-09 5.4E-10 | | | ,.,,.„, ,M _ 0S

































































I | 2.8E-10 2.6E-10 |Red Marrow
| j
stomach wall
| 3.9EI0 3.9E-10 | | 4. 1E ., 4., E . 10 |
SI. contents |1.9E-10 1.8E-10 | 1.4E-09 I.4E-09 | 0.6E-11 9.6E-II | 1.0E-O9 1.0E-09 I 8.7E-10 8 2E-10
111 -all
|
2.2E-10 2.2E-IO | 5.7E-09 5.9E-09 | | 3.6E-09 3.6E-09 | 3.8E-D9 3 75-09
III wall


























Comparison of wild emitted dose equivalents <Sv/Sq> to the results in IMP PuM i cat i on 30 for
selected inhaled radionuclides end their d.uqhters. values reported ore oreeter than or equal to































4.81-10 4.6*. 10 | 2.71-11 2.71-11 | 7.11-10 7.11-10 | 3.31-09 3.31-09 | 4.01-09 4 01-09
Red harrow
|









I | 4.11-09 4.11-09 |
III -all
|
1.5E-09 1.SE-09 | 5.91-11 6.81-11 | | 4.61-09 4.81-09 | 8.2E-09 8.1E-09
L,v,r
I I






















































Program ICRP DOSE ICRP DOSE
I







































7.31 07 6.9E-07 2.41-09 2.41-09


















































2-0E-08 1.8E-0S 1. IE-OS 1. IE-OS I
'""
I | | | j
S! * content, I
, , ,, „_





5 ' 3E '° 5.1E-10 | o.TE-10 O.TE.,0
LLI ».l| | 4 2E-09 4 2E-09 ! , , '
'• 5E '°* 'W "°°
I















































| , CHP 00SE | ICRp DOSE
| ICRP DOSE | IMP DOSE | ICRP
rZ« !
* , ""°' '*""
!















SI contents | 1.0E-09 1.0E-09 |
W-l «U
| 3.5E-09 3.5E-09 | 2.1E-09 2.1E-09 I !r 1 ! 5 - ,e -w 5 - ,e -m
i
4











Bone Surface | j I
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Appendix A
Listing of Computer Programs
1-17
ATOMNO FOR
SUBROUTINE HAKE: ATOHHO FORTRAN
PURPOSE: Search for atomic number of the nuclide




DATA ZNAHE/'H-', -HE', 'LI', 'BE', 'B-','C-','»-','0-','F-'
,
'NE'.'NA',


















SUBROUTINE HAKE : DECAY FORTRAN
PURPOSE: Provide the decay scheme of a radionuclide















OPEN CUNIT-1, FILE- ISOTlPS',ACCESS-DIRECT',RECL-«,FORM- FORMATTED
i'.STATUS—OLD')
OPEN CUNIT-2, FILE"' ISOTOPE',ACCESS-DIRECT', RECL-59.FORM-FORMATTE
U>', STATUS—OLD')
OPEN CUNIT-3, FILE—ALPHA' .ACCESS—DIRECT', RECL-20, FORM-' FORMATTED'
&, STATUS—OLD')
OPEN (UN I T-4, FILE— BETA',ACCESS—DIRECT', RECL'39, FORM" FORMATTED',
&STATUS—OLD')
OPEN (MUX, FILE— POSITRN', ACCESS—DIRECT', RECL -31. FORM«'FORMATTE
SO', STATUS- 'OLD')





Coopering the given nuclide name


















IF (ERT .EO. UOR0)THEN





















Pointer to first alpha
Number of betas
Pointer to first beta
Number of positrons
Pointer to first positron
Number of electrons
Pointer to ffrst electron
Number of photons




&N, 11, 12,13, 14,15, 16,17,18
25 FORHAT(A8, 13, I3,G10.0,A1, 11,13,12, 13,12,14, 12, 13, 13, 14, 13, 14)
ALPHA













BE1 > Endpoint energy in HeV
862 » Average energy in Hev
BE3 > Intensity
39 IC1*0










P0S1 * Endpoint energy in HeV *
P0S2 > Average energy in HeV •




IF (13 .EO. 0)GO TO 59

























PH01 > Energy in Mcv
PH02 > Intensity
69 m«0
IF (17 .EQ. 0)0OT0 79







Convert half lives into days
79 IF(C .EO. 'S')THER
HLIFE'HLIFE/66400.
ELSE IF (C .EO. 'N')THEN
KLIFE«HLIFE/(60.«2«.)
ELSE IF (C .EO. 'R'lTHEN
KIIFE.BL1FE/24.









* SUBROUTINE NAME: 0ECAT1 FORTRAN
* PURPOSE: Find half-lives and names of the given isotope
* end its daughters
* DECAY HODE: A >B >C »
* DATA FILES REQUIRED: a) ISOTIPS FILE
* b) ISOTOPE FILE
* c> DAUTER FILE
* DESCRIPTION OF VARIABLES:
WORD > Name of the given isotope
RHALF > Vector of half-lives of the given isotope
* and its daughters
• ULIFE > Vector of half-life units of the given
isotope end its daughters
• BRA > Vector of branching ratios of the given
isotope (BRA(1)-1) and its daughters
RADIO > Vector of names of the given isotope and
* its daughters















IF (UORD(1:1) .BE. 'R'JTHEN
ML321

















IF CITR .EO. 0)GOTO SO








U >H«lf life units <S,N,H,D,Y)
K >Nuaber of daughters
L >Pointer to first daughter
H >Nunber of alphas
N- ->Pointer to first alpha
11 >Nunber of betas
12 >Pointer to first beta
13 >Number of positrons
14 >Pointer to first positron
15 >Number of electrons
16 >Pointer to first electron
17 Htunber of photons






19 >Pointer to daughter isotope
TIELD->Branchtng ratio of daughter
I«1
30 IF (K -EO. 0)GOTO 45
YSAVE«0.
I SAVE -0
If K > 1 and the decay node is A >B1, and A >B2,
DECAY1.F0R
then save the pointer end yield of only the higher
Drenching retio
DO 35 J2"L,L»K-1
READ<12, 40, REC-JZ,ERR'70>I9, YIELD
40 FORKAT(I3,1PEI3.6>


















55 FORMAK//,' ERROR: No match found in file "ISOTIPS" for the given
iredionuc I ide! !',/,' SOURCE: DECAY1 FORTRAN',/,' CORRECTIVE ACTION:
& Try another nuclide!! ',////>




65 FORMAT!//,' ERROR: Unable to reed the decey scheme from file "ISOT
SOPE" for the given redio nuclide! I ',/,' SOURCE: DECAY1 FORTRAN',/
S,' CORRECTIVE ACTION: Try another nuclide! I ',////)




75 F0RMAT(//,' ERROR: Unable to read the branching ratio and pointer
lof daughter nuclide in file "OAUTER"! I ',/, ' SOURCE: DECAY1 FORT
iRAN',/,' CORRECTIVE ACTION: Try another nuclide! I ',////)




85 FORMATC//,' ERROR: Unable to read the decey scheme of the daughter
I fro« file "ISOTOPE"!',/,' SOURCE: DECAY1 FORTRAN',/,' CORRECTIVE
&ACTION: Try enother nuclide! I ',////)



























































































FILEDEF ISOTIPS DISK 1SOTIPS FILE A1 (PERN XTENT 496
F1LEDEF ISOTOPE DISK ISOTOPE FILE A1 (PERH XTENT 496
FILEDEF ALPHA DISK ALPHA FILE Al (PERH XTENT 360
FILEDEF BETA DISK BETA FILE Al (PERH XTENT 1700
FILEDEF POSITRN OISX POSITRN FILE A1 (PERH XTENT 138
FILEDEF ELECTRN DISX ELECTRN FILE Al (PERH XTENT 3882
FILEDEF PHOTON OISX PHOTON FILE A1 (PERH XTENT 7480
FILEDEF ABSFRAC DISX ABSFRAC FILE Al (PERH XTENT 4560
FILEDEF BFFRAC DISX BFFRAC FILE A1 (PERH XTENT SOI
FILEDEF DAUTER DISX DAUTER FILE Al (PERH XTENT 291
FILEDEF RETENT DISX RETENT FILE Al (PERH XTENT 460
FILEDEF INDEXI DISX INDEXI FILE Al (PERH XTENT 46
FILEDEF INDEXO DISX INDEXO FILE Al (PERH XTENT 46
FILEDEF EXCEPT DISX EXCEPT FILE Al (PERH XTENT 695
FILEDEF LIST OISX LIST FILE Al (PERH XTENT 26


















































WORD > Na»e of the given isotope
K2 > Atonic i«ttr of the nuclide






CHARACTER'S UORD ,RAD!OC50),NuCLID, ISOTOP
CHARACTER«15 UNITS13)






DATA AMAD, CUSS, F1,a,c«>T,MAIS,lSAr,MO«E,»0«,llu,INRE/1.,'D',0., 0,1
«,2«2, 0,2,1,2/
OATA SEX,OUI/'F',2/
DATA FFILE /4"DUX«Y '/
OATA ltS/1,2,3,4,5,6,7,8,9,10,11,12,18,13,14,15,16,17/
DATA KT/12,6,7,8,9,11,10,1,13,4,18,14,5,15,16,3,2,17,19/
DATA THAHE/' Lungs', 'Thyroid', 'Testes', 'Ovaries', 'Red Marrow' , 'Stool
ioch nail', 'SI • contents', 'ULI nail', 'ill nail', 'Liver', 'Kidneys',
i'Bledder nail', 'Muscle', 'Bone Surface', 'skin', 'Spleen', 'uterus', 'P
tancreas', 'Total Body', 'Oonads', 'Adrenals', 'Lens', 'Thymus', 'Brain'/
DATA SNAME/'BlacMer','sto«ech',
'SI', 'Ull'.'UI', 'Kidneys', 'Liver',
t'Lungs', 'Muscle', 'Ovsries', 'Pancreas', 'Trab Bone', 'Skin', 'Spleen',








15 FORMAT(2(/),29X,' DOSE VERSION 1.0, 1987'./)
WRITE C',20)
20 F0RHAT(19X, 'Written by: Amiruddin Huda')
WRITE <\22)
22 F0RMAT<19X, 'Address: c/o Dr. R. E. Fan')
WRITE <*,25)
25 F0RKATC19X,' Department of Nuclear Engineering')
DOSE FOR
WRITE (*,30>
30 raMWIM,' k»».« st.t. university,
WHITE t',35)
35 FOMHTOm.' Monh.tton, Kansas 66502- //>
PRINT*,'"
IwmwiiimMti




40 FORMAT,//, 5X,' PROGRAM MANE: DOSE FORTRAN')
WRITE (*,45)
45 F0RMAT<5X,' BASIS: ICRP Methodology')
WRITE C,50)
SO F0RMATC5X,' PURPOSE: TO CALCULATE')
WRITE (*,55>
55 F0RMAT(/,BX,'., SpMifie mitt* dose equivalent, KFIFTY (Sv/Bq)
4 in target organs')
WRITE (\60)







" "**'• AL '
"*" °f the nucii* ,>
"c"*"''
8
"'"" D"' i™d *' r COnCen,r" i '»'' "« <*""•« of th, nu
WRITE (\75)
75 FORHAT./.oX,'., stifle Effect,,, £„,r,y Tlbl . for ,7 aoure„ , ,Sy targets')
WRITE (',80)













- IBM-PC/XT/AT or co-patible
.icrocomputer'
• mm •'' '
"
"""""infr™e '"*""' °" <"• ojrtwUM ,yste,
PRIMT •,' Select integer or V
* PRINT *






- Data input fro. the keyboard'
DOSE FOR
PRINT •/ 1 - Data input from a file'
PRINT V 2 - Preparation of a data input file'
PRINT •




IF(NDATA .NE. .AND. (NOATA



















IF (NOATA .EO. DGOTO 255
' Identification of nuclide *
«**H«MMWWM«WMHH«Hl l t l >ltMl l il*Hmi lllimMW»«H»«W«
125 CALL CLEAR
PRINT •
PRINT '.'NOTE: TO INITIATE TERMINATION PRESS <RETURN>II'
PRINT •
WRITE (*,130)
130 FORKATdOl/),' Enter radionuclide identification, i.g., cs-137',/)
READ (\5,ERR = 125,END=9000)WORD
ri iiimiw
WORD lUCASEIWORD, 1,2)
W*«»IIWM*im» iM > *I«MII » >«>«MM < * l«miMiW««
Call subroutine DECAY1 for daughters •
CALL DECAY1 (WORD, RNALF.UL1FE, BRA, RADIO, NO, *125)
00 142 1=1, NO
ISOTOP-RADIO(I)
DOSE FOR
Convert half-lives into days
IF (ULIFE(I)
.EO. 'S'JTHEN
RHALFl I )=«HALF( I 1/86400.
ELSE IF (ULIFECI)
.EO. 'H')TNEN










IF (I .HE. DTHEN
IF (IS0T0(>(1:2)












In case of noble radioactive gases or elemental tritiu











Identification sex of subject
135 CALL CLEAR
WRITE (*,140)














150 FORMATC///,' Would you like to see the specific effective energy ,





1"'./.' 2 »0' ,////,' Select option by integer-—.')
READ (*.115,E«R=K5,EH0»151)OUI





IF (OUI .M, 1) THEK
155 CALL CLEAR
PRINT »,' Enter file specification for table (less than or equal
& to 7 characters):'
REAO (*,121,ERR*155,EHD*156)FFILE(1!






165 FORMAT(10(/),' Enter integer for units selection',//,' 1 >,a,//
*' 2 ',A,//,' 3 >,A,/)
REAO (*,115,ERR'160,EHD-161)HU




IF (NO .GT. DTHEH
170 CALL CLEAR
PRIHT *,' THE DAUGHTERS OF THE GIVEN HUCLIDE ARE:'
DO 175 I=2,HO
175 PRIHT ', RADIO(I)
PRIHT *
PRIHT *
PRIHT *,' Uculd you like to see their s-tables too?'
PRIHT *
PRIHT •,' 1 Yes'
PRIHT *,' 2 Ho'
PRIHT •
PRIHT ",' Select option by integer---.'
READ (*,115,ERR-170,EHD-171)MOH






Ouery calculation of dose coonittments
176 CALL CLEAR
PRINT *,' Choose one of the following:'
PRINT •
PRINT *,' 1 Continue data entry for calculation of dose con
aittments'
PRIHT *,' 2 Conclude data entry and STOP'
DOSE .FOR
PRINT *,' 3 Proceed with calculations of S-natrix only
IF (NDATA ,n. 2>THEN










IF (INRE .EH. 2JBOTO 9009
IF (INRE .EO. 3 .AND. (NDATA .EO. 0))GOTO 260
IF (INRE -NE. 1 .AND. (NDATA .EO. 2))THEN
WRITE(75,10)UOR0,SEX,OUI,NU,HON, INRE, OPT, HA IS, I SAY , MORE, KZ.CL
USS,AMAD,F1,FFILE(1),FFILE(2),FFILE(4)
IF (INRE .EO. 3)THEN
NDATA=1
REUIND(7S)




7 IF (NDATA .EO. DTHEN
READ(75, 10,ERR=9009,END*9009)UORO,SEX,OUI ,NU,HON, INRE, OPT, HAI
SS.ISAY, »ORE, KZ, CLASS, AMAU,F1,FF I IE < 1 > , Ff I IE (2) , FF I IE < 4 >
NUCLID-UORO
CALL DECAY1 (UORO.RHALF.ULIFE, BRA, RADIO, NO, •9009)
DO 179 l«1,N0
ISOTOP'RADIOd)
Convert half. lives into days
IF (ULIFE(I) .EO. 'S'lTHEN
8HAL F < I >.RRALF( I )/86400.
ELSE IF (ULIFE(I) .EO. '»')THEN
RHALF(I)>RHALF(l)/(60.*24.)
ELSE IF (ULIFE(l) .EO. 'H'lYKEN
RHALF(l)>RHALF(I)/24.
ELSE IF (UIIFE(I) .EO. 'Y')THEN
RHALF(I).RHALF(I)"365.25
END IF
IF (I .NE. DTHEN
IF (IS0TOP(1:2) .EO. 'AR' .OR. (IS0T0P(1:2> .EO. 'KR') .OR.













185 FORMAT(10(/),' MODE OF INTAKE OF THE RADIONUCLIDE:',/)
UKITE ('.IM)




205 FORMAT!///,' select Option by Integer >',/>
READ C\115,ERR = 180,END-1B1)OPT




IF (WOR0(1:2) .ED. 'AR' .OR. !W0RD!1:2) .EQ. '«') .OR. !W0R0!1:






215 FORMAT(5(/),' Would you like to see the nuaber of transforation
&s of the nuclide in source organs?',//,' 1 Yes',/,' 2 N
fto', ////,' Select option by integer --->',//)
READ (*,115,ERR<210,EM»211)MAIS




IF (MAIS .EQ. DTHEN
216 CALL CLEAR
PRINT *,' Enter file specification for transfonaetions:'
PRINT *,' (less than or equal to 7 characters I)'
READ (•,121,ERR'216,EN0'217)FFILE!O




IF (NO .GT. DTHEN
220 CALL CLEAR
WRITE i'.ZZS)
225 FORMAT(5(/),' Would you like to aee the nuaber of transfor
&mations of the daughters too?',//,' 1 Yes',/,' 2 No',////,
ft' SELECT OPTION BY INTEGER---*',/)
READ (•,115,ERR-220,END-221)!SAY







Atomic Number of the given radionuclide
KZ'O
CALL ATOmo (WDR0(1:2),ICZ)




Obtain data for inhalation claas and transfer to body fluid






Identification of aerodynamic diameter for inhalation
IF (OPT .EO. 2>THEN
230 CALL CLEAR
WRITE (*,235)
235 F0RMAT(//,' Is the activity Median aerodynamic diameter equal to
8 I micrometer?',//,' 1 Yes',/,' 2 No',////,' Select option by inte
Soer--->',/)
READ (*,115,ERR-230,END»231)LOT




IF (LOT .EO. 2)TNEN
240 CALL CLEAR
WRITE (*,245>
245 FORMAU/,' Enter the value of AMAD (micrometers) between 0.1
tend 20 micrometers I')
READ(*,*,ERR-240,END-241 )AHAD






Query filename for output table
DOSE. FOR
250 CALL CLEAR
PRINT •,' Enter file specification for dose cornni ttnent results:'
PRINT *,' (less than or equal to 7 characters I)'
READ C,121,ERR-250,END'252)FFILE(2)




IF (NDATA .NE. 2>THEH
IF (U0R0(1:2) .EO. 'AR' .OR. (U0RD(1:2> .EO. '«') .OR. (UOPOO:
42) .EO. 'XE') .OR. (U0K><1:2) .EO. 'H-'))TheH
GOTO 268
END IF




PRINT •, ' - Conclude data entry and STOP'
PRINT *, ' 1 - Continue data entry'
PRINT *, ' 2 - Proceed Kith calculations'
PRINT •
PRINT *, ' Select integer 0, 1, or 2'
PRINT *
READ (•,115,ERR»251,E»0«253)MORE






IF CHORE .EO. DTNEN
GOTO 125












IF (OPT .EO. JjTHEN
IF <WO»<1:2> .»E. 'AR' .AND. (UOR0(1:2> .NE. '«•) .AND. (UOROI







ELSE IF (OPT .HE. 3)THE»
IF (WOtt(1:2> .EC. 'AS' .0«. (WOR0(1:2) .£0. '«•>
.OH. <UOR0<1:




CALL DECAY1 (WORD, RHALF.ULIFE, IRA, RADIO, NO, •9009)
DO 256 I=1,H0
ISOTOP>RADIO(I)
Convert helf-lives into days
IF (ULIFE(I) .EG. 'S')THEN
RflAL F ( I )=8KAl F ( I )/S6400
.
ELSE IF (ULIFE(I) .EG. 'IOTHEN
RHALF(I)«RHALF(I>/(60.'2».)
ELSE IF (ULIFE(I) .EG. 'R'HHEN
RKAlF(I)-RHALF(l)/2«.
ELSE IF (ULIFE(I) .EG. 'T'lTHEN
RHALF(I)'RHALF(I>*J65.25
EM) IF
IF (I .HE. WHEN
IF <ISOTOP(1:2) .EO. 'AR' .OR. (IS0T0P(1:2> .EG. '«')








Calculation and printing results of S-mtrix
260 CALL CLEAR
IF (OUI .EG. DTHEN







PRINT *, ' Calculating s-aatrix for ',RADI0(l)
WRITE (*,270)FFILE(1)









275 FORMAT (/,' *•»*••,
* V'«. '*'*«.'*'./.6X,'* S-FACTORS FOR TKE AD
SULT Br METHODS OF ICRP-30, V. 1.0, 1987 *'./,6X,'",64X, '*',/,6X
«,'* eased on
: "Radioactive Decay Data Tables"', 18X,"',/ 6X'"
*',16X,'D.C. Kocher, 0OE/T1C-11026 (1981)', 15X,'"' / 6X<« Written
«by: Aj.iruddinHud.',34X,'"./,6X," Address : c/o Or RE
t F.»',32X,'» ,/,6X."' ,16X.'0eparWnt of nuclear ErsineeringMSX
*.'*\/.6X,'"',16X,'Kansaa State University',25X,'"',/,6X,"» 16X '





















WRITE (55,300) T«AKE(ICT(IC)),(SFACT(KT (K),ICS(J»,.I.1 4)
IF (H0ATA
.EQ. 0>THEH




















WRITE (55,300) T1«ME(XT«)),(SFACT(ICT(X),KS(J)),J.5 8)
IF (HDATA
.E0. 0)THEH





























































IF (INRE .EO. 4)GOTO 177
IF (INRE .EO. 3 .AND. (NDATA .EO. 0))GOTO 125
IF (INRE .EQ. 3 .AND. (NDATA .HE. OHGOTO 9009
Calculation of Dose Col
IF (OPT .EQ. 3)THEN
IF (U0RD(1:2) .NE. 'AR' .OR. (U0RD(1:2) .»E. '«') .OR. (UORDd:





IF (U0RD(1:2) .EO. 'AR' .OR. (U0R0(1:2> .EO. <KR') .OR. (WORDd:






IF (OPT .EO. DTHEN
PRINT •,' Calculating ingestion dose for '.NUCLID
PUNT •,' F1 (CI to body fluids) ',F1
PRINT *,' Subject - ',SEX
ELSE IF (OPT .EO. 2)TNEN
PRINT *,' Calculating inhalation dose for '.NUCLID
PRINT *,' Inhalation class « '.CLASS
PRINT V F1 (01 to body fluids) - ',M
PRINT V Subject ',SEX
ELSE IF (OPT .EO. 3)THEN






SSK, ORGAN, *125, •9009)
IF (UORDd :2) .EO. 'AR' .OR. (UORD(1:2) .EO. 'K«') .OR. (UORDd:




.EO. 'BA' .OR. (NUCL1D(1:2)
.EO. 'RA') .OR. (NUCLI
80(1:2) .EO.
-SK') .OR. (NUCLID(1:2) .EO. 'CA'))TNE»
MaMMO.
ELSE IF (NUCLI0(1:2) .EO. 'RE' .OR. (NUCLID(1:2)
.EO. 'TC'»THEN
QMHH.




ELSE IF (NUCLID .EO. 'TE-131N ' .OR. (NUCLID .EO. 'TE-131 ')
.OR.
S (NUCLID .EO. 'TE-132 ')








«. 'IE- 134 '))TNEN
HMMMI,
END IF



































ISFORMATIONS OF ',A,' V. 1.0, 19«7',6X,'«',/,6X, '•'.MX.'-./.oX '•
I Based on
: "Radioactive Decay Data Tables"', 18X,'"' / 6X'"' 1
toX.'D.C. tocher, DOE/TIC-11026 (1981>',15X,— ,/,6X, '• Written by
i
: A.iruddin Hud...34X, ...,,,«... Add™. : c/o Or. R.E. Fa
»«'.32X,"',/,6X,
— ,16X,'0epart.ent of Nuclear Engineerino',15X, '«




































ELSE IF (OPT .Ed. WHEN
URITE(85,420)
URITE(S5,425)F1






IF (NDATA .EQ. OJTHEN
URITE (*,J*5)
END IF
15 FORMAT(////,20X,' SOURCE ORGAN', 10X, 'TRANSFORMATIONS (/Bq>',/>
IF (US(12,I) .EO. 0.1GOTO 350
Nuclides uniformly distributed in volume of mineral bone *
IF (NUCLID(1:4> .EO. 'P-33' .OR. («UCLID(1:6) .EO. 'NB-93H') .OR
i. (NUCLIDd :5> .EO. 'NB-94') .OR. («UCLI0(1:5) .EO. 'U-232'j .OR.
S(NUCLID(1:5)
.EO. 'U-233')
.OR. (NUCUDd :5) .EO. 'U-234') .OR. (N
UCL1D(1:S> .EO. 'U-235') .OR. (NUCLID(1:5) .EO. 'U-236') .OR. (NUC
(LID(1:5> .EO. 'U-238') .OR. (NUCL1D(1:2) .EO. 'NA') .OR. (NUCLIDd
»:2) .EO. 'CR') .OR. (NUCL1D(1:2) .EO. 'RB') .OR. (BUCLIDd:5) .EO.
4 'ZN-65') .OR. (NUCLID(1:6> .EO. 'PS-205')
.OR. («UClI0d:6) .EO.
«'PB-210'> .OR. (NUCL1D(1:4) .EO. 'BE-7') .OR. (NUCLI0d:5> .EO. 'B
SE-10'J .OR. (NUCLIDd:4) .EO. 'V-49'l .OR. (NUCLID(1:6) .EO. 'PD-1
403')
.OR. (NUCLID(1:6> .EO. 'PD-107') .OR. (NUCIID(1:6) .EO. 'SN-1
S13-) .OR. (NUCLIDd :7) .EQ. 'SN-119H') .OR. (NUCLIDd :6) .EO. 'SN-
J123') .OR. (HUCLI0d:6> .EO. 'SN-126') .OR. (NUCLIDd:6> .EO.
-TA-
UB2') .OR. (NUCLID(1:5)
.EO. 'W-UV) .OR. (NUCLIDd:5) .EO. 'W-18
45')
.OR. (NUCLIDd:!) .EO. 'U-IFJ8' ))THE«
US(I2,D- USd2,I)>0.2
US< 18, I )>(US(12, 1 >/0.2)TJ.8
Alkaline eartha *
*Wtl" «*««« >W «M I «WMtMMMW*«WlWW«
ELSE IF (NUCLID(1:2) .EO. 'SR- .OR. (NUCLIDd:2) .EO. 'BA') .OR. (
t»UCLI0(1:2) .EO. 'CA') .OR. (NUCLIDd :2> .EO. 'RA'))THEN
DOSE. FOR
IF (RNALFO) .GT. 15>THEN
US(12,I)-US(12,I>*0.2









350 DO J55 K-1,18
IF (US(K,I> .EO. 0.)GOTO 355
IF (K .EQ. 17)THEN
IF (ROB .IT. 70000. )THEN
UBITE(85,351)US(IC,1)'B6400.
IF (NDATA .EO. 0)THE«
USITEC,35I)US(IC,I)*8«00.
END IF










362 F0RHAT(//,16X,' Hasa of other tissue '.F9.2,'
'IF (DOB .LT. 70000. JTNEN











Print results of dose cceiai ttments
IF (NDATA .EG. 0)THEN





365 FORHAT(//,' Results of Dose CoanittMents sre in file ',A)
DOSE -FOR
URITE(65,370)




• " "",/.IX, '*' ,6W, <".I,U. '" ,», ' ICRP-30 INTERNAL
I DOSE CALCULATIONS, V. 1.0, 19«7',8X,'*',/,6X," Sued on : »Ra
idioactive Decay Data Tables"', 1SX,'*',/,6X,'"',16X,'D.C. Kocher, D
&OE/TIC-11026 (1981>',15X,'",/,6X," Written by : Amiruddin Huda
S',34X,'«',/,6X,'* Address: c/o Dr. R.E. Fan',32X, '*',/, 6X,"
&',16X, 'Department of Nuclear Engineering' ,1SX, '•',/, 6X, '*' ,16X,'Ke
ansae State University, 25X,'",/,6X,'",16X, 'Manhattan, Kansas 665




375 FORMATO0X, 'Radionuclide : ',I7X,A>
IF (NUCLI0(1:2) .EO. 'AR' .OR. (NUCLI0<1:2> .EO. 'KR'> .OR. (NUCLI





331 FORHARIOX.'Mode of intake : ',15X. 'Submersion')
IF(«0 .OT. 1 HHEN
WRITE(65,332XRADI0(1),1=2,N0)
URITE(65,333XBRA(I),l-2,NO)




332 FORMATdOX.'Oeughter Products : \12x,3A)
333 FORHATdOX, 'Branching Ratios : *,12X,3(F6.3,2X)>
END IF





,/,6X, '•' ,2X, 'Target' ,6X. 'Dose Equivalent Rate
& ',' •',' Weighted Dose Equivalent ','•', /,6X,'*',2X, 'Organ ',6X,
t'per unit concentration' ,
'
•',' Rate per unit concentrn. ','*',/,
6
*X,'*',14X,'in e 8emi-inf inite ',' *',' in a semi-infinite
t ','*'./,6X,'«',14X,'cloud (Sv/HD/(Bq/m-3)',' •',' cloud (Sv/Hr)/
l(Sq/nT3} '.'",/,6X,
'
""'" »"»* ««*i»mm imium» -
****** ~e~~~.





IF (I .EO. DTHEN
WT-0.12
ELSE IF (I .EO. 2)THEN
WT-0.03
POSE-FQP
ELSE IF (I .Ed. 20HHEH
UT"0.25
ELSE IF (1 ,B«, 5)THEH
UT-0.12
ELSE IF (I .Ed. 13)THEH
UT»0.15




















IF (RISK .EO. (OTHEII




S F0RHAT(6X, '••,37X,'",26X, '•',/, 6X,'
S** *
'
.1M.'" MX. '*',/. 6X,'*'
&,5X, 'Derived Air Concentration « '.1PE8.1,' Bq/ar3',16X,'*',/,6x,'
&*',64X,'«',/,6X. '«***"" •«***""**""««•***«« •—
ELSE





4', 5X, 'Stochastic Risk', 8X, 'Non-Stochastic Risk (Organ)', 9X, '*',/,
6





IF (SEX .EO. 'H')THER









IF (NDATA .EQ. 0)THEN
URITE (*,3S5>
END IF
385 FORHATdOX, 'Subject : ' ,22X, 'Female'
)
END IF
IF (OPT .EO. 2)THEN
URITE(65,388)
IF (NDATA .EQ. 0)THEN
URITE(*,388>
END IF
388 FORHATdOX, 'Hade of Intake : ',15X,' Inhalation')
URITE(65,390)CLASS
IF (NDATA .EQ. 0>THEN
URITE(*,390>CLASS
END IF
390 FORHATdOX, 'Inhalation Claas : '.I3X.A)
UR1TE(65,395)AHAD
IF (NDATA .EQ. 0)THEN
URITE(*,395)AHAD
END IF
395 FORHATdOX, 'Particle AHAD (urn) : ',10X,F5.2)
URITE(65,400)F1
IF (NDATA .EQ. 0)THEN
URITE(*,400)F1
END IF
400 FORHATdOX, 'Body fluid transfer fraction : \F8.5)
IF (NO .CT. 1 .AND. (NO At. 4JJTKEN
URITE<65,405)(R«DI0(I),l=2,NO>
WRITE(65,41S)(BRA(l),l'2,NO)




405 FORHATdOX, 'Daughter Products : ',I2X,3A>
415 FORHATdOX, 'Branching Ratios : ',12X,3(F6.3,2X)>
ELSE IF (NO M. 4>WEN
WRITE (65,406)
IF (NDATA .EQ. 0)THEN
URITE (*,406)
END IF
DO 407 1=2, HO
URITE (65,408)RADIO(I),BRA(I)





IF (NDATA .EQ. 0)THEN
URITE (»,305)
END IF




ELSE IF (OPT .EO. WHEN
WHITE(6S,420)
MtITE(65,425)F1
IF <MDATA .EO. 0)THEN
WHITE(*,420>
WHITE(',425)F1
420 FORKAT(TOX,'Mode of intake : ',15X,' Ingestion')
425 FORNATOOX/Body fluid transfer fraction : '.Fa. 5)
END IF
IF (NO .GT. 1 .AW. (NO .IT, 4))THEN
UKlTE(65,426)(NADIO(I),I>2,NO)
URITE(65,428)(BRAm,I=2.NO>
IF CNOATA .EO. 0)THEN
JR1TEC,426X«ADI0< I ), l«2,NO>
UR1TE(\428KBRA(I),J=2,N0)
ENO IF
426 FORMATOOX, 'Daughter Products : '.12X.3A)
428 FORHATOOX, 'Branching Ratios : ',12X,3(F6.3,2X)>
ELSE IF (NO .GE. 4)THEN
WHITE (65,406)
























* ",/,6X,'*',2X, 'Target', 6X, 'Specific Committed',' •
&',' Doses greater than or equal •',/,6X,'*',2X, 'Organ ',6X,'Dose
&Equivalent',4X,'*',' to 10 percent of the maximum »' ,/,6X,'*',14X,
•'(Sv/8q)',12X,"V dose', 25X, '*',/,'
» *
"',/,6X,'«',33X," Weigh
its Weighted Dose', 7X, '•',/, 6X,'*',33X,'*',10X,'Equivslent (Sv/Bq)






IF (HFIFTY(I) .EO. O.HNEX
IF <NUCIID<1:2) .EO. 'TC .OH. <XUCLIO<1:2) .EO. '«E'))THEX





U>ITE(6S,U»TNAHE( I ) ,DOSE< I
)



















.EO. 'TC .OH. («UCLID(1:2>
.EO. 'RE'WHEN























IF (REND* ,m. 0)TKEX
U»<TE<i5,460)REHOR,UTF,M!EMOR















462 F0RHAT(6X,'*«*««*"« * *"««i««—»«« tf.«*»„«,, Kx ,
i"\/,6X,"
. CAUTION: Stomach uall is not *',8X,<SUM . '.IPE^l!


























'Stochastic Risk'.SX, 'Hon-Stochastic Disk (Org.









'Annual Limit on Intake '.1PE8.1 - Bo' 20X
EM) IF






475 FOWAT(6X,'",5X, 'Derived Air Concentration » MPE8.1 > Ba/m-3-
A.16X,'*')
END IF













«B FORMAK//,' ERROR: Th. nod* "Submersion" can only be chosen for
4 noble gases, and elemental tritiuel',/,' SOURCE: DOSE FORTRAN',/
t,
'
CORRECTIVE actios: Check ths symbol and try again 11'////)
DOSERR(2>-0
IF (NOATA .HE. 0>COT0 9009
PAUSE ' TO RESUME PRESS <RETURN>!!'
GOTO 125
ELSE IF (0OSERR(3) .GT. 01THEH
WRITE (•,*90)
490 FORMAK//,' ERROR: The entered symbol could not be found in the
& chert of nuclides for atomic number! ',/, ' SOURCE: OOSE FORTRAN' /
»,' CORRECTIVE ACTION: Try again 11',/////)
DOSERR(3)>0
IF (WATA .NE. 0)OOTO 9009





PRINT *,'0o you really wish to terminate the program?'
PRINT •
PRINT ",' 1 Tea'
PRINT •,' 2 No'
READ(*,115,ERR-9001,EW9000)IDO
IF (I0O .NE. 1 .ANO. (IOO .HE. 2DG0T0 9000
IF (IOO ,E0. DTHEN
























SUBROUTINE NAME: ENERGY FORTRAN
PURPOSE: Gives an upper and lower bound on energy of gamm
to help interpolate the absorbed fraction in tissue
SUBROUTINE E«E»GY<E.ELO,EHI , ILO)

















































SUBROUTINE BAKE: F1VALU FORTRAN
PURPOSE Fractional transfer of eiemem froa 01 system to
body fluids













SUBROUTINE NAME : FACTOR FORTRAN
PURPOSE: Generate matrix of specific effective
energy for prescribed radionuclide










, 19.6,37. 1 ,8.27. 1500. , 150. , 1040. ,209. , 160. , 1810






IF (NDATA .£0. 0>T»EN


















FUNCTION SUBPROGRAM NAME: FRAC FORTRAN
PURPOSE; Retrieve fractional transfer of isotope to the
body fluid compartment, F1





The user chooses the proper Fl according to the ingesti




5 FORHATC///.' Enter the approprist. value of F1 from the given Choi
4CES:',/)





IF (I .EO. 1 .AND. (S .Eg. 0))GOT0 10









15 FORHATC//,. ERROR: Value of F1 not found in the catalogue of nucli
Sde. in ICRP Publication 30',// SOURCE: FRAC FORTRAN',/,' CORRECT!





FUNCTION SUBPROGRAM NAME: II FORTRAN
PURPOSE: Convert the source organ name in alphameric
characters to an integer from source list
FUNCTION IKC2)
CHARACTER*20 C2






























.EO. ' TOTAL BODY /JTNEM
11.17
ELSE IF(C2




.EO. • BRAIN . )THEII
11-19
ELSE IF(C2
.EO. ' ADRENALS »)THEII
11.20
ELSE IF(C2






SUBROUTINE NAME I I CUSS FORTRAN
PURPOSE: Find inhalation ctass of the given radionuclide






PKINT •,' INHALATION CLASS'
PRINT •,' ,
PRINT •,' CLASS Y— > AVIO RETENTION: cleared slowly (years)'
PRINT •,' CLASS W—> MODERATE RETENTION: intermediate clearance (
iHMfcO1
PRINT •,' CLASS 0---> MINIMAL RETENTION: rapid clearance (days)'
PRINT •
PRINT *
PRINT ,' M you wish to examine recommendations aidino selection'
PRINT *,' of the pulmonary clearance classification,'












PRINT V Now ENTER the inhalation class of the given radionuclide










SUBROUTINE NAME : ICRP FORTRAN
PURPOSE: Call appropriate subroutine for dose committments
according to the mode of intake
DESCRIPTION Of VARIABLES
INTAKE ---> l| ingestion, 2: inhalation, 3: submersion
y™ * Heme of the given isotope, e.g., IN-113N
SEX > H or F
M » Fractional transfer, CI to body fluids
CLASS > Pulmonary uptake classification
A** * Activity median aerodynamic diameterlmicrometer;
W** > Fleas of 'other tissue'
a » Atomic masber of the given nuclide
115 > Matrix of transformations of nuclide, i in
source organ, j
HFIFTY > Specific committed dose equivalent to target
organ or tissue



















LL I»"ALE(MORO,I3, SEX.CLASS.F1, HFIFTY, FHP.FTB.FP, ROB, us, »15)
ELSE IF (INTAKE .ED. 31THEN
CALL SUBMER(UOR0,HFIFTY,DER, RISK,ORGAN, *15)
END IF
Particle Size Correction
IF (AHAD .NE. DTHEN

























SUBROUTINE NAME: INGEST FORTRAN
PURPOSE: Calculate Specific Cammed Dose Equivalent (Sv/Bq)













WORD >Nane of the given isotope
K2 >Atoaiic Number
HFIFTY-->Specific Committed Dose Equivalent (Sv/Bq)
NJO—*-->Nunber of daughters plus one {for the parent)
RHALF--->Vector of half-lives of the given isotope and
its daughters
ULIFE--->vector of half-life units of the given isotope
and its daughters
BRA— -->Vector of branching ratios of the given isotope
(BRA'1), and its daughters
RADIO--->Veetor of names of the given isotope, and its
daughters





CHARACTER'S RADIO<50), WORD, ISOTOP,ERT,MOTS
REAL MRC6
N0=0
. Subroutine for half-lives and names of the given parent
»««»»«
* isotope and its daughters
*
DECAY MODE : A >B >C >
CALL DECAYHUORD.RHALF.ULIFE, BRA, RADIO, MO,*12)
MOTS«WORD
DO 5 1=1, HO
ISOTOP«RADIOCI)
INGEST .FOB
IF (1 .NE. DTHEN
IF (IS0TOP(1:2) M, .„. M . ( 1SOTOP(1 . 2) Ea . ,„,, w _
S0T0P(1:2>







Convert units of half-livos into days and calculate
the radiological constants
7 00 10 lal.NO
IF (ULIFE(I)
.EO. 'S')THEN













For alkaline earths (.a, Ca, Ra, Sr), Tc, Re, Te-131, Te-132 •
Te-131m, T.-133, Te-133», Te-134, and C, source-organ
transfonnations are not evaluated but retrieved directly









.OR. (M0TS(1 : 2) .EO 'C-')
I .OR. (HOTSC1.-2)



















initial activity, FT of the given radionuclide and its
daughters in transfer compartment
**•**»*»*•*»••»•
FT of the parent (given) radionuclide
INGEST .FOP
IF (I .EO. DTNEN
AST<1)»1./<24.»RCONST(1»








FT of the daughters
,.,.«..«...,.,
AST(I)-AST(1-1)-RCO»ST(I)/(24.»»CO(1ST(I))












Half life of clearance from transfer compartment
TSAVE=THALF(KZ>
TCONST-—>The rate of loss of the stable element from the
body fluid compartment
When transfer is instantaneous, to avoid an infinite









Outer loop to calculate N50 in each target organ, KTARG
"here the target list is as follows:






* Testes 3 •
• Ovaries a •
* Red marrow S •
* Stomach wall 6 •
• SI * contents 7 •
* ULl wall a •
* LLI wall 9 *
* Liver 10 •
* Kidneys 11 •
* Bladder wall 12 •
* Muscle 13 •
* Skeleton (BS cells) 1t •
• Skin 15 •
Spleen 16 •
* Uterus 17 •
• Pancreas It •
* Total body 19 •
• Initializing the source organ transformations as zero *
* for the given isotope and its daughters *
HIXItllUUlllltlllWMIllllllllll '»*« MHWIIIHUHII










Skipping ovaries and testes as target organs when the sex
of the subject is male and female respectively
If <SEX ,E0. 'M'lTHEN
IF (KTARO ,H. 4)GOT0 25
ELSE IFCSEX .Eg. 'F'lTHEN
IF (KTARG .E0. 3>G0T0 25
END IF




Loop for adding contribution f rem all the sources in each *
* target organ
The source list is as follows:
* SOURCE ORGAN JSORCE MO.
• Bladder content 1
* Stomach content 2
• SI content 3
* UL! content 4












• Total body 17
' All other 15
00 30 JS0RCE«17,1,-1
Skipping ovaries and testes as source organs when the sex *
of the subject is me e end fern le respectively
IF (SEX .EQ. 'M')TME»
IF (JSORCE .Ed. 10JGOTO 30
ELSE IF (SEX .EQ. 'F'UHEH
IF (JSORCE ,E0. 15)0010 30
EMC IF
For alkaline Berths (Ba, Ca, Ra, Sr), Tc, Re, Te-131, Te-132
Te-131n, Te-133. Te-133ai, Te-134, and C, source-organ
transformations are not evaluated but retrieved directly
from data file "EXCEPT"
IF (MOTS(1:2)
.E0. 'BA' .OR. (M0TS(1:2>
.EO. 'CA') .OR. (MOTS(1:2)
S .EO. 'RA') .OR. (M0TS(1:2) .EO. 'SR') .OR. (M0TS(1:2>
.EO. 'C-')
i .OR. (MOTS(1:2)
.EO. 'TO .OR. (MOTS(1:2) .EO. 'RE') .OR. (MOTS
i.EO. 'TE-131 •) .OR. (MOTS .EO. 'TE-132 ')
.OR. (MOTS .EO. 'TE-1









IF (KTARG .GT. 1 )GOTO 45





IF (MOTS(1:1> .EO. 'T'jTNEN
M1=33
ELSE IF (HOTS(1:1> .EO. 'S'jTHEN
K1=26
ELSE IF (HOTS(1:1) .EO. 'R'HHEN
H1»14








IF (MOTS .EO. ERDTHEB
IF (T .EQ. FDTHEN
ICOMT=IRECOD
GOTO 36







IF (ICON! .EO. 0)GOTO 70
END IF
READ (80,32, REC»1C0NT,ERR»75)J,(US(JS0RCE,1),I«1, NO)
32 FORMAT(I2,10E9.2)
IF (J .M. JSORCE)THEN









Initializing the fraction retained in source organ from
the body fluid compartment, end the biological half-life







Skipping retention fractions for source organs stomach,
51, LL1, ULI
I F( JSORCE .EO. 2 .OR. (JSORCE .EG. 3) .OR. (JSORCE .EQ. 4) .OR. (J
&SORCE .EQ. 5))GOT0 40
With given KZ, the following subroutine, TFRAC will give
retention fraction, F2 and biological half life, BHALF
in source organs. If several organs, i of mass (SHASS), Mi
are associated with different retention fractions for a
given KZ, then for 'total body' as a source organ, the
mass is taken to be 70000-(sum of Mi) and the retention
fractions to be the ones associated with source organ,
'all other'
CALL TFRAC(KZ,F2,BHALF, JSORCE, SMASS,*12>
If a source organ does not have a unique retention fraction, *
it is skipped because often it is included in the source *
'total body' *
IF (F2(1) .EQ. 0. .AND. BHALF<1)
.EQ. 0.)GOTO 30
The subroutine TRNSFM evaluates the source-organ
transformations, US in organ JSORCE for the isotope and
its daughters





CALL TRNSFM(FT,F2,8HALF,RCONST,NO,BRA,US,TCONST, JSORCE, F1,IPROG,FG
& I , SHASS , UROB , MROB , KZ
)








Loop to calculate product of (SEE*US) from contribution
of all the radionuclides (parent daughters)




IF (JSORCE .EO. 12)7HE«
IF (KTARG .EO. 5 .OR. (KTARG .EO. 14))THEK
**w«M»www*t t m »nmn ii»Mi>mm
Function subprogram SPEFF calculates the specific effective
energy, SEE deposited in target organ, KTARG due to source
organ, JSORCE
Loop=0 implies photon decay from radionuclides
SEE=SPEFF(UC*D, JSORCE, KTARG,THASS,LCOP,MOTS,RKALF(1»
IF (UORD(1:5) .EO. 'SORRY'HHEK
PAUSE 'TO RESUME PRESS <RETURN>!'
RETURN 1
END IF
GRNSUH>GRNSUH»(US( JSORCE, I >*SEE*86400.
)
DO 55 LOOP'1,2
Radionuclides assumed to be uniformly distributed in volume










.EO. 'U-236') .OR. (NOTS(1:5) .EO. 'U-238
»') .OR. (MOTS(1:2) .EO. 'KA'J .OR. («OTS(1:2) .EO. 'CR') .08. (UOR
SDO:2) .EO. 'RB') .OR. (KOTS(1:5>
.EO. 'ZB-65') .OR. (HOTS(1:6>
.E












I (M0TS(1:6) .EO. 'SN-113') .OR. (HOTS(1:6) .EO.
-SB-123')
.OR. (HO
STS(1:7> ,E0. 'SH-119M') .OR. (KOTS(1:6>








UTRAB»0.2niS( JSORCE, 1 >*86400.
UCORT*0.8*US(JSORCE, 1 )*66400.
ELSE IF (HOTS(1:2)
.EO. 'BA' .OR. («OTS(1:2)
.EO. 'CA') .OR. (MOTS
















Loop=1 implies charfled particle dose in trabecular bone
52 IFUOOP .£0. DTHER
SEE=SPEFF(UOB0,JSO8CE,l!T»RG,TBASS,L°Of',»O7S,RH»LF<l)>
IF (W0RD<1 :5> .ES. 'SORRY'HHEN






































71 FORMATC//,' ERROR: Huctide not found in catalogue of ICRP Publicat
lion 30',/,' SOUKCE: INCEST FORTRMI




76 F0«NAT(//,' ERROR: Unabla to read US values fro» file "EXCEPT"!',/
t,' SOUKCE: INCEST FORTRAN
• , / , ' CORRECTIVE ACTIO*: Check the identi
Ification and try again!')
EM)
INHALE FOR
SUBROUTINE NAME : INHALE FORTRAN
•
PURPOSE: Generate a vector of committed dose equivalent •
(Sv/Bq) in target organ due to inhaled nuclide •
AUXILIARY PROGRAMS REQUIRED: a) PCLASS FORTRAN •
b) DECAY! FORTRAN •
C) FRAC FORTRAN •
d) RESPIR FORTRAN •
e) THAIF FORTRAN *
f) REFHAN FORTRAN *
g) TFRAC FORTRAN »
h) TftNSFH FORTRAN •
i) SPEFF FORTRAN *
DATA FILES REQUIRED: a) EXCEPT FILE »




•WORD---> Kane of the given isotope
KZ > Atomic number *
HFIFTY-> Specific committed dose •
H * Number of daughters + one for the given isotope •
RHALF--> Vector of half-lives of the given isotope and its •
daughters .
ULIFE--> Vector of half-life units of the given isotope .
and its daughters •
BRA > Vector of branching ratios of the given isotope •
(BRA(1)»1) and its daughters .









CHARACTER*! ULIFE(50), SEX, CLASS, TYPE, SORT
CHARACTER'S RADIO(50),UORD,ISOTOP,£RT,IIOTS
REAL MROB
Subroutine for half-lives and names of the given isotope
and its daughters
DECAY MODE : A > B > C >
INHALE .FOR
CALL DECAY1(U0RD,RHALF,ULIFE, BRA, RADIO, NO,*12)
MOTS=UORD
DO 5 M, NO
ISOTOP«RADIO(I)
IF (I .HE. DTKEN
IF CISOTOP{1:2) .N. 'AR' .OR. (l$OTOP(1:2) .EQ. 'KR') .OR. (IS






Convert units of half-Lives into days and calculate the
radiological constants
7 DO 10 I»1,NO
IF (ULIFECE) .EQ. 'S')THEN
RHAL F C I )>RHALF( I )/8MO0.
ELSE IF (ULIFE(I) .EQ. 'H')THEN
RHALF( I )=RHALF( I >/(60.*24.
)
ELSE IF (ULIFE(I) .EQ. 'H')THEN
RHALF(I)«RHALF(!)/24.
ELSE IF (ULIFE(I) .EQ. 'Y')THEN




Fraction of inhaled stable element transferred to the
body fluids via the GI tract, FBF
FBF of the parent (given) radionuclide
IF (I .EQ. 1)THEN
AST(1)=1./FLOU(24.+RCONST(1)>









FBF of the daughters
ASTCi)=AST(]-])-RCONST<l)/FLOU(24..RCC*SU1>>









Fractions of inhaled material deposited in three respiratory *
regions, the nasal passage (N-P), the trachea and bronchial -
tree <T-B), and the pulmonary region (P>, the balance being •
the fraction exhaled. It is assumed that the activity median -




Subroutine for fraction and clearance rates for transfer of
the material between compartments
Initializing all clearance rates and fractions as zero
DATA FA,FB,FC,FD,FE,FF,FC,FH,FI,FJ /10*0./
DATA CLA,CLB,CLC,CLO,CLE,ClF,CLG,ClN,CLI,CU /10*0./
CALL KESPIR (CLASS, FA,FB,FC,FD,FE,FF,FG,FN,FI,FJ,CLA,CLB,CLC,CLD,C
SLE,CLF,CL.,CLH,CLI,CLJ>
Transformations in various compartments of the lung
DO 25 1 = 1, NO
aaaa saaeai
Transformations of the parent radionuclide

























Transforations of the daughters
AA(I>»AA(I-1)«RCONST(I>/FLC«(CLA«CONSTCI)>
AB(l>.ABO-1>-RC™ST(I>/FL»<CLB»RCO»SI(l>)
AC( I )-AC( I • 1 >'«CONST( ! >/FLOU(CLC-MICONST( I )
)
AD(I).AD(I-1)*RCO»SI(I)/FLOU(CLD-M1COHST(I))










AF( I >»AF( I
-1 VRCONSH I >/FLOU(CLF-H(CONST( I )
)
AG( I )«G( I - 1 )"RCO»ST(I )/FLOU(CLORCOHSI( I ))
AD1(I>-((AF(!>'CLF>»(AG<I>*CLG))/FL»(CL0«RCO»ST(I)>
END IF







Fraction of the inhaled radionuclide transferred directly to •
the body fluid compartment, FBFOIR »








Total initial activity, FT of the given radionuclide and




For alkaline earths (Be, Ca, Da, Sr), Tc, Re, Te-131, Te-132, *
Te-I31m, Te-133, Te-133m, Te-13«, and C, source-organ
transformations are not evaluated but retrieved directly »
from data file "EXCEPT" e
IF (H0TS<1:2)
.EO. 'BA' .OR. (HOTS(1:2)
.E0. 'CA') .OR. (HOTS(1:2>
S .EO. 'RA') .OR. (WTS<1:2)
.EO. 'SR') .OR. <H0TS(1:2)
.EO. 'C-')
8 .OR. (KOTSC1:2) .EO. 'TO .OR. <HOTS(1:2)
.EO. 'RE') .OR. (M0TS(

















The rate of loss of the stable element from the •
body fluid compartment .
When transfer is instantaneous, to avoid an infinite quantity*
in the calculation of TCONST, it is assumed as zero *






1 CALCULATION OF NFIFTY
'»»n'mniunnim
" TARGET LIST
• TARGET ORGAN ICTMG NO. *
' Lings 1 •
• Thyroid 2 •
* Testes 3 •
Ovaries A •
Red narrow 5 •
Stomach Mall 6 •
SI contents 7 •
ULI vail S •
LLI nail 9 •
Liver 10 •
Kidneys 11 •
Bladder nail 12 •
Muscle 13 •





Total body 19 •
Initializing the source- organ transformations as zero for *
the given isotope and its daughters «
t«itMiiiiuuiiiuuijiaiui>iu***** **•• W*«iM»>«*ttMm«IM>l«f«









Outer loop to calculate N-50 in each target organ, KTARG
00 50 KTARG*1,19
Skipping ovaries and testes as target organs when the sex
of the subject is male and female respectively
INHALE FOR
IF CSEX .EG. 'M')THEN
IF (KTARG .EO. 4JGOTO SO
ELSE IF<SEX .EQ. 'F')THEN
IF (ICTARG .EO. 3>GOTO SO
END IF












* Loop for adding contribution from all
»**•*•**••******•••******
the sources in each *
* target organ
* THE SOURCE LIST IS AS FOLLOWS:
* SOURCE ORGAN JSORCE NO. •
* Bladder content 1 •
Stomach content 2 •
* SI content 3 •
* ULI content « •
* LLI content S •
* Kicheys 6 •
* Liver 7 *
Lungs a •
* Muscle 9 •
* Ovaries 10 •
• Pancreas 11 •
Mineral bone 12 «
* Skin 13 •
Spleen 14 •
* Testes 15 •
• Thyroid 16 •
* Total body 17 •
• All other 18 •
Maaaaaaaaaaaaaaauaaaaaaa aaaaa leeaeai **********«««««>***««»*«»in>««w
DO 55 JSORCE-17,1,-1
INHALE .FOR
Skipping ovaries and testes as source organs when the sex of
the subject is male and female respectively
IF (SEX .EO. 'lOTHEN
IF CJSOBCE .EO. 10)GOI0 55
ELSE IF (SEX .EO. 'F')THEN
IF (JSCOCE .EO. 15)G0T0 55
END IF
For alkaline earths (Be, Ca, Ra, Sr), Tc, Re, Te-131, Te-132,
Te-131m, Te-133, Te-I33«, Ie-134, and C, source-organ
transformations ape not evaluated but retrieved directly
from data file "EXCEPT"
IF (MOTS(1:2> .EO. 'SA' .OH. (M0TSO:2> .EO. 'CA') .00. (MOTS(1:2
I .EO. 'RA') .OR. (HOTS(1:2) .EO. 'SR') .OH. (M0TS(1:2>
.EO. 'C-')
t .OR. (M07S(1:2> .EO. -IC) .OK. (M0TS(1:2) .EO. 'RE') .OR. (MOTS
Hit) .EO. 'TE-131') .OR. (MOTS(1:6> .EO. 'TE-132') .OR. (MOTS(1:7
t .EO. 'TE-1J1H')
.OR. (MOTS(1:6) .EO. 'TE-133') .OR. (MOTS(1:7)
U. 'TE-133M') .OR. (MOTS(1:6) .EO. 'TE-134'»TNEN
IF (KTARO .GI. DGOTO 70
IF (ICOHT .EO. 0)THE»
OPENdJNIT^O, FILE" INOEXI', FORM" 'FORMATTED', ACCESS—DIRECT
UECL'34)
H>EN(UNIT"80,FILE"EXCEPT', FORM" FORMATTED', ACCESS-DIRECT
wtri am
IF (M0TS(1:1) .EO. 'T'>TNEN
M1-33











REAJH50, 57, REC=1ND,ERR=100)ERT,T, TYPE, IRECCO.U, SORT, IREKOD
7 FORMAT(AS,F8.5,A1,l«,F8.5,A1,K>
IF (HOTS .EO. ERT)THEN
IF (T .EO. F1 .AMD. (TYPE .EO. CLASSWKEN
ICOMT>IRECOD
GOTO 58








IF (ICOKT .EQ. 0)COTO 100
END IF
IF (ICOKT .EQ. 6°6)GOTO 70
READ(SO,S9,REC>ICOHT,E>R'105)J,(US(J$C«CE,I),I'1,HO)
I FORHAT(I2,10E9.2)
IF (J .HE. JSORCE)THE»









Initializing the fraction retained in source organ from the
body fluid compartment, and the biological half-life of the






Skipping retention fractions for source organs stomach,
51, LLI, ULI, end lung
IFCJSORCE .EQ. 2 .OR. (JSORCE .EQ. 3) .OR. (JS0RCE
.EQ. 4) .OR. (J
&SORCE .EQ. 5) .OR. (JSORCE .EQ. 8})GOT0 65
With given KZ, the following subroutine, TFRAC wilt give
retention fraction, F2 and biological half-life, BHALF in
source organs. If several organs, i of mass (SMASS) Hi are
associated with different retention fractions for a given KZ,
then for 'TOTAL BOOT' as source organ, the source mass is
taken to be 70000-(SUH Hi) and the retention fractions to be
the ones associated with source organ 'ALL OTHER'
CALL TFRAC(KZ,F2, BHALF, JSORCE, SHASS,*12)
If a source organ does not have a unique retention fraction,
it is skipped because often it is included in the source
INHALE .FOR
IF (F2C1) ,E0. 0. .AND. 8HALF<1)
.Eg. O.JGOTO 55
65 IF (KTARG .GT. DGOTO 70
US for Respiratory system
IF (JSORCE .EQ. 8>THEH
DO 67 1*1, NO






The subroutine TRNSFN evaluates the source-organ trans- •
formations, US in organ JSORCE for the isotope end its *
daughters *
IPR0G=1
CALL TRNSFn(FT,F2,BNALF,RCONST,N0,8RA,US,TCONST, JSORCE, Fl,!PROG,FG
&1 ,SMASS,UR0S,nR0B,K2)




IF (JSORCE .EO. 17)TMEN
R0B*HR0B
END IF
Loop to calculate product of (SEEniS) from contribution of
all radionuclides




IF (JSORCE .EO. 12JTNEN
IF (KTARG .Eg. 5 .OR. (KTARG .EO. H))THEN
Function subprograia SPEFF calculates the specific effective *
energy deposited in target organ, KTARG due to source organ, •
JSORCE e
Loop*0 implies photon decay from radionuclides •
SEE=SPEFF(UORD, JSORCE, KTARG, THASS,L0OP,M0TS,RHALF(1)>
INHALE -FOR
IF (UORD(1:5) .EO. 'SORRY' (THEN
PAUSE ' TO RESUME PRESS <RETURN>M'
RETURN 1
END IF
GRNSUM=GRNSUM+(US( JSORCE, I )*SEE»86400.
)
DEPOT =US< JSORCE, I )-SEE-86400./FLOU(FT(I))
TNP(JSORCE,I).FL0U<(CL*"«(I)).(CL9-AB(l)-FBF(I)))-DEPOI
TTFJ(JSCSCE,1>=FL0U((CLC«AC(I>)»(CLD-AD(I)-FBF(I>>>'DEP0?
TP( JSORCE, I >»FlOU((CLE*AE(Im(CLI-AI(I)>»(a.0-AO1(I>'FBF(t>
1))*DEP0T
00 80 L0OP=1,2
Radionuclides assumed to be uniformly distributed in volu
IF (MOTSd:*) .EO. 'P-33' .OR. (M0TSd:6> .EO. 'RB-93M') .OR. (HOT
SS(1:5) .EO. '«B-W> .OR. (H0TS(1:5) .EO. 'U-232') .OR. (H0TSd:5)
( .EO. 'U-233') .OR. <M0TSC1:5) .EO. 'U-234') .OR. (H0TS(1:S> .EO.
«'U-235") .OR. (MOTS(1:5) .EO. 'U-236') .OR. (H0TS(1:5) .EO. 'U-238
»') .OR. <MOTS(1:2) .EO. 'HA') .OR. (HOTSd:2) .EO. 'CR') .OR. (WOR
10(1:2) .EO. 'RB') .OR. (MOTS(l:5) .EO. 'ZN-65') .OR. (M0TS(1:6) .E
M. 'PB-205') .OR. (M0TS(1:6) .EO. 'PB-210') .OR. (MOTSd:*) .EO. '
1BE-7') .OR. (M0TSd:5) .EO. 'BE-10') .OR. (MOTSd:*) .EO. 'V-*9'>
t.OR. (MOTSd :6) .EO. 'PO-103') .OR. (M0TS(1:6> .EO. 'PD-107") .OR.
S (M0TS(1:6> .EO. 'SR-113') .OR. (M0TSd:6) .EO. 'SH-IO') .OR. (MO
1TS(1:7) .EO. 'SN-119M') .OR. (MOTSd :6) .EO. 'SN-126') .OR. (MOTS(
11:6) .EO. 'TA-182') .OR. (M0TS(1:5) .EO. 'U-1B1') .OR. (MOTS(1:5)
t.EO. 'U-1BS') .OR. (MOTS(1:S) .EO. "U- 188' ))THEN
JTRAB=0.2*US( JSORCE, 1>*86400.
UCORT.O. B*US( JSORCE, I I'SMCO.
ELSE IF (MOTS(1:2> .EO. 'BA' .OR. (M0TS(1:2) .EO. 'CA') .OR. (MOTS
1(1:2) .EO. 'RA') .OR. (M0TSd:2) .EO. 'SR'))THEH
IF (RHALFd) .ST. 15>THEN
UTRA8*0.2*US( JSORCE, I )*86*00.
UCORT'O. o»US( JSORCE, I)*86*00.
ELSE
UTRAB<O.S*US( JSORCE, I )*86400.
UCORT-0. 5*US(JSORCE, I )*86400.
END IF
ELSE
Radionuclides to be on bone surfaces
UTRAB>0.5*US( JSORCE, I )*S6400.
UCORT=0. 5"US( JSORCE. I )'8&400.
Loop=l implies charged particle dose in trabecular bone
IHHALE.FOR
12 IFCLOOP .EQ. DTHEN
SEE*SPEFF<UORD,JSORCE,irTARG,THASS, LOOP,HOTS, RHALF(I))
IF <UORD(1:5) .EO. 'SORRT')THEN














Loop=2 implies charged particle doce in cortical bone
SEE>SPEFF(UORD,JSORCE,ltTARC, TMASS, LOOP,HOTS,RHALF(I))
IF (U0RD(1:5) .EO. 'SORRT')THEN



















IF (UORO<1:5) .EO. 'SORRT')TKEN
PAUSE I TO RESUHE PRESS <RETURN>H'
RETURN 1
END IF
GRNSUM«GRNSUH»(US<JSORCE, I >*SEE'8M00 .
)
Fraction of coajaitted dose equivalent in the target tiasue
resulting from deposition in the N-P, T-B, and P regions
DEPOT
-US(JSORCE , I )*SEE*86400.




ttb< jsorce, i )>flou(ac( i >«d( i))'1u( i >*see"s6400.
ipc js08ce, i >«fl0u(a01 ( i >.ae( i )»af( i ).ag( i hah( i ) )-bra( i >'see"86
MOB.
ELSE IF(JSORCE .EO. 2 .OR. (JSORCE .EO. 3) .08. (JSORCE .EO. 4)
t .OR. (JSORCE .EO. 5»THEN
TNP( JSORCE , I )=FL0U(CLB-»B( 1 )"DEP0T/FGI ( I ))
ITB( JSORCE, I >"FLOU(CLD«AO(I)*DEPOT/FGI(I»
T1>(JSORCE,l)'FL0U(CLD*AD1(!)*DEPOT/FGl(m
ELSE
TNP(JSORCE, I >»FLOU( ( (CLA«AA( I ».(CLB*AB( I >'FBF( I » >*DEPOT/FT
1(1)1
TTS( JSORCE, I )-FLOU(((CLC"AC(I)>«(CLD"AD(I>"FBF(I)))»DEPOT/FT
1(D)

















n»>imnM in>iw t tnt«tM iiMmnn mm
Specific committed dose
,
H-50 in each target organ •
««••«*«•»««>««.—






101 F0RHAK//,' ERROR: Nuclide not found in catalogue of ICRP Publicat




106 FORMAK//,' ERROR: Unable to read US values from file "EXCEPT"!',/
«,' SOURCE: INHALE FORTRAN',/,' CORRECTIVE ACTION: Check the identi
afication and try again!')
ENO
INTRPT FOR
FUNCTION SUBPROGRAM NAME : INTRPT FORTRAN
PURPOSE: Interpolates the values of Absorbed fraction
AUXILIARY PROGRAM REQUIRED: .) ENERGY FORTRAN
DATA FILE REQUIRED: a) ABSFRAC FILE

















10 FORMATC//,' ERROR: Unable to read the value of absorbed fraction f
4or the given photon energy, source, and target fro* file "AB
4SFRAC"',/,' SOURCE: INTRPT FORTRAN',/,' CORRECTIVE ACTION: Check t





SUBROUTINE NAME : PCLASS FORTRAN




PRINT •, 'PULMONARY CLEARANCE CLASSIFICATION OF INORGANIC COMPOS.
PRINT ','
PRINT •
PRINT ", 'CLASS »••
PRINT «, " •'






















Oxides and hydroxides--* lanthanides, actinides Groups
a (V and VI), 1b,2b(IV and V)
3b except Sc(3*),and 6b
Helides--> lanthsnide fluorides
Nitrates--> none
TO RESUME PRESS <RETURN*M'






















PRINT *, 'Class D--> Minimal retention: rapid clearance (days)
PRINT ' -
PRINT',' Carbides--, see hydroxides
PRINT •,« Sulfides-> all except class u
PRINT *,' Sulfates- > all except Class u
Carbides--> Cations of all Class U hydroxides except '
those listed as class Y carbides '
Sulfides--> Croups 2a(V VI), *a(IV-VI), 5a(IV-VI),1b'
2b, and 6txv»VI) i
Sulfates-* Groups 2a(IV-VII), and Sa(IV-VI) <
Carbonetes--> lanthanides, Bi(3+), Group 2a(IV-VII) '
Phosphates--* Zn(2*). Sn(3»), Ng(2«), Fe(3»), Bi(3») '
and lanthanides t
Oxides end hydroxides--* Groups 2a(II-VII),3a(III-VI),'
4a(III-VI), Sa(lV-VI), oa(IV-'
VI), 8, 2b(VI),U>, 5b, and 7b'
Sc(3») /
Nelides--* lanthanides (except fluorides), Groups 2a, 3a'
(III-V1). 4a(IV-VI),5a(lv-VI),8,1b,2b,3b(lv
-V),«b,5b,ob,and 7b <
Nitrates--* all cations whose hydroxides are Class Y '














PRINT •,' Enter integer 1 to repeet or to continue.
READ (*,*,ERR'5,END>5)NCON
IF (NCON .NE. 1 .AND. (NCON .NE. 0))GOTO 5
IF (NCON .EQ. DGOTO 1
CALL CLEAR
END
Carbonates--> all except Class U
Phosphates- -> all except Class U
Oxides and Hydroxides--> Groups 1a, 3a(II>, 4a(!I), Sa
(II, III), oa(III)
Halides--> Groups la and 7a
Nitrstes--> all except Class U
Noble Gases--> Group
Note: Uhere reference is mode from one chemical form to
another, it implies that an in vivo conversion
occurs, e.g. hydrolysis reaction
REFMAN.FOR
FUNCTION SUBPROGRAM NAME: REFHAN FORTRAN





ELSE IF (KIARC .EO. 2JTHEN
REFMAN-19.6
ELSE IF (KTARG .Eg. 3)THEN
REFMAN"37.
1
ELSE IF (KTARG .EO. 4)THEK
REFNA»«8.27
ELSE IF (KTARG .EG. 5>THEN
REFH»N=1500.
ELSE IF (KTARG .EQ. 6)THE«
REFMAN«150.
ELSE IF (KTARG .EG. 7>THE»
REFMAN-1040.
ELSE IF (KTARG .EG. 8)IHE«
REFHAN>20°.
ELSE IF (KTARG .EG. 9>THEH
REFKAN«t60.





ELSE IF (KTARG .EG. 12JTHEN
REFHAN-A5.1
ELSE IF (KTARG .EG. 13JTKEN
REFKAH .48200.
ELSE IF (KTARG .EG. KJTHEN
REFHAN-10SOO.
ELSE IF (KTARG .EG. I5JTNEN
REFHAN'2830.
ELSE IF (KTARG .EG. 16)IHE»
REFHAN'174.




ELSE IF (KTARG .EG. 1S)THEN
REFMAK-60.}






SUBROUTINE NAME I RESPIR FORTRAN
PURPOSE: Provide fraction of Material deposited, and its
clearance rate from each compartment of the lung




DESCRIPTION OF VARIABLES •
" FA* of material deposited in the body fluid compartm-*
ent from the nasal passage region (N-P) *
• FB- -> Fraction deposited in the GI tract from the nasal passage *
* FC- -> Fraction deposited in the body fluid compartment from the "
trachea and bronchial tree region (T-B) •
* F0- -> Fraction deposited in the GI tract frost the trachea and *
bronchial tree region CT-B) *
* FE- -> Fraction deposited In the body fluids from the pulmonary *
region (P) •
• FF- -> Fraction
half-life
transferred to T-B region from P region with a *
• FG- •> Fraction transferred to T-B region from P region with a *
different half-life #
* FH- -> Fraction
P region
transferred to the lymphatic system (L) from *
• fl- -> Fraction deposited in the body fluids from L region with *
a half-li fe
* FJ- -> Fraction deposited in the body fluids from L region with •
a different half-life •
-> Clearance
CLEARANCE RATES (/DAYS) •
• CLA- rate of material from N-P to body fluids *
• CLB- -> Clearance rate of material from N-P to GI tract *
* CLC- -> Clearance rate of material from T-B to body fluids *
* CLD- -> Clearance rate of material from T-B to GI tract *
CLE- -> Clearance rate of material from P to body fluids *
• CLF- -> Clearance rate of material from P to T-B region *
* CLG- •> Clearance rate of material from P to T-B region *
• CLH- -> Clearance rate of material from P to L region *
CLI- -> Clearance rate of material from L to body fluids *
* CLJ* -> Clearance rate of material from L to body fluids *


























































SUBROUTINE NAKE : RESULT FORTRAN
PURPOSE: Evaluate Weighted Coanitted Dose Equivalent using
the 10X exclusion principle, the OAC, and the ALI








Finding- the five organs or tissues of the reaannder receiving
the highest dose equivalents; the exposure of all other
























Weighted committed dose equivalent, NOOSE
DO 20 1>1,19
IF (I .EQ. DTHEN
UT-0.12
UOOSE(I)-UT««FIFTY(I)




ELSE 1F(I .EO. 3 .«. (I .EC. 4))7HE«
UT-0.25
UOOSE<!J=tfT'MFIFT»(l)
ELSE I Ft I .R. 5>THEN
UT'0.12
UDOSE(I)>WT*HFIFTYCt)
ELSE IF(I .EO. 13>THE»
UT-0.15
WDOSE<l>-UT"HFIFTlr(I>

















Weighted comnitted dose equivalent, UDOSE which is greater
than or equal to 10X of the aaxiaua weighted value of H-50





















else 1fcisorce .eo. 7ithen
NTARG<2)'10
ELSE IF C1SORCE .Eg. 11ITHEN
NTASG(3)'1>
ELSE IF (ISOCCE .EQ. 14ITHEN
NIARC-<4).16






Assigning a ccmitted dose equivalent to the "REMAINDER" Kith
weighting factor
DO 45 1«1,19









IF (I .EQ. 13 .0*. (I .EO. 14))GOTO 55
DO 60 J" 1,5
IF (I .EO. NTARG(J))COTO 55
60 CONTINUE



































IF <SAVE .NE. 0.1THEN
ALI»0.5/SAVE
END IF




FUNCTION SUBPROGRAM NAME: SOURCE FORTRAN
PURPOSE: Provide mass of the source organ when source <
integer is given as input
FUNCTION SOURCECICOHP)
IF (ICOHP .EO. 6JTHEN
SOURCE-J10.
ELSE IF (ICOHP .EO. 7HHEN
SOURCE-1800.
ELSE IF (ICOHP .EO. 10)THEN.
SOURCE-11.
ELSE IF (ICOHP .EO. 11JTHEN
SOURCE>100.
ELSE IF (ICOHP .EO. 12)TNE«
SOURCE=5000.
ELSE IF (ICOHP .EO. H)TNEN
SOURCE-180.
ELSE IF(1C0HP .EO. 15>THEN
SOURCE =35.
ELSE IF (ICOHP .EO. I6)THEN
SOURCE -20.
ELSE IF (ICOHP .EO. 17)THEK
SOURCE =70000.
ELSE IF (ICOHP .EO. 19)THEN
SOURCE'K50.
ELSE IF (ICOHP .EO. 20JTHEN
SOURCE'H.






FUHCTI0H SUBPROGRAM MAKE : SPEJF FORTRAII
PURPOSE: Calculates the specific effective energy deposited
in target organ, KTARG due to source organ, JSORCE










Coloring source organ, JSORCE and target, KTARG. uhen
source organ is not equal to the target organ, ICOM-1
else I coco
IF(JS0RCE




.EO. 2 .AND. KTARG .EO. 6)THEN
COM
ELSE IFUSORCE
















.EO. 7 .AND. KTARG .EO. 10)TNEN
ICOM
ELSE IFCJSORCE




















.EO. 12 .AND. KTARG .EO. H)THEN
I COCO
ELSE IFCJSORCE




.EO. 14 .AND. KTARG
.EO. 16>THEN
SPEFF.FOR
ELSE IF(JSORCE .EO. 15 .AND. KTARG .EO. 3>THEN
]COH*0
ELSE IF(JSORCE .EO. 16 .AND. KTARG .EO. 2)THEN
I COM)





Begin with 'Total body' as source.
The character variable 'SAVE' stores the name of the
previous radionuclide and hence when it is equal to
'WORD', the function 'SPEFF' does not have to call
'DECAY' again
IF (SAVE .EO. WOKDJGOTO 5
ICOUNT>0
CALL DECAT (VORD.ICOUHT)







IF (13 .HE. (DTHEN
DO 6 I"I7»1,I7»I3
EGAMMA(I)«0.511
rCAWA( I ).2. 'TPOSK I - 1 7)
CONTINUE
END IF
IF(ICTARO .EO. 6 .OR. (KTARG .EO. 7) .OR. (KTARG .EO. 8) .OR. (KTAR
iG .EO. 9) .OR. (KTARG .EO. 12DTHEN
GOTO 55
ELSE IF(ICTARG
.EO. 5 .OR. KTARG .EO. K>THEN
GOTO 105
END IF




IF <!CW .EQ. DTHEN
[F CJSOfiCE .EO. 17)THEH
AF«1./69900.
SPEFF-SPEFF*(TALPHA( I )>EALPHA( I )«AF«OF>




ELSE IF (JSORCE .EQ. 2)THEN
Af«150./(2'250.*69900.>
ELSE IF (JSORCE .EQ. 3>THEN
AF»640./(2'«K>.«69900.)
ELSE IF (JSORCE .EQ. 4)7HEH
AF-210./(2«220. '69900.)
















15 IF (II .EQ. 0)GOT0 25
QF=1
DO 20 I»1,I1
IF (ICON .EQ. DTHEN
IF (JSORCE .EQ. 17)THEN
AF=1./69900.
SPEFF-SPEFF«(YBETA( I )*EBETA( I )*QF'AF)
ELSE IF (KTARG .EO. 19) THEN
IF (JSORCE .EQ. DTHEN
AF.45.1/(2"2I10.*699(IO.>
ELSE IF (JSORCE .EQ. 2)THEN
AF-150./(2*250. '69900.)
ELSE IF (JSORCE .EQ. 3>THEN
AF<640./(2>AOO.*69900.
)
ELSE IF (JSORCE .EQ. OTHER
AF-210./(2"220. •69900.)












SPEFF»SPEFF.( (rSETA( 1 >*EBETA( I >»OF*AF>/TKASS>
END IF
20 CONTINUE
25 IF (13 .EO. OJGOTO 35
OF-1
00 30 1-1 , 13
IF (ICOH .EO. DTNEN
IF (JSORCE .EO. 17JTHEN
AF-1./69900.
SPEFF.SPEFF->(rPOST(I>'EPOST(l)«OF*AF)
























SPEFF-SPEFF*( (TPOSTC I >*EPOST( I )*OF'AF)/TMASS>
END IF
30 CONTINUE
35 IF (15 .EO. 0)GOTO 45
QF«1
DO 40 1-1 , IS
IF (ICOH .EO. DIKES
IF (JSORCE .EO. 17)TKEN
AF-1./69900.
SPEFF-FQF
SPEFF'SPEFF*(YELEC( I >'EELEC( I j'OF'AF)
ELSE IF (KTARG .EO. 19) THEN
IF (JSORCE .EO. DTHEN
AF-45.1/(2'200. '69900.)
ELSE IF (JSORCE .EQ. 2>THEN
AF'150./(2«250.'69900.
>
ELSE IF (JSORCE .EO. 31THEN
AF»640./(2«400. '69900.
)
ELSE IF (JSORCE .EO. OTHER
AF=210./(2«220.'69900.)


















IF (EGAHHA(I) .LT. O.ODTNEN
IF (ICON .EO. DTHEN
IF (JSORCE .EO. 17)THEN
AF«1.0/69900.
SPEFF-SPEFF«(YGAHHA( I )«E0AHMA( I )'0F'AF)
ELSE IF (KTARG .EO. 19)THEH
IF (JSORCE .EO. DTHEN
AF-45. 1/(2*200. '69900.
)
ELSE IF (JSORCE .EO. 2)THEN
AF'150./(2«250. '69900.
ELSE IF (JSORCE .EO. 31THEN
AF-640./(2«400.'69900.
ELSE IF (JSORCE .EO. 4)THEN
AF-210. /(2*220. "69900.
















The function INTRPT interpolates the values of absorbed
Fraction, AF for the given energy, EGAMHA(I)
ICHECJCO
AF=IHTRPT(EGAHMA(I),JSORCE,KTARG,ICHECX)








Target organs of the GI tract and bladder
ALPHA
55 IF (H .EC. 0)GOT0 65
Mao
IF (ICON .EQ. WHEN






IF (KTARG .EO. 6)THEN
AF=(0.5*0.01)/250.
ELSE IF (KTARG .EO. 7)THEN
AF«(0.5*0.01)/400.
ELSE IF (KTARG .EO. SITHEN
AF"(O.5*0.01)/22O.
ELSE IF (KTARG .EO. 9)THEN
AF»(0.5*0.01>/135.




IF (AF .EO. 0.)GOTO 65





IF (ICOH .EO. DTHEH






IF (KTARG .EQ. 6)THE«
AF.(0.5*1.0>/250.
ELSE IF (KTARG .EQ. 71THEX
AF"(0. 5*1. 01/400.
ELSE IF (KTARG .EO. 8)THEN
AF"(0.5'1.0)/220.
ELSE IF (KTARG .EO. 9)THEH
AF-(0.5*1 .01/135.




IF (AF ,E0. O.jGOTO 95
IF (11 .EO. 0)GOTO 75
DO 70 I-1.I1
SPEFF-SPEFF*(YBETA( I 1«EBETA( I 1»0F*AF1
70 CONTINUE






85 IF (15 .EO. 0)GOTO 95
DO 90 1—1,15
SPEFF-SPEFF*(YELEC( I 1"EELEC( I )-OF*AF)
90 CONTINUE
SPEFF.FOR






IF <IC0M .EQ. WHEN







































.EQ. 0. .AND. (JSORCE .EQ. 12»GOTO 185
Target organs in bone
IF (K .EO. 0)GOTO 125
OF-20
00 120 I-1.H









































.EO. '»') .OR. (WTS(1:5>
.EO.
-2«-o5'>




« .EO. 'BE-7') .OR. (HOTS<l:5)
.EO. 'BE-10')







































* Alpha emitter on bone surfaces
AF.0.25
EHO IF
ELSE IF (LOOP .GT. DTHEH
Alpha emitter uniform in volume
SPEFF.FOR
IF (H0TS(1:4) .EO. 'P-33' .OR. (HOTS(1:6) .£0.
-HB-93H-) .0
in. <M0TSO:5> .EO. 'NB-94') .OR. (M0TS(1:5) .EO. 'U-232') .OR. (MO
»TS(1:S) .EO. 'U-233') .OR. (M0TS<1:5)
.EO. 'U-234') .OR. <H0IS(1:5
t) .EO. 'u-235') .0«. (M0TS(1:5) .EO. -11-236')
.0«. (M07S(1:S) .EO.
t 'U-238') .0«. (I(0TS(1:2) .EO. 'HA') .OH. (MTS(1:2) .EO. 'CR') .0
«. (M0TS(1:2) .EO. 'RB') .OR. (H0TS(1:5> .EO. 'ZK-65') .OR. (MOTS(
tUm .EO. 'PB-205') .OR. (M0TS(1:6> .EO. 'PB-210')
.OR. (H0IS(1:4)
t .EO. 'BE-7') .OR. (M0TS<1:5)
.EO. 'BE-10') .OR. (M0TS(1:4> .EO. •
SV-49') .OR. (M0TSO:6> .EO. 'PO-103') .OR. (M0TS(1:6>
.EO. 'PD-107
»') .OR. <K0TS<1:6> .EO. 'SN-113') .OR. (1(015(1:7) .EO. 'SM-119M')






.EO. 'W-181') .OR. (HOT




ELSE IF (M0TS(1:2) .EO. 'SR' .OR. (IBTS(1:2) .EO. 'CA') .OR
». (H0TS(I:2) .EO. 'RA') .OR. (K0TS(1:2> .EO. 'BA'»THEH

















IF (LOOP .EO. I)THE«
Alpha emitter uniform in volume
IF (M0TS(1:4> .EO. 'P-33' .OR. («0TS(1:6) .EO. 'NB-93M')
.0
U. (H0TS(1:5)
.EO. 'NB-94') .OR. (M0TS(1:3)
.EO. 'U-232') .OR. (MO





.EO. 'U-236') .OR. (M0TS(1:5)
.EO.


















































































IF (KTARG .Ed. UHHEN
Trabecular bone
IF (LOOP .EQ. DTHE*
Beta emitter uniform in volu
IF (MOTSO:*) .EO. 'P-33' .08. (HOTS(1:6) .EQ. 'KB-93II') .0
«. («0TS(1:5> .EO. 'M-M') .OH. (MOTS(1:5) .EO. 'U-232') .OS. (HO
*TS(1:5) .EO. 'U-233') .OK. (H0TS(1:S) .EO. 'U-234') .0*. (H0TS(1:5
«) .EO. 'U-235') .OK. (H0TS<1:5> .EO. 'U-2J6') .OK. (M0IS<1:5> .EO.
t 'U-238') .OK. <H0TS<1:2> .EO. 'K»') .OK. (H0TS(1:2) .EO. 'CK') .0
M. (M0TS(1:2> .EO.
-KB') .OK. (K0TS(1:5) .EO. 'ZH-65') .OK. (HOTS(
t1:6) .EO. 'PB-205')
.OK. (H0TS(1:6) .EO. 'PB-210') .OK. <H0TS(1:4)
t .EO. 'BE-7') .OK. (K0TS(1:5> .EO. 'BE-10') .OK. (H0TS<1:4) .EO. '
«V-49'> .OK. (A0TS(1:6> .EO. 'PD-103") .OK. («0TS(1:6> .EO. 'P0-107
«') .OR. (M0TS(1:6) .EO. 'SK-113') .OK. (A0TS(1:7) .EO. 'SH-119H')
l.OK. (WTS(1:6) .EO. 'SH-123'J .OK. (H0IS(1:6) .EO. 'SK-126') .OK.
t (N0TS(1:6) .EO. 'TA-182') .OK. («0TS(1:5) .EO. 'U-UV) .OK. (MOT
»S(1:5> .EO. 'U-185') .OK. («0TS(1:5) .EO. 'U-1M'»THEK
AF-0.025
Alkaline earths
ELSE IF (M0TS(1:2) .EO. 'SR' .OK. (N0TS(1:2)
.EO. 'CA'> .OK












Beta emitter on bone surfaces
IF (EBETA(I) .LT. 0.2)THEN
AF-0.25





ELSE IF (LOOP .CT. 1)THE«



































































































IF (LOOP .EC. DTHEN
«M «lMM IM«««IHI« t i|








.EO. 'U-Z32') OH (HO
«TS(1:5)













































































165 [F (13 .EO. OjGOTO 175
00 170 1.1,13
IF (ICON .EO. 1JTHEN
IF (JSORCE .EO. 17)THE»
»F.1 ./69900.






IF (KTARG .EO. K)THE«
Trabecular bone
IF (LOOP .EO. 1JTHEH
Positron emitter uniform in volume
IF («0TS(1:«) .EO. 'P-33' .OH. (HOTS(1:6)
.EO. 'BB-93H')
.0
if. (HOTS(1:5) .EO. 'NB-94') .OK. (NOTS(1:5> .EO. 'U-232') .OR. (MO
STS(1:5) .EO. 'U-233') .OK. (M0TS(1:5)
.EO. 'U-254') .OK. (MOTS(1:5
i> .EO. 'U-235') .OK. (MOTS(1:5) .EO. 'U-236') .OK. (KOTS(1:5)
.EO.
« 'U-238') .OK. (MOTS(1:2>
.EO. 'HA') .OK. (MOTS(1:2) .EO. •«')
.0
SK. (BOIS(1:2> .EO. 'KB') .OR. (M0TS(1:5)
.EO. 'ZN-65') .OK. (HOIS(
•1:6) .EO. 'PB-205')
.OK. (MOTS(1:6) .EO. 'PB-210')
.OK. (NOTS(1:4)
I .EO. 'BE-7') .OR. ("X)TS(1:5> .EO. 'BE-10') .OR. (MOTS(1:«)
.EO. '
W-49')
.OK. (M0TS(1:6> .EO. 'PO-103')
.OK. (MOIS(1:6)
.EO. 'PO-107
S'> .OK. (KOTS(1:6) .EO. 'SH-113') .OK. (KOTSO.-7) .EO. 'SH-119H')
S.OR. (MOTS(1:6) .EO. 'SH-123') .OR. («OIS(1:6) .EO. 'SH-126') .OK.
t (MOTS(1:6> .EO. 'TA-182') .OK. (HOTS(1:5) .EO. 'W-181') .OR. (HOT




.EO. 'SR' .OR. (H0TS(1:2) .EO. 'CA') .OR
t. («0TS(1:2) .EO. 'RA') .OR. (N0TS(1:2> .EO. 'BA'))THEH











Positron emitter on bone surfaces






ELSE IF (LOOP .CI. IjTHEN
PositPon esiitter unifone in volune
IF (HOTSO:*) .EO. 'P-33' .C*. (KOTS(1:6) .EO. 'NB-93H') .0
SR. (M0TSO:5) .EO. 'NB-9*') .OR. (H0TS<1:5) .EO. 'U-232') .0«. <»0
«TS(1:5) .EO. 'U-233') .OR. («OtS(1:5) .EO. 'U-234') .OR. (MOTSCltS
*> .EO. 'U-235') .OR. (HOTSCItS) .EO. 'U-236') .OR. (N0TS(1:5> .EO.
i 'U-238') .OR. <H0TSO:2> .EO. 'HA') .OR. <H0T$C1:2> .EO. 'CR') .0
«. (H0TS<1:2) .EO. 'RB'> .OR. <K0TS(1:5) .EO. '211-65')
.OR. (WTS(
t1:6) .EO. 'PB-205') .OR. («0TS(1:6> .EO. 'PB-210') .OR. (NOTSd:*)
S .EO. 'BE-7') .OR. (M0TS<1:5>
.EO. 'BE-10') .OR. (H0TS(1:4) .EO. '
»V-«9') .OR. (N0TS<1:6> .EO. 'P0-103')
.OR. (KOTS<1:6> .EO. 'PD-107
»') .OR. (WTS(1:6) .EO. 'SH-113') .OR. <K0TS(1:7) .EO. 'SR-119M')
i.OR. (M0TS(1:o) .EO. 'SH-123') .OR. (M0IS(1:6)
.EO. 'SN-126') .OR.
t (M0IS<1:6) .EO. 'TA-182') .OR. <«0TS(1:5>
.EO. 'U-181') .OR. (HOT
«C1:5> .EO. 'U-185'j .OR. (H0TS(1:5) .EO. 'U-188'»THEH
AF-0.015
Alkaline earths
ELSE IF <H0TS<1:2> .EO. 'SR' .OR. <«OTS(1:2) .EO. 'CA') .OR
t. (M0IS(1:2) .EO. 'RA'j .OR. (M0tS(1:2) .EO. 'BA'WHEN
IF (PLIFE .ST. 15>IKE»
AF-0.015
ELSE







Positron emitter on bone surfaces









iiHM««nnMM»mn i*mmMnmn tM*n « iM
Trabecular bone
IF (LOOP .Eg. DTHEH
Positron emitter uniform in volu






.EO. 'U-232') .OR. (MO
1TS(1:5> .EO. 'U-233') .OR. (KOTS(1:5> .EO. 'U-234') .OR. (M0TS(1:5
l> .EO. 'U-235'j .OR. (MOTS(1:5> .EO. MJ-236') .OR. (H0TS(1:5) .EO.
t 'u-238')
.OR. (M0TS(1:2>
.EO. 'NA') .OR. (M0IS(1:2) .EO. 'CR') .0
1R. (KOTS(1:2>
.EO. 'RB'> .OR. (WTS(1:5> .EO. '2N-65') .OR. (H0TS(
11:6) .EO. 'PB-205')
.OR. (M0TS(1:6) .EO. 'PB-210')
.OR. (N0TS(1:*>
1 .EO. 'BE-7') .OR. <«OTS(1:5>
.EO. 'BE-IO') .OR. (»0TS(1:«) .EO. '
IV-W) .OR. (WTS(1:6> .EO. 'PD-103') .OR. (H0TS(1:6) .EO. 'PD-107
»') .OR. (M0TS(1:6)
.EO. 'SR-113') .OR. (HOTS(1:7)
.EO. 'SJM1M')
t.OR. (M0TS(I:6)
.EO. •SH-123") .OR. (HOTS(1:6> .EO. 'SN-126'J .OR.








«*««l«t**«Wtt««W«WWWWM.M IMIM.MnM. I »Mm





1. (HOTS(1:2> .EO. 'RA') .OR. ("OTS(l:2>
.EO. 'BA'))IHE»


















175 IF (15 .EO. 0)GOTO 182
DO 180 1-1,15
IF (1C0M .EO. WHEN











IF (LOOP .EO. DTHEN
* Electron emitter uniform in volume •
«•*»»««—««»—«^—.......... *»Mmimiu„ulutill.„
IF (HOTS(1:4)





























































ELSE IF (HOTS(l:2> .EO. 'SR' .OH. («0TS(1:2> .EO. 'CA') .OR
I. (H0TS(1:2> .EO. 'RA') .OR. <HOTS(l:2) .EO. 'BA')>THE«
IF (PLIFE .GT. 15>T»EN
AF.0.025
ELSE







Electron emitter on bone surfaces






ELSE IF (LOOP .GT. 1HNEN
Electron emitter uniform in volume
IF (HDISd:*) .EO. 'P-33' .OR. («0TS(1:6) .EO. 'NB-93H') .0
SR. (H0TS(1:5) .EO. '«B-W> .OR. (M0TS(1:5) .EO. 'U-232') .OR. (HO
SIS(1:5) .EO. 'U-233') .OR. («0TS(1:5) .EO. 'u-234') .OR. (M0TS(1:5
S) .EO. 'U-235'J .OR. (M0IS(1:5) .EO. 'U-2J6') .OR. (H0TS(1:5) .EO.
S 'U-238') .OR. (M0TS(1:2) .EO. 'NA') .OR. (H0TS(1:2) .EO. 'CR'J .0
SR. (H0TS(1:2) .EO. 'RB') .OR. (M0TS(1:5> .EO. 'ZN-65') .OR. (HOTS(
*1:6) .EO. 'PB-205'J .OR. (H0TS(1:6)
.EQ. 'PB-210'J .OR. (M0TS(1:«)
t .EO. 'BE-7') .OR. (H0TS(t:5) .EO. 'BE-10') .OR. (H0TS(1:4)
.EO. •
tV-W) .OR. (H0TS(1:6> .EO. 'P0-103') .OR. (N0TS(1:6) .EO. . 'PO-107
«') .OR. (MOTS(1-.0> .EO. 'SN-113') .OR. (K0TS(1:7) .EO. 'SN-119".')
S.OR. (M0TSO:6) .EO. 'SN-123') .OR. (H0TS(1:6) .EO. 'SN-126') .OR.
t (H0TS(1:6) .EO. 'TA-1S2') .OR. (N0TS(1:5) .EO. 'U-1B1') .OR. (MOT
IS(1:5) .EO. 'U-185') .OR. (M0TS(1:5) .EO. 'W-tM'»THEN
AF-0.015
*«««*tllHII«H« « m>H >HM»t«M > iHHt«W«W>«
Alkaline earths •
ELSE IF (K0TS(1:2> .EO. 'SR' .OR. (H0TS(1:2)
.EO.
I. (H0TS(1:2) .EO. 'RA') .OR. (K0TS(1:2> .EO. '1A'»THEN












Electron emitter on bone surfaces









IF (LOOP .EO. DTNEN
**Mima*aMmmMaaa—mammiMammM*—mm9—m——tmmM a—a
Electron emitter uniform in volume •
IF (H0TS(1:4> .EO. 'P-33' .OR. (M0TS(1:6) .EO. 'NB-93M') .0
«. (M0TS<1:5) .EO. 'IIB-94') .OH. (»TS(1:5) .EO. 'U-232') .OR. (MO
«TS(1:5) .EO. 'U-233') .OR. («OTS(l:5) .EO. 'U-23*') .OR. (HOtS(t:5
t) .EO. 'U-235') .OR. (MOIS(1:5) .EO. 'U-236') .OR. (M0TS(I:5> .EO.
t 'U-238') .OR. (H0TS(1:2) .EO. 'HA') .OR. (K0TS(1:2) .EO.
-CR') .0
tR. (M0TS(1:2) .EO. 'RB'> .OR. (M0TS(1:S) .EO. 'ZN-65') .OR. (MOTS(
U:6> .EO. 'PB-205') .OR. («0TS(1:6) .EO. 'PB-210')
.OR. (K0TS(1:4)
( .EO. 'BE-7') .OR. (M0TS(1:5) .EO. 'BE-10') .OR. (H0TS(1:*> .EO. '
W-49-) .OR. (H0TS(1:6) .EO. 'PD-1CS')
.OR. (M0TS(1:6) .EO. 'PD-107
I') .OR. CIDTKIlM .EO. 'SN-113') .OR. («0TS(1:7) .EO. 'SN-11v»')
S.OR. (MTS(1:«) .EO. 'SN-123') .OR. (M0TS(1:6) .EO. 'SN-126') .OR.
S (H0IS(1:6) .EO. 'TA-182') .OR. («0TS(1:5> .EO. 'U-U1') .OR. (HOT
SS(1:5) .EO. 'U-t«5') .OR. (M0TS(1:5) .EO. 'U-188'))THE»
AF«0.35
Alkaline earths •
« « « »«< *MH«mH .tM tM iimMMM IH .I .. IH»M l i
ELSE IF (K0TS(1:2) .EO. 'SR' .OR. (H0TS(1:2> .EO. 'CA') .OR
t. (H0IS(1:2) .EO. 'HA') .OR. (H0TSO:2> .EO. 'BA'))TREII





























IF (ICON .EO. DIKEN
IF (JSORCE .10. 17)THEN
AF-1. 0/69900.























SUBROUTINE K*HE : SUBKER FORTRAN
PURPOSE: CU date file. "LIST" and
-NOBLE" for doee
etajivalent rate in target organs froa submersion
in a semi-infinite cloud of noble gases or
elemental trititaa
DESCKJPTION OF VARIABLES
WORD --•> Name of the given iaotope
URATE --> Dose equivalent rate in target organa or tissues
from submersion in unit concentration of the
iaotope
DER > Derived Air Concentration
RISK ---> OAC determined by the non-stochaatic Halt


































9 FORNAT(1PE8.1,tPE8.1, 13,12, 1PES.1,13,1PE8.1,I3,1PE8.1, 13 1PE8 1 13
*.1PE8.1,I3,1PE8.l,I3,1PES.1,I3,tPE8.1,I3,1PE8.1,l3,tPE8.1,I3 1PE8
«1.I3,1PE8.t,I3,1PE8.l)
DO 10 1-1,13 •
IF (JSORCE(I)
.EO. OjGOTO 10






21 FORKATC//,' Error: Nuclide not found in the IC8P Publication 30' /




26 FORNAT(//,' ERROR: Unable to reed dose equiv.lent rates froa data
ifile "NOBLE" I',/,' SOURCE: SUBMER FORTRAN',/,' CORRECTIVE ACTION:





SUBROUTINE NAME: TFRAC FORTRAN *
* PURPOSE: Retrieve the retention frictions, F2 and the •
* biological half-lives, BHALF of the nuclide *
in source organs *
* DATA FILE REQUIRED: a) RETENT FILE *
* AUXILIARY SUBROUTINES REQUIRED: *
*
a) 11 FORTRAN •
-
b) SOURCE FORTRAN •















Function subprogram II converts C2, the source organ
alphameric characters to an integer from source list I
compare with JSORCE
IF (I .EO. 1)THEN
IF <D .84. 0. .,
END IF









0. (G -EG. 0.))GOTO 10
. (G .EQ. 0.))GOTO 5
JSORCEJTHEN
Function subprogram SOURCE gives the I




; of the source
TFRAC.FOR
When source organ is 'Total body 1 and several organs of
mass Hi are associated with different retention fractions,
then the masses of all these organs are first summed, i.e.
(sua of Hi) and then 'Total body' is assigned a mass of
70000-<sua of Hi) and retention fractions which are
associated with 'all other'. The records are entered in
in such a way that for a given KZ, entry of 'all other' is
always at the end after all organs, i
IF (JSORCE .EQ. 17)THEM

















15 F0RMAT(//,' ERROR: Unable to read retention fractions, and biologi
Seal half-lives in source organ, from file "RETENT"' ,/, ' SOURCE: T
SFRAC FORTRAN',/,' CORRECTIVE ACTIO*: Try another nuclide!!',/////)





FUNCTION SUBPROGRAM NAHE: THALF FORTRAN
PURPOSE: Provide half-life of clearance from body fluid
compartment given an atomic number of a nuclide
FUNCTION THALFOC2)
IF <KZ .EQ. 9 .OR. OCZ .EQ. 19) .OR. (KZ .EQ. 79) .OR. (KZ .EQ. 81
S))THEN
THALFeO.
ELSE IF(KZ .EQ. 15 .OR. (KZ .EQ. 24) .OR. (KZ .EQ. 27) .OR. <KZ .E
&Q. 90))THEN
THALF=0.5
ELSE IF <KZ .EQ. 43 .OR. KZ .EQ. 75)THEN
THALF-0.02
ELSE IF (KZ .EQ. 44 .OR. KZ .EQ. 45)THEN
THALF=0.3
ELSE IF (KZ .EQ. 52)THEN
THALF=0.8








SUBROUTINE NAME : TRNSFN. FORTRAN
PURPOSE: Calculates source-organ transformations, i
DESCRIPTION OF VARIABLES
UTJ(l)- > Source-organ transformations of the isotope
under consideration, j in the body fluid
(transfer) compartment.
UROB<I>— - > The total number of transformations of
radionuclide,!' in 'rest of the body' of
mass, 70000-<sum of Mj) where Mj is the
mass of organ j for each unique retention
fraction.
USCJSORCE, !)---> Source-organ transformations of nuclide,!
w * Transformations in each compartment of the
source organ.





*(1:50), FGI (1:NO>, TEMPO :3,t:50),UROB(1:NO)
REAL MROB
Calculating the biological constants, BCONST from the











There are separate methods of calculating source-organ

















IF (JSORCE .EQ. 3)GOI0 110
IF (JSORCE .EO. 4)COTO 120
IF (JSORCE .EQ. 5}G0T0 130
END IF
Special Treatment for iodine
IF (KZ .EQ. 53)GOTO 300
Outer most loop for calculation of US of nuclide species,
j
In case of instantaneous transfer to tissue compartment,
calculation of UTJ(I) in transfer compartment is skipped








Loop for outer sua tem.SUH in the calculation of UTJ(J)
SUM«0.
DO 20 I»1,J
Loop for outer product tern, PROD of RCONST in the equation
for calculation of UTJ(J)
PR0D-1
.
• Parent case •
IF (1+1 .GT. J) GOTO 30






Loop for inner sum term.SuMI in the equation for
calculation of UTJ(J)
DO 35 M=l ,
j
PRCD1-1.
Loop for inner product term,PR001 in the c
equation for calculation of UTJ
DO 40 K=I,J










Loop for calculation of total source-organ transformations
from contribution of different compartments of each source
DO 65 L«1,3
IF (F2CL) .EQ. Q.JGOTO 65
SUM2-0.
TISSUE COMPARTMENT
Loop for outer sum term,SUM2 in calculation of source-organ
transformations, UJ in each compartment of the source organ











Loop for inner product term,PROD3 in the equation *
00 95 t-I,J






• Initial activity, ACTJ of species,] in source organ. •
IF (TCONST .Ed. O.HHEH










IF CJSORCE -EQ. 17)THEN
Redistribute transformations uniformly through out all




Source-organ transformations with source as 'total body'
» *« HUH IM I I M ««««»
uSCJSORCE,J)«US<JSORCE,J>*7uO00.'SMASS
ELSE
IF (UROBtJ) ,H. O.JGOTO 15






• STOMACH in case of INGESTION •
100 DO 105 J» ,M
• Parent case •












SMALL INTESTINE in case of INGESTION
If F1>1, it is assumed that the radionuclide peases directly
from the stomach to body fluids and does not pass through
other sections of the GI tract
110 IF (F1 .EQ. I.IGOIO ISO
BFCNST-F1*6./<1.-F1)
DO 115 J*1,NO
' Parent case •
'**»*'" 't*"""'"*"**»«"nn«»M"nm »HM i«»min.. .»« «««
















UPPER LARGE INTESTINE in case of INGESTION

























LOWER LARGE INTESTINE in case of INGESTION




























• STOMACH in cut of INHALATION •
140 DO 142 J=1,NO
• Parent cas* *
IF (J .EQ. 1JTHEN
US(JSORCE, 1 )«BRA<1 >-FCI ( 1 )/FL0U(24.+tC0MST(1)
)
* Daughters ' case *
ELSE
• Loop for outer sun term, SUM -
MM,
00 143 I>1,J
Loop for outer product tarn, PROD* •
PD004.1.









Loop for inner product tenp.PROOS
00 147 X>I r J













SMALL INTESTINE in caw of inhalation














Loop for outer product tone, PROD*
mot-i.
IF (I*f .CT. NUOGOTO 4
DO 5 K-I+1.NUC




Loop for inner tw tem,SUH5
00 6 H-I.NUC
PR0D5-1.
Loop for inner product term,PR005
DO 7 K«I,MUC












Loop for outer sun torn,SUM
SUN4-0.
DO 153 1>1,J
Loop for outer product tern, PROM
PRC04-1
.





Loop for inner sue term, SUMS
DO 156 H«I,J
PR005-1
Loop for inner product term,PR0D5
DO 157 K"I,J






SUN4»SUM4.FLOW(PI!0O4'24. 'TEMPO , I >«SUH5/BRA( 1 )
)
153 CONTINUE




UPPER LARGE INTESTINE in cue of INHALATION •
160 IF (F1 ,E9. 1.JG0T0 180
BFCNST«F1*6./(1.-F1)
DO 162 J<1,N0






IF (INN .EO. 1 .AND. <«UC .EO. 1»THEN
TEHP(I»N.NuC)«R».(1>'FGI(1)/FLCV(24.»RCONST(1»





DO 103 1=1, NUC
* Loop fop outer product tem,PR0D4
PR0D4-1.









" Loop for inner product tem,PROD5
*******"'« «" «""« «»m t IMm. . l
DO 107 K=I,HUC
IF (K .EO. M)GOTO 107
PR005.FL0U(PR00S'(RC0NST(K)-RC0NSTOI»>
107 CONTINUE
IF (INN .EO. DTNEN
SUH5.SUH5»((1.-UXP(-(24.0»«CONST(M»*365.25-50.))/FLOU((24..RCO
UST(H)>*PR00S)>





IF (INN .EO. DTNEN
SUM4-SUH4»FLOU(PR004«FGI ( I >'SUM5/BI!»( I )
)
ELSE IF (INN .EO. 21TNEN
SUH4-SUH4*FLOW(PROD4*TEHP(








Loop for outer sum term,SUM4
TRNSFM.FOR
SUB4»0.
DO 163 t-1 , J
Loop for outer product torn, PROM
PR0D4-1.









Loop for inner product term.PROOS
00 167 Id, J






SUH4"SUM4tFL0W(PR004'6.«TEI(P<2, 1 )«SUO/BJU(l ))
163 CONTINUE





LOUER URGE INTESTINE in case of INHALATION












IF (INN .EO. 1 .AND. (NUC .EQ. 1))THEN
TE«*(INN,NUO»BRA(1>«FGI(1>/FLOU(24.->RCONST(1>>












• Loop for outer product tern, PROM *
^ >Hi«M*H «»»m «>l*mM> IM«HM II»WMM III
PR004= 1
.





*m»m«m» «>m i i tmnMn i i.
Loop for Inner sun term,SUH5
00 206 H>I,NUC
PR0D5-1.
Loop for inner product term,PR0D5
M* "' *m >»*» »«
DO 207 K>I,NUC
IF (It .EO. H)G0T0 207
PR005-FLOU(PR005'<«CONSI(K)-RCO«ST(H)»
207 CONTINUE
IF (INN .E0. DTNEN
SUM5-SUH5*((1.-UXP(-(24.0*RC0NST(H))>365.25*50. ))/FLOU((24.»CO
*NST(IO)-PR005>>
ELSE IF (INN .E0. 2)THEN
SUN5«UM5»((1.-UXP(-(6.*BFCNST-HiCONST(H))'365.25'50.»/FLOU((6.
•0*f)FCNST~RC0NST(l<))*PRC05))







SU«4«SUN4»FL0U(PIK]O4-F0I ( I )-SUH5/BRA( I ))
ELSE IF (INN .E0. 2)THEN
SU«4.SU44»FLOU(PR»4'TEHP( I , I )-24.*SUH5/BR»( I ))
ELSE IF (INN .E0. 3)THEN













Loop for outer product term, PRODI
PR004=1
.















SUM4.SUM4.FLOW<P«004«1 ,S«TEMP<3, 1 >"SUM5/BRA< I )
)
173 CONTINUE





Three compartment model for iodine








UBF-FT1 I )'<RC0NST( I >»BODY>"<RCONSTC I )*BSORCE)/DENON














































SUBROUTINE NAME : TERROR FOSTHAH
PURPOSE: Error handling siijroutine for DECAY FORTRAN
SUBROUTINE YERROR(OECERR)
INTEGER DECERRC7)
IF (DECERRC1) .GT. COTH.EN
WRITE <",5)
S FORMATl//,' ERROR: No match found in file "ISOTIPS" for the gi
Sven radionuclide! ',/,' SOURCE: DECAY FORTRAN'./,' CORRECTIVE ACTIO
SN: Try another nuclide !!',////>
DECERR(1)*0
RETURN
ELSE IF (DECERRC2) .GT. 0)TNEN
WRITE (',10)
10 FORHAT(//,' ERROR: Unable to read the decay scheme of the nuc
Slide in file "ISOTOPE"!
',/, • SOURCE: DECAY FORTRAN',/,' CORRECTIVE







15 FORMAT!//,' ERROR: Unable to read the alpha energy and intern
Sity from file "ALPHA" for the nuclide!',/,' SOURCE: DECAY FORTRAN







20 FORHATC//, 'ERROR: Unable to read the beta energy and intensit
SY FROM FILE "SETA" FOR THE NUCL10EI ',/, ' SOURCE: DECAY FORTRAN






25 F0RMAT<//,' ERROR: Unable to read the positron energy and inten
SSITY FROM FILE "POSITRN" FOR TKE NUCLIDE!',/,' SOURCE: DECAY FORT







30 FORHATC//, 'ERROR: Unable to reed the electron energy end inten
Ssity from file "ELECTRN" for the nuclide!',/,' SOURCE: DECAY FORT






35 F0RMAK//,' ERROR: Unable to reM the photon energy and intensi
Sty from file "PHOTON" for the nuclide!',/,' SOURCE: DECAY FORTRAN'
YERROR.FOR
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ABSTRACT
A software package written in the FORTRAN-77 language uses the
methods described in Part 1 of Publication 30 of the International
Commission on Radiological Protection (ICRP) to calculate committed
dose equivalents from an internal radionuclide to organs and tissues of
an adult "reference man". An alternate version for use on an IBM-PC or
a compatible micro-computer is also available.
The program considers any of the three major modes of intake of a
radionuclide, namely, ingestion, inhalation, or submersion in a cloud
of inert radioactive gas or elemental tritium. Except for the source
of radiological decay data, the general principles, definitions,
mathematical models, and calculational procedures follow closely those
described in ICRP-30. The program calculates specific committed dose
equivalents (Sv/Bq) in 19 target organs, annual limit of intake (Bq)
,
and derived air concentration (in the case of inhalation or submersion)
of a radionuclide. Also, weighted committed dose equivalents (Sv/Bq)
for selected target organs receiving greater than or equal to 10
percent of the maximum dose is shown. In addition, a table of specific
effective energies in 17 sources and 19 target organs in three units
(MeV/g, rad/uCi.h, and mSv/GBq.h), and a table for number of
transformations in source organs per unit intake of activity of the
radionuclide (/Bq) can be generated upon request. The features of
independent subroutines and alterable data files on radiological decay
and biological characteristics make modifications and update of the
program simple and straightforward.
